
<html lang="en"     class="pb-page"  data-request-id="70529859-4c6b-4c66-83e5-697d9afc157a"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;issue:issue:10.1021/jmcmar.2013.56.issue-23;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/jm4010835;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Reductions in log P Improved Protein Binding and Clearance Predictions Enabling the Prospective Design of Cannabinoid Receptor (CB1) Antagonists with Desired Pharmacokinetic Properties" /></meta><meta name="dc.Creator" content="Bruce A.  Ellsworth" /></meta><meta name="dc.Creator" content="Philip M.  Sher" /></meta><meta name="dc.Creator" content="Ximao  Wu" /></meta><meta name="dc.Creator" content="Gang  Wu" /></meta><meta name="dc.Creator" content="Richard B.  Sulsky" /></meta><meta name="dc.Creator" content="Zhengxiang  Gu" /></meta><meta name="dc.Creator" content="Natesan  Murugesan" /></meta><meta name="dc.Creator" content="Yeheng  Zhu" /></meta><meta name="dc.Creator" content="Guixue  Yu" /></meta><meta name="dc.Creator" content="Doree F.  Sitkoff" /></meta><meta name="dc.Creator" content="Kenneth E.  Carlson" /></meta><meta name="dc.Creator" content="Liya  Kang" /></meta><meta name="dc.Creator" content="Yifan  Yang" /></meta><meta name="dc.Creator" content="Ning  Lee" /></meta><meta name="dc.Creator" content="Rose A.  Baska" /></meta><meta name="dc.Creator" content="William J.  Keim" /></meta><meta name="dc.Creator" content="Mary Jane  Cullen" /></meta><meta name="dc.Creator" content="Anthony V.  Azzara" /></meta><meta name="dc.Creator" content="Eva  Zuvich" /></meta><meta name="dc.Creator" content="Michael A.  Thomas" /></meta><meta name="dc.Creator" content="Kenneth W.  Rohrbach" /></meta><meta name="dc.Creator" content="James J.  Devenny" /></meta><meta name="dc.Creator" content="Helen E.  Godonis" /></meta><meta name="dc.Creator" content="Susan J.  Harvey" /></meta><meta name="dc.Creator" content="Brian J.  Murphy" /></meta><meta name="dc.Creator" content="Gerry G.  Everlof" /></meta><meta name="dc.Creator" content="Paul I.  Stetsko" /></meta><meta name="dc.Creator" content="Olafur  Gudmundsson" /></meta><meta name="dc.Creator" content="Susan  Johnghar" /></meta><meta name="dc.Creator" content="Asoka  Ranasinghe" /></meta><meta name="dc.Creator" content="Kamelia  Behnia" /></meta><meta name="dc.Creator" content="Mary Ann  Pelleymounter" /></meta><meta name="dc.Creator" content="William R.  Ewing" /></meta><meta name="dc.Description" content="Several strategies have been employed to reduce the long in vivo half-life of our lead CB1 antagonist, triazolopyridazinone 3, to differentiate the pharmacokinetic profile versus the lead clinical ..." /></meta><meta name="Description" content="Several strategies have been employed to reduce the long in vivo half-life of our lead CB1 antagonist, triazolopyridazinone 3, to differentiate the pharmacokinetic profile versus the lead clinical ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="November 20, 2013" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm4010835" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Â© 2013 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm4010835" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm4010835" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm4010835" /></link>
        
    
    

<title>Reductions in log P Improved Protein Binding and Clearance Predictions Enabling the Prospective Design of Cannabinoid Receptor (CB1) Antagonists with Desired Pharmacokinetic Properties | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm4010835" /></meta><meta property="og:title" content="Reductions in log P Improved Protein Binding and Clearance Predictions Enabling the Prospective Design of Cannabinoid Receptor (CB1) Antagonists with Desired Pharmacokinetic Properties" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/large/jm-2013-010835_0019.jpeg" /></meta><meta property="og:description" content="Several strategies have been employed to reduce the long in vivo half-life of our lead CB1 antagonist, triazolopyridazinone 3, to differentiate the pharmacokinetic profile versus the lead clinical compounds. An in vitro and in vivo clearance data set revealed a lack of correlation; however, when compounds with &lt;5% free fraction were excluded, a more predictable correlation was observed. Compounds with log P between 3 and 4 were likely to have significant free fraction, so we designed compounds in this range to give more predictable clearance values. This strategy produced compounds with desirable in vivo half-lives, ultimately leading to the discovery of compound 46. The progression of compound 46 was halted due to the contemporaneous marketing and clinical withdrawal of other centrally acting CB1 antagonists; however, the design strategy successfully delivered a potent CB1 antagonist with the desired pharmacokinetic properties and a clean off-target profile." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm4010835"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm4010835">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm4010835&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm4010835&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm4010835&amp;href=/doi/10.1021/jm4010835" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2013</span><span class="cit-fg-volume">, 56</span><span class="cit-fg-issue">, 23</span><span class="cit-fg-pageRange">, 9586-9600</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/56/23" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm401049v" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm4016312" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Reductions in log P Improved Protein Binding and Clearance Predictions Enabling the Prospective Design of Cannabinoid Receptor (CB1) Antagonists with Desired Pharmacokinetic Properties</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Bruce+A.++Ellsworth">Bruce A. Ellsworth</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Philip+M.++Sher">Philip M. Sher</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ximao++Wu">Ximao Wu</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gang++Wu">Gang Wu</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Richard+B.++Sulsky">Richard B. Sulsky</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Zhengxiang++Gu">Zhengxiang Gu</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Natesan++Murugesan">Natesan Murugesan</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yeheng++Zhu">Yeheng Zhu</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Guixue++Yu">Guixue Yu</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Doree+F.++Sitkoff">Doree F. Sitkoff</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kenneth+E.++Carlson">Kenneth E. Carlson</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Liya++Kang">Liya Kang</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yifan++Yang">Yifan Yang</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ning++Lee">Ning Lee</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Rose+A.++Baska">Rose A. Baska</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=William+J.++Keim">William J. Keim</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mary+Jane++Cullen">Mary Jane Cullen</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Anthony+V.++Azzara">Anthony V. Azzara</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Eva++Zuvich">Eva Zuvich</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael+A.++Thomas">Michael A. Thomas</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kenneth+W.++Rohrbach">Kenneth W. Rohrbach</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=James+J.++Devenny">James J. Devenny</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Helen+E.++Godonis">Helen E. Godonis</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Susan+J.++Harvey">Susan J. Harvey</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Brian+J.++Murphy">Brian J. Murphy</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gerry+G.++Everlof">Gerry G. Everlof</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Paul+I.++Stetsko">Paul I. Stetsko</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Olafur++Gudmundsson">Olafur Gudmundsson</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Susan++Johnghar">Susan Johnghar</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Asoka++Ranasinghe">Asoka Ranasinghe</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kamelia++Behnia">Kamelia Behnia</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mary+Ann++Pelleymounter">Mary Ann Pelleymounter</a></span></span></li><span class="comma-separator">,Â andÂ </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=William+R.++Ewing">William R. Ewing</a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">Research and Development, Bristol-Myers Squibb, Co., P.O. Box 5400, Princeton, New Jersey 08543-5400, United States</span></div><div class="corresp-info"><strong>*</strong>Phone: +1-609-818-4965. Fax: +1-609-818-3550. E-mail: <a href="/cdn-cgi/l/email-protection#2b69595e484e056e4747585c44595f436b69667805484446"><span class="__cf_email__" data-cfemail="5210202731377c173e3e21253d20263a12101f017c313d3f">[emailÂ protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm4010835&amp;href=/doi/10.1021%2Fjm4010835" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2013</span></span><span class="cit-volume">, 56</span><span class="cit-issue">, 23</span><span class="cit-pageRange">, 9586â9600</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 4, 2013</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>17 July 2013</li><li><span class="item_label"><b>Published</b> online</span>20 November 2013</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 12 December 2013</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm4010835" title="DOI URL">https://doi.org/10.1021/jm4010835</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2013 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D9586%26pageCount%3D15%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DBruce%2BA.%2BEllsworth%252C%2BPhilip%2BM.%2BSher%252C%2BXimao%2BWu%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D56%26issueNum%3D23%26contentID%3Djm4010835%26title%3DReductions%2Bin%2Blog%2BP%2BImproved%2BProtein%2BBinding%2Band%2BClearance%2BPredictions%2BEnabling%2Bthe%2BProspective%2BDesign%2Bof%2BCannabinoid%2BReceptor%2B%2528CB1%2529%2BAntagonists%2Bwith%2BDesired%2BPharmacokinetic%2BProperties%26numPages%3D15%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D9600%26publicationDate%3DDecember%2B2013">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm4010835"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1384</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">7</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm4010835" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Reductions in log P Improved Protein Binding and Clearance Predictions Enabling the Prospective Design of Cannabinoid Receptor (CB1) Antagonists with Desired Pharmacokinetic Properties&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Bruce&quot;,&quot;last_name&quot;:&quot;A. Ellsworth&quot;},{&quot;first_name&quot;:&quot;Philip&quot;,&quot;last_name&quot;:&quot;M. Sher&quot;},{&quot;first_name&quot;:&quot;Ximao&quot;,&quot;last_name&quot;:&quot;Wu&quot;},{&quot;first_name&quot;:&quot;Gang&quot;,&quot;last_name&quot;:&quot;Wu&quot;},{&quot;first_name&quot;:&quot;Richard&quot;,&quot;last_name&quot;:&quot;B. Sulsky&quot;},{&quot;first_name&quot;:&quot;Zhengxiang&quot;,&quot;last_name&quot;:&quot;Gu&quot;},{&quot;first_name&quot;:&quot;Natesan&quot;,&quot;last_name&quot;:&quot;Murugesan&quot;},{&quot;first_name&quot;:&quot;Yeheng&quot;,&quot;last_name&quot;:&quot;Zhu&quot;},{&quot;first_name&quot;:&quot;Guixue&quot;,&quot;last_name&quot;:&quot;Yu&quot;},{&quot;first_name&quot;:&quot;Doree&quot;,&quot;last_name&quot;:&quot;F. Sitkoff&quot;},{&quot;first_name&quot;:&quot;Kenneth&quot;,&quot;last_name&quot;:&quot;E. Carlson&quot;},{&quot;first_name&quot;:&quot;Liya&quot;,&quot;last_name&quot;:&quot;Kang&quot;},{&quot;first_name&quot;:&quot;Yifan&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Ning&quot;,&quot;last_name&quot;:&quot;Lee&quot;},{&quot;first_name&quot;:&quot;Rose&quot;,&quot;last_name&quot;:&quot;A. Baska&quot;},{&quot;first_name&quot;:&quot;William&quot;,&quot;last_name&quot;:&quot;J. Keim&quot;},{&quot;first_name&quot;:&quot;Mary&quot;,&quot;last_name&quot;:&quot;Jane Cullen&quot;},{&quot;first_name&quot;:&quot;Anthony&quot;,&quot;last_name&quot;:&quot;V. Azzara&quot;},{&quot;first_name&quot;:&quot;Eva&quot;,&quot;last_name&quot;:&quot;Zuvich&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;A. Thomas&quot;},{&quot;first_name&quot;:&quot;Kenneth&quot;,&quot;last_name&quot;:&quot;W. Rohrbach&quot;},{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;J. Devenny&quot;},{&quot;first_name&quot;:&quot;Helen&quot;,&quot;last_name&quot;:&quot;E. Godonis&quot;},{&quot;first_name&quot;:&quot;Susan&quot;,&quot;last_name&quot;:&quot;J. Harvey&quot;},{&quot;first_name&quot;:&quot;Brian&quot;,&quot;last_name&quot;:&quot;J. Murphy&quot;},{&quot;first_name&quot;:&quot;Gerry&quot;,&quot;last_name&quot;:&quot;G. Everlof&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;I. Stetsko&quot;},{&quot;first_name&quot;:&quot;Olafur&quot;,&quot;last_name&quot;:&quot;Gudmundsson&quot;},{&quot;first_name&quot;:&quot;Susan&quot;,&quot;last_name&quot;:&quot;Johnghar&quot;},{&quot;first_name&quot;:&quot;Asoka&quot;,&quot;last_name&quot;:&quot;Ranasinghe&quot;},{&quot;first_name&quot;:&quot;Kamelia&quot;,&quot;last_name&quot;:&quot;Behnia&quot;},{&quot;first_name&quot;:&quot;Mary&quot;,&quot;last_name&quot;:&quot;Ann Pelleymounter&quot;},{&quot;first_name&quot;:&quot;William&quot;,&quot;last_name&quot;:&quot;R. Ewing&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2013&quot;,&quot;month&quot;:&quot;11&quot;,&quot;day&quot;:&quot;20&quot;,&quot;issue&quot;:&quot;23&quot;,&quot;volume&quot;:&quot;56&quot;,&quot;pages&quot;:&quot;9586-9600&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm4010835&quot;},&quot;abstract&quot;:&quot;Several strategies have been employed to reduce the long in vivo half-life of our lead CB1 antagonist, triazolopyridazinone 3, to differentiate the pharmacokinetic profile versus the lead clinical compounds. An in vitro and in vivo clearance data set revealed a lack of correlation; however, when compounds with &lt;5% free fraction were excluded, a more predictable correlation was observed. Compounds with log P between 3 and 4 were likely to have significant free fraction, so we designed compounds in this range to give more predictable clearance values. This strategy produced compounds with desirable in vivo half-lives, ultimately leading to the discovery of compound 46. The progression of compound 46 was halted due to the contemporaneous marketing and clinical withdrawal of other centrally acting CB1 antagonists; however, the design strategy successfully delivered a potent CB1 antagonist with the desired pharmacokinetic properties and a clean off-target profile.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm4010835&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm4010835" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm4010835&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm4010835" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm4010835&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm4010835" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm4010835&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm4010835&amp;href=/doi/10.1021/jm4010835" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm4010835" /></input><a href="/doi/pdf/10.1021/jm4010835" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (1 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm4010835&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm4010835%26sid%3Dliteratum%253Aachs%26pmid%3D24182233%26genre%3Darticle%26aulast%3DEllsworth%26date%3D2013%26atitle%3DReductions%2Bin%2Blog%2BP%2BImproved%2BProtein%2BBinding%2Band%2BClearance%2BPredictions%2BEnabling%2Bthe%2BProspective%2BDesign%2Bof%2BCannabinoid%2BReceptor%2B%2528CB1%2529%2BAntagonists%2Bwith%2BDesired%2BPharmacokinetic%2BProperties%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D56%26issue%3D23%26spage%3D9586%26epage%3D9600%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">Â»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290851" title="Half-life">Half-life</a>,</li><li><a href="/action/doSearch?ConceptID=291171" title="Antagonists">Antagonists</a>,</li><li><a href="/action/doSearch?ConceptID=292588" title="Partition coefficient">Partition coefficient</a>,</li><li><a href="/action/doSearch?ConceptID=290676" title="Substituents">Substituents</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/56/23" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jmcmar.2013.56.issue-23/production/jmcmar.2013.56.issue-23.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_null" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/medium/jm-2013-010835_0019.gif" alt="" id="_i1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/large/jm-2013-010835_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4010835&amp;id=f_null"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Several strategies have been employed to reduce the long in vivo half-life of our lead CB1 antagonist, triazolopyridazinone <b>3</b>, to differentiate the pharmacokinetic profile versus the lead clinical compounds. An in vitro and in vivo clearance data set revealed a lack of correlation; however, when compounds with <5% free fraction were excluded, a more predictable correlation was observed. Compounds with log P between 3 and 4 were likely to have significant free fraction, so we designed compounds in this range to give more predictable clearance values. This strategy produced compounds with desirable in vivo half-lives, ultimately leading to the discovery of compound <b>46</b>. The progression of compound <b>46</b> was halted due to the contemporaneous marketing and clinical withdrawal of other centrally acting CB1 antagonists; however, the design strategy successfully delivered a potent CB1 antagonist with the desired pharmacokinetic properties and a clean off-target profile.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62371" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62371" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The cannabinoid receptor 1 (CB1) is a G-protein-coupled receptor (GPCR) with high expression in the central nervous system (CNS) that promotes feeding when activated by endogenous cannabinoid agonists such as anandamide and 2-AG.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> The CB1 receptor antagonist, rimonabant (SR141716), which had been marketed in Europe as Acomplia for the treatment of obesity, binds to the human CB1 receptor with nanomolar affinity and blocks signaling of the receptor.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> In the RIO clinical trials in North America and Europe, 20 mg qd of rimonabant was shown to reduce body weight of obese subjects by â¼4.7% over placebo during the first year of treatment. This weight loss was then maintained over the second year of treatment.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Rimonabant was withdrawn by Sanofi SA from consideration for regulatory approval by the FDA in the U.S., and its marketing was voluntarily suspended in Europe. The European Commision later withdrew marketing authorization due to psychiatric side effects.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a></div><div class="NLM_p">The structures of CB1 antagonists have been reviewed;<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> however, there are only a few reports that describe efforts to affect in vivo clearance of CB1 antagonists via changes in log P. Letourneau et al. have described their efforts to reduce metabolism within their chemical series via reduction in log P from 5.6 to 4.6, resulting in an improved microsomal stability.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Griffith et al. reported the discovery of otenabant via reductions in log P relative to rimonabant (<i>e</i> log D = 4.0 vs 5.8) that led to greater microsomal stability and low metabolic clearance.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> While those efforts to reduce log P were employed to <i>increase</i> half-life, we wished to <i>reduce</i> the long in vivo half-life of our lead CB1 antagonist <b>3</b> in an attempt to provide a differentiated pharmacokinetic (PK) profile versus other CB1 antagonists.</div><div class="NLM_p last">The most clinically advanced CB1 antagonists, rimonabant, taranabant, and otenabant, exhibit long elimination half-lifes (<i>T</i><sub>1/2</sub> of 9â15 days, 3â4 days, and 5â8 days, respectively)<a onclick="showRef(event, 'ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref8 ref9 ref10">(8-10)</a> in humans. Compounds with long elimination half-lives may add significant time and expense to early clinical trials, and there may be significant delay in drug withdrawal for patients experiencing adverse events.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Drug accumulation to steady-state and drug washout studies typically require 4 times <i>T</i><sub>1/2</sub>,<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> as demonstrated by the reported 13 days required for taranabant to reach steady state and 28 day monitoring of drug elimination for otenabant in human PK studies.<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9, 10)</a> Whereas a single-dose PK assessment can be made for compound with a 12 h half-life with 4 days of monitoring, it may take as much as 120 days of monitoring for each dose level of a compound with 15 day half-life. Furthermore, there is a significant delay in drug clearance in the event of an adverse event.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> For example, diazepam (washout half-life of 79 h) exhibited fatigue and sedation side effects 2 weeks after drug withdrawal while oxazepam (washout half-life of 10.7 h) side effects subsided rapidly after drug withdrawal.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> By developing a CB1 receptor antagonist with a shortened elimination half-life, it was hoped that our early clinical program would move quickly and that rapid drug washout would improve safety in the case of reversible adverse events. To accomplish this goal, herein we describe efforts to discover potent and selective CB1 antagonists with predictable half-life using medicinal chemistry principles that may be applicable beyond the field of CB1. These strategies may be useful when applied to other lipophilic receptor ligands that have high MW or log P, leading to long in vivo half-life.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77464" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77464" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Our lead series of CB1 antagonists originated from high-throughput screening (HTS) hits and evolved through a series of pyrazine carboxamides (<b>1</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>) as reported previously.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> To lower log P and improve physicochemical properties<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> (e.g., aqueous solubility), we explored alternative cores, resulting in the discovery of the triazolopyridazine (TZP) series.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> An effort to replace two chlorophenyl substituents and the benzyl group of compound <b>2</b> revealed that pyridine groups in compound <b>3</b> conferred the desired solubility and log P improvement while maintaining good human CB1 receptor (<i>h</i>CB1) binding affinity. Compound <b>3</b> was found to have a long half-life in all species tested (<i>T</i><sub>1/2</sub> = 15, 108, and 26 h in rat, dog, and monkey, respectively),<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> so the medicinal chemistry effort focused on an attempt to maintain the compoundâs positive characteristics while decreasing in vivo half-life.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/medium/jm-2013-010835_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/large/jm-2013-010835_0002.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Evolution of the triazolopyridazine series of CB1 receptor antagonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/large/jm-2013-010835_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4010835&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In an effort to introduce a methyl group as a metabolic soft spot, methyl magnesium bromide was found to add to the 6-position of the TZP ring which, upon rearomatization by air or DDQ, led to the formal replacement of methyl for hydrogen at the C6-position (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>).<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Unfortunately, an alkyl substituent at this position significantly decreased in vitro affinity (compound <b>4</b> vs <b>3</b>, Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). In contrast, a methoxy group at this position (compound <b>5</b>, Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>) was equipotent in vitro to compound <b>3</b>. Compound <b>7</b>, an <i>O</i>- to <i>N</i>-methyl isomer of <b>5</b>, was also a potent CB1 antagonist. These compounds, however, did not yield desired improvements of in vivo efficacy or half-life in rats vs compound <b>3</b>.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/medium/jm-2013-010835_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/large/jm-2013-010835_0008.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Methyl Grignard Addition to Triazolopyridazinone <b>3</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/large/jm-2013-010835_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4010835&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Pharmaceutical Properties of Pyridazinone Core Substitutions</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/medium/jm-2013-010835_0011.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/medium/jm-2013-010835_0012.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">The term â<i>e</i> log Pâ refers to experimentally measured log P.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a></p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">MED represents the minimally efficacious dose that produces statistically significant food reduction in nonfasted rats feeding ad libidum over a 20 h period.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></p></div><div class="footnote" id="t1fn3"><sup>Table c</sup><p class="last">Terminal half-life (<i>T</i><sub>1/2</sub>) and clearance [Cl] were measured in SpragueâDawley rats upon iv administration of 3 mg/kg of test compound.</p></div><div class="footnote" id="t1fn4"><sup>Table d</sup><p class="last">Log P was not measured for this compound; calculated log P of compound <b>8</b> is 4.6.</p></div></div><div></div></div><div class="NLM_p">We found that the N5-position (X = N) could tolerate significantly larger substituents than the simple methyl group as found in compound <b>7</b>. For example, compound <b>8</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>) provided encouragement that there may be a new binding pocket that could be exploited. Having extensively searched for polar moieties to replace the N2-lipophilic CF<sub>3</sub>-benzyl group of compound <b>2</b> with limited success,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> we hoped we could exploit this new pocket to introduce a polar substituent at N5. We started this exploration with two central tenets: (1) the C8-pyridine moiety of compound <b>3</b> had brought several favorable traits, including polarity, so we wished to incorporate a pyridine or a suitable substitute and (2) we chose to minimize the substituent in the N2-pharmacophoric space because large hydrophobic moieties counteracted the benefits of the polar C8-pyridine moiety. Transposition of the C8 pyridine and the C7 chlorophenyl groups, a product that was synthesized as the result of a nonregioselective route, led to greater affinity for compound <b>11</b> as compared to compound <b>10</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>).</div><figure id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/medium/jm-2013-010835_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/large/jm-2013-010835_0003.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. SAR of 4-pyridine positional isomers.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/large/jm-2013-010835_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4010835&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As we explored the SAR of the N5-benzyl substituent in this transposed series, we found similar activity trends to that exhibited by the N2-benzyl compounds in the original series, suggesting that the two isomeric structures may be occupying the same binding pockets in the CB1 receptor, as depicted in Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>. As further support for this hypothesis, mutagenesis studies reveal that compound <b>11</b> and compound <b>3</b> lose 20â40-fold binding affinity against mutant F200A while the affinity is recovered in mutant F200L, suggesting similar interactions with the CB1 receptor.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> While that observation argued against the likelihood of finding more potent polar substituents at N5 of compound <b>12</b>, it was immediately recognized that the properties of the transposed triazolopyridazin-diones (TZP-diones) were favorable despite bearing the same substituents. With some sacrifice of in vitro affinity, we found significant improvement in crystalline aqueous solubility (40 vs 1 Î¼g/mL for <b>12</b> and <b>7</b>, respectively) as well as desired reductions of in vivo half-life in rats (6 vs 35 h for <b>12</b> and <b>7</b>, respectively).</div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/medium/jm-2013-010835_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/large/jm-2013-010835_0004.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Comparison of proposed binding modes and of <i>h</i>CB1 <i>K</i><sub>i</sub> values for <i>N</i>-2-CF<sub>3</sub>-pyridyl- vs <i>N</i>-5-CF<sub>3</sub>-pyridyl-triazolopyridazinediones <b>7</b> and <b>12</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/large/jm-2013-010835_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4010835&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Capitalizing upon the SAR of the earlier TZP series, incorporation of a 6-methyl-2-trifluoromethylpyrid-3-yl side chain increased affinity by â¼2â3-fold (compound <b>13</b>) and a slightly larger N2-alkyl substituent (compound <b>15</b>) further improved CB1 binding affinity (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). Compound <b>15</b> was efficacious in reducing food intake by 43% acutely,<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> and in a 4-day study<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> it reduced body weight by 4% when administered qd at 10 mg/kg to ad libidum fed rats (resulting in plasma concentrations of 4 Î¼M at <i>C</i><sub>max</sub> and AUC<sub>0â24</sub> = 48 Î¼M h). In the same study, rimonabant gave 5% body weight reduction when administered at 10 mg/kg qd. Several liabilities had been resolved at this point: compound <b>15</b> displayed good in vitro affinity and in vivo efficacy while maintaining relatively low log P and shortened in vivo half-life relative to compound <b>3</b>.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. SAR of Pyridyl-Containing TZP-diones</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/medium/jm-2013-010835_0013.gif" alt="" id="fx3" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="center" /></col><col align="char" char="." /></col><col align="center" /></col><col align="center" /></col><col align="char" char="=" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center"><i>h</i>CB1 <i>K</i><sub>i</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char=".">SD (nM)</th><th class="colsep0 rowsep0" align="center">MED in rats @Â 8Â h<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a> (%Â redn)</th><th class="colsep0 rowsep0" align="center">rat <i>T</i><sub>1/2</sub> [Cl] (mL/min/kg)</th><th class="colsep0 rowsep0" align="center" char="=">CYP isoform IC<sub>50</sub> (Î¼M)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">R<sub>1</sub> = H</td><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="center">28</td><td class="colsep0 rowsep0" align="char" char=".">9.3</td><td class="colsep0 rowsep0" align="center">3 mg/kg</td><td class="colsep0 rowsep0" align="center">6Â h</td><td class="colsep0 rowsep0" align="char" char="=">2C19Â =Â 4.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">R<sub>2</sub>Â =Â Me</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="center">(21%)</td><td class="colsep0 rowsep0" align="center">[13]</td><td class="colsep0 rowsep0" align="char" char="=">2C9 = 1.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="char" char="=">3A4 = 6.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="7" align="left">âââ</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">R<sub>1</sub> = Me</td><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="center">9.0</td><td class="colsep0 rowsep0" align="char" char=".">4.3</td><td class="colsep0 rowsep0" align="center">3 mg/kg</td><td class="colsep0 rowsep0" align="center">3.3Â h</td><td class="colsep0 rowsep0" align="char" char="=">2C19Â =Â 0.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">R<sub>2</sub> = Me</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="center">(33%)</td><td class="colsep0 rowsep0" align="center">[6.3]</td><td class="colsep0 rowsep0" align="char" char="=">2C9 = 2.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="char" char="=">3A4 = 6.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="7" align="left">âââ</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">R<sub>1</sub> = H</td><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="center">15</td><td class="colsep0 rowsep0" align="char" char=".">6.9</td><td class="colsep0 rowsep0" align="center">n.d.</td><td class="colsep0 rowsep0" align="center">2.4Â h</td><td class="colsep0 rowsep0" align="char" char="=">2C19 = 11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">R<sub>2</sub> = Et</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center">[37]</td><td class="colsep0 rowsep0" align="char" char="=">2C9 = 4.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="char" char="=">3A4 = 18</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="7" align="left">âââ</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">R<sub>1</sub>Â =Â Me</td><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="center">4.5</td><td class="colsep0 rowsep0" align="char" char=".">1.5</td><td class="colsep0 rowsep0" align="center">10 mg/kg</td><td class="colsep0 rowsep0" align="center">5Â h</td><td class="colsep0 rowsep0" align="char" char="=">2C19 = 2.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">R<sub>2</sub> = Et</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="center">(51%)</td><td class="colsep0 rowsep0" align="center">[9.9]</td><td class="colsep0 rowsep0" align="char" char="=">2C9 = 4.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="char" char="=">3A4Â =Â 9.1<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">Due to shorter in vivo half-life, MED was determined at 8 h instead of 20 h.</p></div><div class="footnote" id="t2fn2"><sup>b</sup><p class="last">Materials and methods for CYP inhibition assays are found in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>.</p></div><div class="footnote" id="t2fn3"><sup>c</sup><p class="last">CYP 3A4 inhibition study in human liver microsomes. Upon re-evaluation in hepatocytes, compound <b>15</b> CYP 3A4 IC<sub>50</sub> = 3 Î¼M.</p></div></div></div><div class="NLM_p">Compound <b>15</b> was synthesized according to the sequence depicted in Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>. Commercially available 4-pyridylacetic acid was <i>O</i>-alkylated with bromide <b>17</b>, followed by cyclization to butenolide <b>18</b>. Base-catalyzed air oxidation generated anhydride <b>19</b> and reaction with hydrazine gave pyridazin-dione <b>20</b>. Dehydrative chlorination of <b>20</b> was achieved with POCl<sub>3</sub> to give pyridazine dichloride <b>9</b>. Displacement of dichloride <b>9</b> was effected with NaOH, resulting in a separable mixture of regioisomers. Alkylation of <b>21a</b> with 3-(chloromethyl)-2-methyl-6-(trifluoromethyl)pyridine gave chloride <b>23</b>. The triazolo-ring was formed via chloride displacement with hydrazine and cyclization with 1,1â²-carbonyldiimidazole to give bicyclic intermediate <b>24</b>. Alkylation with ethyl iodide completes the 9-step linear sequence, enabling the synthesis of several grams of compound <b>15</b> for advanced efficacy and safety studies.</div><figure id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/medium/jm-2013-010835_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/large/jm-2013-010835_0009.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compound <b>15<sup>a</sup></b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/large/jm-2013-010835_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4010835&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions: (a) KOtBu, DMF, 88%; (b) air, KOtBu, THF; (c) hydrazine hydrate, EtOH, HCl, 32% (2 steps); (d) POCl<sub>3</sub>, 85 Â°C, 72%; (e) NaOH, CH<sub>3</sub>CN, 75%; (f) K<sub>2</sub>CO<sub>3</sub>, DMF, 66%; (g) hydrazine (anhyd) pyridine; (h) 1,1â²-carbonyldiimidazole, THF, 73% (2 steps); (i) EtI, K<sub>2</sub>CO<sub>3</sub>, DMF, 67%.</p></p></figure><div class="NLM_p">Several liabilities were discovered during the preclinical in vitro and in vivo characterization of compound <b>15</b>. CYP inhibition was a concern because efficacy in humans was predicted to require micromolar plasma exposures of <b>15</b>. In higher species PK studies, compound <b>15</b> was also shown to have variable (15â50%) bioavailability and medium to high clearance.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Allometric scaling led to a predicted high clearance (39 mL/min/kg) in humans. While the goal of this program was to deliver a compound with shortened half-life (relative to compound <b>3</b>), compound <b>15</b> was predicted to overshoot this goal.</div><div class="NLM_p">Confident that a sufficiently short half-life was possible, we set out to identify a compound with appropriate half-life and bioavailability for predicted qd administration in humans while eliminating the CYP inhibition liability observed for compound <b>15</b>. We discovered SAR (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>), suggesting that the 4-pyridyl group of compound <b>15</b> was associated with CYP inhibition, but a 4-cyanophenyl derivative (<b>28</b>) displayed increased in vitro affinity as well as reduced CYP inhibition. However, substitution of a 4-cyanophenyl for a 4-pyridyl group at C7 ran counter to the program goals of decreased log P (4.6 vs 3.9) and increased solubility,<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> and this compound also displayed unacceptably long elimination half-lives in dogs (70 h) and cynomologous monkeys (40 h).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. CB1 and CYP Isoform SAR of C7-Aryl-triazolopyridazinediones</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/medium/jm-2013-010835_0014.gif" alt="" id="fx4" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Ar</th><th class="colsep0 rowsep0" align="center">R<sub>1</sub></th><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char="."><i>h</i>CB1 <i>K</i><sub>i</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char=".">SD (nM)</th><th class="colsep0 rowsep0" align="center" char="."><i>e</i>Â logÂ P</th><th class="colsep0 rowsep0" align="center">CYP isoform IC<sub>50</sub> (Î¼M)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">4-pyridyl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">6.9</td><td class="colsep0 rowsep0" align="char" char=".">4.0</td><td class="colsep0 rowsep0" align="center">2C19 = 11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="center">2C9 = 5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="center">3A4 = 18</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">4-pyridyl</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="char" char=".">4.5</td><td class="colsep0 rowsep0" align="char" char=".">1.5</td><td class="colsep0 rowsep0" align="char" char=".">3.9</td><td class="colsep0 rowsep0" align="center">2C19 = 3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="center">2C9 = 6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="center">3A4 = 3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3-methyl-4-pyridyl</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left"><b>27</b></td><td class="colsep0 rowsep0" align="char" char=".">8.4</td><td class="colsep0 rowsep0" align="char" char=".">3.5</td><td class="colsep0 rowsep0" align="char" char=".">4.2</td><td class="colsep0 rowsep0" align="center">2C19 = 32</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="center">2C9 = 5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="center">3A4 = >40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">4-cyanophenyl</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left"><b>28</b></td><td class="colsep0 rowsep0" align="char" char=".">1.4</td><td class="colsep0 rowsep0" align="char" char=".">0.58</td><td class="colsep0 rowsep0" align="char" char=".">4.6</td><td class="colsep0 rowsep0" align="center">2C19 > 40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="center">2C9 > 40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="center">3A4 > 40</td></tr></tbody></table></div></div><div class="NLM_p">In an attempt to introduce a metabolic soft spot to reduce its in vivo half-life, we incorporated a methyl group at various positions on compound <b>28</b>. Most of the derivatives in Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a> had undesirable levels of <i>h</i>CB2 binding IC<sub>50</sub>s from 77 to 400 nM, making them undesirable for progression, but two compounds within the table (<b>28</b> and <b>32</b>) highlight a disconnection that became apparent (vide infra, Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>A) more broadly for the chemotype: that in vitro metabolic stability determinations did not predict in vivo clearance or half-life, making it difficult to overcome a major program goal without performing an untenable number of in vivo PK studies.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Methyl Scan of Compound <b>28</b> in an Attempt to Introduce a Metabolic Soft-Spot</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/medium/jm-2013-010835_0015.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/medium/jm-2013-010835_0016.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>Table a</sup><p class="last">In vitro rat clearance was determined in rat liver microsomes, as described in the <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>. Rat <i>T</i><sub>1/2</sub> was not determined for compounds <b>29</b>â<b>31</b>, <b>33</b>, and <b>34</b>.</p></div></div><div></div></div><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/medium/jm-2013-010835_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/large/jm-2013-010835_0005.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) In vitro metabolism rate (rat liver microsomes (RLM)) vs rat in vivo Cl (mL/min/kg). (B) Unbound RLM Cl (mL/min/kg) vs rat in vivo Cl (mL/min/kg), filtered to show compounds with â¤95% protein binding.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/large/jm-2013-010835_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4010835&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">On the basis of this observation, we analyzed the entire program data set to develop correlations that could be used to predict compounds with shortened in vivo half-life based on in vitro data. There seemed to be little correlation between clearance in vitro and in vivo, as demonstrated in Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>A. In vitro and in vivo clearance correlations that factor in free fraction have been reported, and they express in vitro clearance as unbound Cl<sub>int</sub>.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> These correlations were developed for compounds with log P < 3 and MW <500,<a onclick="showRef(event, 'ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref26 ref27">(26, 27)</a> but many of our potent CB1 antagonists are outside of these limits.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> To improve our correlation, we factored in free fraction by using unbound Cl instead of Cl and we filtered the data set to only consider compounds with protein binding â¤95%.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> A trend emerged (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>B) between unbound in vitro metabolism and in vivo clearance in rats. In the process of culling compounds based on free fraction, we plotted <i>e</i> log P vs protein binding (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>) and found that compounds in the range of <i>e</i> log P 3â4 have a much higher probability of being â¤95% protein bound than compounds with <i>e</i> log P > 4.5.</div><figure id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/medium/jm-2013-010835_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/large/jm-2013-010835_0006.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Graph of <i>e</i> log P vs rat plasma protein binding.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/large/jm-2013-010835_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4010835&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To test the predictive correlation of our model between in vitro clearance and in vivo clearance and half-life, we mined our compound collection to find a derivative in the desired log P range for which we had not yet measured free fraction or clearance. Compound <b>11</b> has a measured log P = 3 with 5% free fraction in rat plasma. The unbound in vitro metabolism (0.0063 nmol/min/mg) and in vivo clearance values (iv Cl = 7 mL/min/kg) were in line with predictions and gratifyingly exhibited an anticipated half-life of 3.5 h in rat. To verify the efficacy of the PK/affinity profile of <b>11</b> as a CB1 antagonist, compound was administered at 10 mg/kg to rats in an acute feeding model<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> wherein reduced feeding was observed at a similar level to 10 mg/kg of rimonabant, the positive control in the study.</div><div class="NLM_p">Using the above criteria, we prospectively considered two compounds with the <i>e</i> log P range of 3â4. Compound <b>35</b>, with <i>e</i> log P = 4.2, had 1% free fraction in rat plasma and demonstrated a shortened half-life (rat, dog, cyno = nd, 45 h, 8 h) relative to benchmark compound <b>28</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>). Compound <b>36</b>, with <i>e</i> log P = 3.6, had 9% free fraction in rat plasma and it also demonstrated a shortened half-life (rat, dog, cyno = 1.1 h, 7 h, 9 h) relative to <b>28</b>. Unfortunately, both compounds had liabilities that made them unsuitable for advancement. Compound <b>35</b> had poor physicochemical properties, making it difficult to formulate and administer to rats. Compound <b>36</b> displayed weak efficacy in the 20 h feeding experiment due to a combination of its short half-life and low plasma and brain exposure over the course of the in vivo experiment. There are many factors beyond clearance that affect in vivo half-life, but these results provided encouragement that compounds with log P between 3 to 4 could meet the goal of higher free fraction that would bring the possibility of predictable half-life in preclinical species.</div><figure id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/medium/jm-2013-010835_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/large/jm-2013-010835_0007.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Potent CB1 antagonists (<i>h</i>CB1 <i>K</i><sub>i</sub> = 5 nM for both <b>35</b> and <b>36</b>) with lowered log P and shortened half-life relative to compound <b>28</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/large/jm-2013-010835_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4010835&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">With the N2 and N5-substituents of the TZP-dione extensively explored, due in part to their late introduction in the synthesis (steps 5 and 9, Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>), the C7-position remained underexplored despite the experience that polar moieties such as the C7-pyridyl group of compound <b>15</b> were tolerated by the CB1 receptor. The synthetic sequence required commitment to the C7 and C8-aryl groups in the first step of the 9-step synthetic sequence (Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>); however, a revised synthesis was developed for late C7 and C8-aryl group introduction, as depicted in Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>, to facilitate the exploration of these substituents.</div><figure id="sch3" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/medium/jm-2013-010835_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/large/jm-2013-010835_0010.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Revised Synthesis of TZP-diones to Enable Late Introduction of C7 and C8-Substituents<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/large/jm-2013-010835_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4010835&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) Br<sub>2</sub>, LiOH, MeOH; (b) <b>22</b>, K<sub>2</sub>CO<sub>3</sub>, DMF, 80% (2 steps); (c) NaOMe, dioxane, 72%; (d) Pd(dppf)Cl<sub>2</sub>, BocNHNH<sub>2</sub>, Cs<sub>2</sub>CO<sub>3</sub>, toluene, 78%; (e) 4-ClPhB(OH)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub>, toluene, 92%; (f) HCl, dioxane; (g) 1,1â²-carbonyldiimidazole, THF, 70% (2 steps); (h) EtI, K<sub>2</sub>CO<sub>3</sub>, DMF, 84%; (i) BBr<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>; (j) Tf<sub>2</sub>O, TEA, CH<sub>2</sub>Cl<sub>2</sub>; (k) Pd(dppf)Cl<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, THF, 2-methylpyrimidinyl-5-boronic acid, 14% (3 steps).</p></p></figure><div class="NLM_p">Dichloropyridazin-one <b>37</b> was brominated under basic conditions, followed by selective N-alkylation with <b>22</b>, to give pyridazinone <b>39</b>. Chlorine displacement with sodium methoxide led to a single regioisomer, <b>40</b>. Palladium-catalyzed N-arylation of Boc-hydrazine gave chloride <b>41</b> that underwent Suzuki coupling to introduce the C-8 substituent at an intermediate stage in the synthesis. Deprotection of <b>42</b> and cyclization with 1,1â²-carbonyldiimidazole led to triazolopyridazin-dione <b>43</b>. Alkylation of the triazolo-nitrogen with ethyl iodide gave protected triazolopyridazin-dione <b>44</b>. Demethylation of the methoxy-group with BBr<sub>3</sub> followed by triflation gave intermediate <b>45</b>, enabling introduction of the C7-group in the final step via Suzuki coupling to give <b>46</b>.</div><div class="NLM_p">This revised synthesis enabled a more rapid exploration of the C-7 substituent, targeting compounds with log P in the range that gave a higher likelihood of having higher free fraction. Compound <b>47</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>) exhibited significant CYP inhibition, and compounds <b>48</b> and <b>49</b> exhibited reduced <i>h</i>CB1 affinity; however, methylpyrimidine <b>46</b> was found to be a potent and selective CB1 antagonist with <i>e</i> log P = 3.8. The compound exhibited reasonable aqueous solubility (17 Î¼g/mL) in crystalline form and excellent DMSO/water solubility to enable an accurate in vitro assessment of off-target activities. Compound <b>46</b> was devoid of CYP inhibition up to 40 Î¼M, meeting another criterion for advancement. The compound demonstrated high (13% and 7%) free fraction respectively in rat and human plasma, in line with the expectation of significant free fraction. Compound <b>46</b> demonstrated low clearance in rat liver microsomes (unbound Cl = 0.0022 nmol/min/mg). However, in vivo clearance was unexpectedly high (43 mL/min/kg), which may have been predicted by its subsequently measured extensive metabolism in rat hepatocytes (5% remaining). Fortunately, this metabolism appeared rat-specific and the compound exhibited the predicted clearance in higher species, leading to a desirable half-life (<i>T</i><sub>1/2</sub> = 5, 42, 12 h) and bioavailabilty (73%, 75%, 51%) in the rat, dog, and cynomologous monkey, respectively.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. CB1 and CYP Isoform SAR of C7-Aryl-triazolopyridazinediones</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/medium/jm-2013-010835_0017.gif" alt="" id="fx7" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/medium/jm-2013-010835_0018.gif" alt="" id="fx8" /></img><div></div></div><div class="NLM_p">Metabolism was the major route of elimination of [<sup>14</sup>C]-labeled compound <b>46</b> when administered orally at 5 mg/kg to bile duct-cannulated rats. Two major oxidative metabolites containing <sup>14</sup>C-label were observed by LC/MS ([M + 2O â 2H] and [M + O + glucuronide], structures undetermined), and these metabolites accounted for 36% and 26% of the dose, respectively. In comparison, excretion of parent was a minor route of elimination (less than 1% of the dose). Within 48 h post dose, 76% and 7% of the radioactivity was recovered in bile and urine, respectively, with 0.8% of parent radioactivity observed in bile and no parent drug in urine. In rats, therefore, the disposition of compound <b>46</b> appears to be primarily mediated by oxidative metabolism, with minimal contribution from direct renal and biliary excretion of the parent compound.</div><div class="NLM_p">The favorable pharmacokinetic properties of <b>46</b>, combined with its potent <i>h</i>CB1 <i>K</i><sub>i</sub>, result in significant reduction in food intake when administered acutely to ad libidum fed rats at 1 mg/kg. Upon multiple day administration at 3 and 10 mg/kg, <b>46</b> caused a statistically significant reduction of body weight over 4 days of 2.8 and 7.2% respectively. Treatment of <b>46</b> in a 28-day study in diet-induced obese rats demonstrated body weight reductions of 2.4, 4.1, and 10.2% when administered po at 1, 3, and 10 mg/kg, respectively.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> In this same study, administration of 10 mg/kg of rimonabant produced a 6.2% body weight reduction.</div><div class="NLM_p last">The safety of compound <b>46</b> was evaluated both in vitro and in vivo. No off-target liabilities were found despite extensive screening against a panel of GPCRs and ion channels; this may be an added benefit of the reduced log P of the compound.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> The potential toxicity profile of <b>46</b> was evaluated when administered orally to dogs for a 12-day period. The results of the toxicological studies will be described elsewhere; however, the effects observed were consistent with known effects of other CB1 receptor antagonists<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> and were not attributed to any off-target liabilities. The findings from the toxicological study, in conjunction with the contemporaneous marketing withdrawal of rimonabant and withdrawals of taranabant and otenabant from clinical development, led to the decision that clinical evaluation of <b>46</b> or other centrally acting compounds in this series would not be pursued.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58151" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58151" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">We report the discovery of a potent, selective CB1 antagonist, compound <b>46</b>, which also demonstrates significantly lower log P as compared to other compounds in its class. The lower log P was a critical element in conferring greater free fraction and allowing better predictive in vivo clearance values based on in vitro microsomal metabolism. The introduction of a metabolic soft spot did not result in compounds with the desired PK profile. A key improvement in the physicochemical properties was achieved when pharmacophoric groups were transposed across an earlier TZP core. A synthetic route was developed that facilitated the introduction of a 2-methyl pyrimidine group that conferred greater polarity to the series while maintaining CB1 antagonist affinity and selectivity. The progression of <b>46</b>, and our entire centrally mediated CB1 antagonism program, was halted due to undesired class-related CB1 effects in vivo. We have described herein the methods that accelerated the discovery of potent CB1 antagonists in this series with lower log P and greater free fraction, resulting in more predictable pharmacokinetics and an improved profile against off-target liabilities.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21241" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21241" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Chemistry</h3><div class="NLM_p last">All anhydrous reactions were carried out using oven-dried glassware under an atmosphere of argon or nitrogen. All reagents and solvents were obtained from commercial vendors and used without further purification unless otherwise indicated. NMR spectra (<sup>1</sup>H, <sup>13</sup>C) were recorded on JEOL JNM-ECP500, JEOL GSX400, and Bruker 400 spectrometers. Chemical shifts were given in parts per million (ppm) downfield from internal reference tetramethylsilane standard; coupling constants (<i>J</i> values) were given in hertz (Hz). Elemental analyses were performed by the Bristol-Myers Squibb Discovery Analytical Science Department. Melting points were taken on a Hoover Unimelt melting point apparatus and were uncorrected. LC/MS data were recorded on a Shimadzu LC-10AT equipped with a SIL-10A injector, a SPD-10AV detector normally operating at 220 nm, and interfaced to a Micromass ZMD mass spectrometer. LC/MS or HPLC retention times were reported using a Phenomenex Luna C-18 4.6 mm Ã 50 mm column eluting with a 4 min gradient of 0â100% solvent B, where solvent A was 10:90:0.1 CH<sub>3</sub>OHâH<sub>2</sub>OâTFA and solvent B was 90:10:0.1 CH<sub>3</sub>OHâH<sub>2</sub>OâTFA. Reactions were monitored by TLC using 0.25 mm E. Merck silica gel plates (60 F254) and were visualized using UV light and 5% phosphomolybdic acid in 95% EtOH. All compounds were found to be >95% pure by HPLC analysis unless otherwise noted.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> 7-(4-Chlorophenyl)-6-methyl-8-(pyridin-4-yl)-2-((6-(trifluoromethyl)pyridin-3-yl)methyl)-[1,2,4]triazolo[4,3-<i>b</i>]pyridazin-3(2<i>H</i>)-one (<b>4</b>)</h3><div class="NLM_p last">To a solution of 100 mg (0.2 mmol) of compound <b>3</b><a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> in 2 mL of THF at â20 Â°C was added 0.2 mL of a 3 M solution of methylmagnesium bromide (0.6 mmol). The mixture was stirred for 30 min, and 2 mL of NH<sub>4</sub>Cl (satd aq) was added to quench the reaction. The solution was diluted with 40 mL each of EtOAc and satd aq NH<sub>4</sub>Cl, and the layers were extracted. The organic layer was dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and evaporated to give 100 mg of a yellow oil. The residue was dissolved in 2 mL of CH<sub>2</sub>Cl<sub>2</sub>, and 47 mg of 2,3-dichloro-5,6-dicyano-<i>p</i>-benzoquinone (DDQ, 0.2 mmol) was added. After 15 min at room temperature, the mixture was stored overnight at â40 Â°C. The crude reaction mixture was loaded onto silica gel for purification to give 18 mg of a yellow oil that was further purified via preparative RP-HPLC to give 12 mg of compound <b>4</b> as a yellow solid (12%). Analytical HPLC (4 min gradient): 2.94 min (97.1% homogeneity index (HI)). HRMS anal. calcd for C<sub>24</sub>H<sub>17</sub>ClF<sub>3</sub>N<sub>6</sub>O [M + H]: 497.1104, found 497.1104. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) Î´ ppm 8.75 (d, <i>J</i> = 1.8 Hz, 1H), 8.49 (dd, <i>J</i> = 1.7, 6.2 Hz, 2H), 8.04 (dd, <i>J</i> = 1.8, 8.2 Hz, 1H), 7.80 (d, <i>J</i> = 8.2 Hz, 1H), 7.40â7.23 (m, 6H), 4.85 (s, 2H), 2.29 (s, 3H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>OD) Î´ ppm 155.26, 150.84, 150.50, 150.17, 141.34, 139.19, 136.87, 136.50, 136.21, 133.87, 133.12, 132.56, 130.04, 126.26, 121.79, 22.14. <sup>19</sup>F NMR (151 MHz, CD<sub>3</sub>OD) Î´ ppm â69.28.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> 7-(4-Chlorophenyl)-6-methoxy-8-(pyridin-4-yl)-2-((5-(trifluoromethyl)pyridin-2-yl)methyl)-[1,2,4]triazolo[4,3-<i>b</i>]pyridazin-3(2<i>H</i>)-one (<b>5</b>)</h3><div class="NLM_p last">To a solution of compound <b>S6</b> (71 mg, 0.14 mmol) in methanol (0.3 mL) was added NaOMe (25 wt % in methanol solution) (0.7 mL, 3.2 mmol). The reaction mixture was heated at 50 Â°C for 20 min, followed by cooling to room temperature and concentration. The residue was diluted with 50 mL each of ethyl acetate and water, and the layers were extracted. The organic layer was separated and dried (Na<sub>2</sub>SO<sub>4</sub>). The dried organic layer was filtered and concentrated under reduced pressure to give 71 mg (100%) of the title compound as a yellow foam. Analytical HPLC (4 min grad): 3.23 min (99.1% HI). LC-MS anal. calcd for C<sub>24</sub>H<sub>16</sub>ClF<sub>3</sub>N<sub>6</sub>O<sub>2</sub>: 512.1, found [M + H] 512.9. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ ppm 8.78 (d, <i>J</i> = 1.6 Hz, 1H), 8.60â8.56 (m, 2H), 7.95 (dd, <i>J</i> = 8.0, 1.9 Hz, 1H), 7.67 (d, <i>J</i> = 8.2 Hz, 1H), 7.38â7.27 (m, 2H), 7.17â7.09 (m, 2H), 7.06â6.98 (m, 2H), 5.28 (s, 2H), 4.04 (s, 3H).</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> 7-(4-Chlorophenyl)-8-(pyridin-4-yl)-2-((5-(trifluoromethyl)pyridin-2-yl)methyl)-[1,2,4]triazolo[4,3-<i>b</i>]pyridazine-3,6(2<i>H</i>,5<i>H</i>)-dione (<b>6</b>)</h3><div class="NLM_p last">To a solution of compound <b>S6</b> (170 mg, 0.33 mmol) in THF (10 mL) was added potassium trimethylsilanol (169 mg, 1.3 mmol). The reaction mixture was heated to reflux at 85 Â°C for 1 h. The mixture was cooled to room temperature, and it was concentrated to a thick oil. The residue was diluted with ethyl acetate, and the resulting solution was extracted with water. The organic layer was dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated under reduced pressure. The residue was purified by reverse phase HPLC to give 29 mg (17%) of compound <b>6</b> as a yellow solid. Analytical HPLC (4 min gradient) retention time = 3.15 min (97.2% HI). LC-MS anal. calcd for C<sub>23</sub>H<sub>14</sub>ClF<sub>3</sub>N<sub>6</sub>O<sub>2</sub>: 498.1, found [M + H] 499.2. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ ppm 12.93â12.85 (m, 1H), 8.71 (s, 1H), 8.58â8.52 (m, 2H), 7.99â7.88 (m, 2H), 7.40â7.34 (m, 2H), 7.32â7.27 (m, 2H), 7.23â7.17 (m, 2H), 5.31 (s, 2H).</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> 7-(4-Chlorophenyl)-5-methyl-8-(pyridin-4-yl)-2-((5-(trifluoromethyl)pyridin-2-yl)methyl)-[1,2,4]triazolo[4,3-<i>b</i>]pyridazine-3,6(2<i>H</i>,5<i>H</i>)-dione (<b>7</b>)</h3><div class="NLM_p last">To a solution of compound <b>6</b> (61 mg, 0.12 mmol) and Li<sub>2</sub>CO<sub>3</sub> (28 mg, 0.38 mmol) in DMF (1 mL) was added iodomethane (2.3 mg, 0.16 mmol), and the mixture was stirred at room temperature for 1 h. The resulting mixture was diluted with ethyl acetate, and the resulting solution was washed with water. The organic layer was dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated under reduced pressure. The residue was purified by reverse phase HPLC to give 29 mg (46%) of compound <b>7</b> as a light-yellow foam. Analytical HPLC (4 min gradient) retention time = 2.71 min (98.6% HI). LC-MS anal. calcd for C<sub>24</sub>H<sub>16</sub>ClF<sub>3</sub>N<sub>6</sub>O<sub>2</sub>: 512.1, found [M + H] 513.0. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ ppm 8.74 (s, 1H), 8.68 (br s, 2H), 7.90 (d, <i>J</i> = 7.7 Hz, 1H), 7.68 (d, <i>J</i> = 7.7 Hz, 1H), 7.39 (br s, 2H), 7.27 (br s, 2H), 7.02 (d, <i>J</i> = 8.2 Hz, 2H), 5.14 (s, 2H), 4.12 (s, 3H).</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> 4,4â²-(7-(4-Chlorophenyl)-3,6-dioxo-8-(pyridin-4-yl)-[1,2,4]triazolo[4,3-<i>b</i>]pyridazine-2,5(3<i>H</i>,6<i>H</i>)-diyl)bis(methylene)dibenzonitrile (<b>8</b>)</h3><div class="NLM_p last">The title compound (3.6 mg, 22.5% yield) was isolated as a yellow solid as a side-product in the synthesis of compound <b>10</b>. Analytical HPLC (4 min gradient) retention time = 3.15 min (90.0% HI). LC-MS anal. calcd for C<sub>32</sub>H<sub>20</sub>ClN<sub>7</sub>O<sub>2</sub>: 569.1, found [M + H] 570.1. <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) Î´ ppm 8.68 (d, <i>J</i> = 6.6 Hz, 2H), 7.69 (m, 8H), 7.45 (d, <i>J</i> = 8.2 Hz, 2H), 7.35â7.27 (m, 2H), 7.23â7.10 (m, 2H), 5.95 (s, 2H), 5.12 (s, 2H).</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> 3,6-Dichloro-4-(4-chlorophenyl)-5-(pyridin-4-yl)pyridazine (<b>9</b>)</h3><div class="NLM_p last">Compound <b>20</b> (4.9 g crude) was dissolved in 30 mL of POCl<sub>3</sub>, and the resultant solution was heated to 85 Â°C for 2 h. The reaction mixture was cooled to room temperature, and the solution was poured over 600 mL of ice. The slurry was agitated for 30 min, and the pH of the resulting solution was carefully adjusted to pH 5 with cooling as needed. The resulting aqueous slurry was diluted with 400 mL of CH<sub>2</sub>Cl<sub>2</sub>, and the layers were extracted. The aqueous layer was re-extracted with 200 mL of CH<sub>2</sub>Cl<sub>2</sub>, and the resulting organic layers were combined, washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and evaporated to give a black oil. The residue was purified via flash chromatography on silica gel that had been pretreated with 2% TEA/hexanes to give 1.7 g of <b>9</b> in 46% yield from 4-pyridylacetic acid. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 8.6 (dd, 2H, <i>J</i> = 1.7, 4.4 Hz), 7.29 (dt, 2H, <i>J</i> = 1.7, 8.3 Hz), 7.02â6.99 (m, 4H).</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> 4-((7-(4-Chlorophenyl)-2-methyl-3,6-dioxo-8-(pyridin-4-yl)-2,3-dihydro-[1,2,4]triazolo[4,3-<i>b</i>]pyridazin-5(6<i>H</i>)-yl)methyl)benzonitrile (<b>10</b>)</h3><div class="NLM_p last">To a solution of compound <b>S4</b> (8.0 mg, 0.023 mmol) in DMF (0.3 mL) was added K<sub>2</sub>CO<sub>3</sub> (5.0 mg, 0.036 mmol), followed by 4-(bromomethyl)benzonitrile (5.0 mg, 0.025 mmol). After 15 min, the reaction mixture was diluted with ethyl acetate, and the resulting solution was washed with water. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure. The crude product was purified by reverse phase HPLC to give 4.2 mg of 4-((7-(4-chlorophenyl)-3,6-dioxo-8-(pyridin-4-yl)-2,3-dihydro-[1,2,4]triazolo[4,3-<i>b</i>]pyridazin-5(6<i>H</i>)-yl)methyl)benzonitrile as a yellow foam. Analytical HPLC (4 min gradient) retention time = 2.70 min (96.0% HI). LC-MS anal. calcd for C<sub>24</sub>H<sub>15</sub>ClN<sub>6</sub>O<sub>2</sub>: 454.1, found [M + H] 455.1. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) Î´ ppm 8.69 (d, <i>J</i> = 6.6 Hz, 2H), 7.84â7.65 (m, 6H), 7.35â7.27 (m, 2H), 7.25â7.07 (m, 2H), 5.95 (s, 2H). A solution of 4-((7-(4-chlorophenyl)-3,6-dioxo-8-(pyridin-4-yl)-2,3-dihydro-[1,2,4]triazolo[4,3-<i>b</i>]pyridazin-5(6<i>H</i>)-yl)methyl)benzonitrile (2 mg, 0.004 mmol), methyl iodide (0.001 mL, 1 mg, 0.006 mmol), and K<sub>2</sub>CO<sub>3</sub> (2.5 mg, 0.02 mmol) in DMF (0.2 mL) was heated at 80 Â°C for 2 h. The mixture was cooled to room temperature, and it was filtered and purified by reverse phase HPLC to give 2 mg (90%) of compound <b>10</b> as a colorless foam. Analytical HPLC (4 min gradient) retention time = 2.78 min (95.0% HI). LC-MS anal. calcd for C<sub>25</sub>H<sub>17</sub>ClN<sub>6</sub>O<sub>2</sub>: 468.1, found [M + H] = 469.1. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ ppm 8.83 (br s, 2H), 7.82â7.64 (m, 4H), 7.61 (d, <i>J</i> = 4.4 Hz, 2H), 7.36â7.29 (m, 2H), 7.07 (d, <i>J</i> = 8.8 Hz, 2H), 5.98 (s, 2H), 3.58 (s, 3H).</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> 4-((8-(4-Chlorophenyl)-2-methyl-3,6-dioxo-7-(pyridin-4-yl)-2,3-dihydro-[1,2,4]triazolo[4,3-<i>b</i>]pyridazin-5(6<i>H</i>)-yl)methyl)benzonitrile (<b>11</b>)</h3><div class="NLM_p last">To solution of compound <b>S3</b> (26 mg, 0.064 mmol) in THF (1 mL) was added potassium trimethylsilanol (25 mg, 0.19 mmol), and the mixture was heated to 85 Â°C for 10 min. The solution was cooled to room temperature, and the pH was adjusted to 7 with 1N HCl. The resulting solution was extracted with ethyl acetate, and the organic layer was extracted with brine. The organic layer was dried (MgSO<sub>4</sub>), filtered, and concentrated to give 26 mg of a yellow solid that was used as is. A solution of the yellow solid (26 mg, 0.051 mmol), 4-(bromomethyl)benzonitrile (11 mg, 0.056 mmol), and K<sub>2</sub>CO<sub>3</sub> (21 mg, 0.15 mmol) in DMF (1 mL) was heated at 80 Â°C for 10 min, and the mixture was cooled to room temperature. The solution was diluted with ethyl acetate, and the organic layer was extracted with water. The organic layer was dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated under reduced pressure. The crude product was purified by reverse phase HPLC, then treated with 1N HCl to give 15 mg (63%) of compound <b>11</b> as yellow solid. Analytical HPLC (4 min gradient) retention time = 2.30 min (98.3% HI). LC-MS anal. calcd for C<sub>25</sub>H<sub>17</sub>ClN<sub>6</sub>O<sub>2</sub>: 468.1, found [M + H] 469.0. <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) Î´ ppm 8.67 (d, <i>J</i> = 6.0 Hz, 2H), 7.81 (d, <i>J</i> = 6.0 Hz, 2H), 7.61 (q, <i>J</i> = 8.2 Hz, 4H), 7.32â7.05 (m, 4H), 5.84 (s, 2H), 3.44 (s, 3H).</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> 8-(4-Chlorophenyl)-2-methyl-7-(pyridin-4-yl)-5-((6-(trifluoromethyl)pyridin-3-yl)methyl)-[1,2,4]triazolo[4,3-<i>b</i>]pyridazine-3,6(2<i>H</i>,5<i>H</i>)-dione (<b>12</b>)</h3><div class="NLM_p last">Compound <b>12</b> was synthesized from compound <b>S5</b> and 2-trifluoromethyl-5-bromomethylpyridine according to the procedure of compound <b>10</b>. Analytical HPLC (4 min gradient) retention time = 2.67 min (99.1% HI). HRMS anal. calcd for C<sub>24</sub>H<sub>17</sub>ClF<sub>3</sub>N<sub>6</sub>O<sub>2</sub> [M + H]: 513.1054, found: 513.1046. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ ppm 8.96 (d, <i>J</i> =  1.7 Hz, 1H), 8.56 (dd, <i>J</i> = 1.7, 16.1 Hz, 2H), 8.14 (dd, 1.7, 8.3 Hz, 1H), 7.69 (d, <i>J</i> = 8.2 Hz, 1H), 7.31â7.27 (m, 2H), 7.15â7.12 (m, 2H), 7.07â7.05 (m, 2H), 6.03 (s, 2H), 3.59 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) Î´ ppm 158.0, 150.9, 149.7, 147.0, 140.4, 138.7, 136.6, 135.9, 134.6, 131.3, 131.2, 129.0, 127.8, 125.2, 120.4, 44.2, 33.7.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> 8-(4-Chlorophenyl)-2-methyl-5-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)methyl)-7-(pyridin-4-yl)-[1,2,4]triazolo[4,3-<i>b</i>]pyridazine-3,6(2<i>H</i>,5<i>H</i>)-dione (<b>13</b>)</h3><div class="NLM_p last">To a solution of compound <b>S2</b> (0.17 g, 0.45 mmol) in 0.5 mL of 1,4-dioxane was added a solution of LiOH (38 mg, 0.9 mmol) in 0.5 mL of water. The mixture was stirred, and Bu<sub>4</sub>NOH (0.03 mL of 40% solution in water, 0.04 mmol) was added. The resulting mixture was heated in a microwave at 150 Â°C for 30 min. The mixture was evaporated to dryness and was used as-is in the next step. To a solution of crude 6-chloro-8-(4-chlorophenyl)-2-methyl-7-(pyridin-4-yl)-[1,2,4]triazolo[4,3-<i>b</i>]pyridazin-3(2<i>H</i>)-one (35 mg, 0.07 mmol) in DMF (0.37 mL) was added compound <b>22</b> (15 mg, 0.07 mL) and K<sub>2</sub>CO<sub>3</sub> (20 mg, 0.15 mmol). The resulting mixture was heated at 65 Â°C for 1 h, and then it was cooled to room temperature. The crude reaction mixture was diluted with MeOH, and it was purified via preparative RP-HPLC to give 16 mg of the O-alkylated regioisomer, 8-(4-chlorophenyl)-2-methyl-6-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)methoxy)-7-(pyridin-4-yl)-[1,2,4]triazolo[4,3-<i>b</i>]pyridazin-3(2<i>H</i>)-one, and 15 mg (38%) of compound <b>13</b> as a yellow solid. Analytical HPLC (4 min gradient) retention time = 2.65 min (100% HI). LCMS anal. calcd for C<sub>25</sub>H<sub>18</sub>ClF<sub>3</sub>N<sub>6</sub>O<sub>2</sub> 526.11, found [M + H] 527.2. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>CN) Î´ 8.45 (dd, 2H, <i>J</i> = 1.8, 4.4 Hz), 7.79 (d, 1H, <i>J</i> = 7.9 Hz), 7.59 (d, 1H, <i>J</i> = 7.9 Hz), 7.34 (dd, 2H, <i>J</i> = 2.6, 8.4), 7.22 (dd, 2H, <i>J</i> = 2.7, 8.3), 7.11 (dd, 2H, <i>J</i> = 1.8, 4.4 Hz), 5.79 (s, 2H), 3.39 (s, 3H), 2.65 (s, 3H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>CN) Î´ 149.6, 136.1, 135.5, 131.9, 128.7, 125.6, 45.1, 33.1, 21.8.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> 8-(4-Chlorophenyl)-2-ethyl-7-(pyridin-4-yl)-5-((6-(trifluoromethyl)pyridin-3-yl)methyl)-[1,2,4]triazolo[4,3-<i>b</i>]pyridazine-3,6(2<i>H</i>,5<i>H</i>)-dione (<b>14</b>)</h3><div class="NLM_p last">A solution of 5-(chloromethyl)-2-(trifluoromethyl)pyridine (32 mg, 0.16 mmol) and NaI (27 mg, 0.18 mmol) in DMF (0.5 mL) was stirred at 50 Â°C for 20 min. The mixture was transferred into a solution of 8-(4-chlorophenyl)-2-ethyl-7-(pyridin-4-yl)-[1,2,4]triazolo[4,3-<i>b</i>]pyridazine-3,6(2<i>H</i>,5<i>H</i>)-dione (70 mg, 0.15 mmol) and LiOH (4 mg, 0.2 mmol) in DMF (0.5 mL). The reaction mixture was heated at 70 Â°C for 30 min, and then it was cooled to room temperature and diluted with ethyl acetate. The resulting organic layer was extracted with water, and the organic layer was dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated under reduced pressure. The crude product was purified by reverse phase HPLC and silica gel chromatography. The product-containing fractions were evaporated and dissolved in ethyl acetate. The organic layer was extracted with sodium bicarbonate, and then it was dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and evaporated to give 6.6 mg (6.6%) of compound <b>14</b> as a yellow foam. Analytical HPLC (4 min gradient) retention time = 2.96 min (98.0% HI). LC-MS anal. calcd for C<sub>25</sub>H<sub>18</sub>ClF<sub>3</sub>N<sub>6</sub>O<sub>2</sub>: 526.1, found [M + H] 527.2. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ ppm 9.01 (s, 1H), 8.82 (d, <i>J</i> = 4.9 Hz, 2H), 8.21 (d, <i>J</i> = 7.7 Hz, 1H), 7.76 (d, <i>J</i> = 8.2 Hz, 1H), 7.65 (d, <i>J</i> = 4.4 Hz, 2H), 7.38 (d, <i>J</i> = 7.7 Hz, 2H), 7.17 (d, <i>J</i> = 8.2 Hz, 2H), 6.07 (s, 2H), 4.25â3.82 (m, 2H), 1.38 (t, <i>J</i> = 7.4 Hz, 3H).</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> 3-(Chloromethyl)-2-methyl-6-(trifluoromethyl)pyridine (<b>22</b>)</h3><div class="NLM_p last">A solution of 1 M LAH in THF (40 mL, 40 mmol) was added dropwise to a cooled (0 Â°C) solution of methyl 2-methyl-6-(trifluoromethyl)nicotinate <b>25</b><a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> (8.8 g, 40 mmol) in 40 mL of dry THF at 0 Â°C under argon atmosphere. The solution was warmed to room temperature over 1 h. The reaction was slowly quenched with 10% aq Rochelleâs salt solution (20 mL) over 10 min, followed by stirring for 1 h. The resulting mixture was diluted with 50 mL of EtOAc and water, and the layers were extracted. The organic phase was dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated to obtain 7.5 g of (2-methyl-6-(trifluoromethyl)pyridin-3-yl)methanol as a colorless oil, which was greater than 98% purity by HPLC/MS. To a solution of (2-methyl-6-(trifluoromethyl)pyridin-3-yl)methanol (14.5 g, 71 mmol) in 100 mL of CH<sub>2</sub>Cl<sub>2</sub> at room temperature under argon atmosphere was added SOCl<sub>2</sub> (16.8 g, 142 mmol) and 1.5 mL of DMF. The reaction solution was stirred for 16 h, followed by evaporation. The residue was dissolved in 200 mL of Et<sub>2</sub>O, and the organic layer was extracted with 10% Na<sub>2</sub>CO<sub>3</sub> (100 mL), then brine (100 mL). The organic phase was dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated to give 13.7 g (48%) of compound <b>22</b> as a tan oil. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>CN) Î´ 7.96 (d, 1H, <i>J</i> = 7.7 Hz), 7.64 (d, 1H, <i>J</i> = 7.9 Hz), 4.78 (s, 2H), 2.67 (s, 3H). <sup>13</sup>C NMR (100 MHz, CD<sub>3</sub>CN) Î´ 158.4, 146.0 (q, <i>J</i> = 34.0 Hz), 138.3, 134.9, 124.1 (q, CF3, <i>J</i> = 275 Hz), 118.2, 42.5, 20.8.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> 4-(4-Chlorophenyl)-3-(pyridin-4-yl)furan-2(5<i>H</i>)-one (<b>18</b>)</h3><div class="NLM_p last">Potassium <i>tert</i>-butoxide (40 mmol; 4.7 g) dissolved in MeOH (20 mL) was added to 4-pyridylacetic acid hydrochloride (20 mmol; 3.5 g) slurried in MeOH (20 mL). After stirring for 15 min, the solvent was removed under reduced pressure and the residue was dissolved in dry DMF (30 mL). To this solution was slowly added 2-bromo-4â²-chloroacetophenone (20 mmol; 4.8 g), and the solution turned to a reddish-brown color. After 1 h at room temperature, the reaction mixture was poured into water (200 mL) and this solution was extracted with dichloromethane (2 Ã 100 mL). The combined organic extracts were dried (MgSO<sub>4</sub>), filtered, and concentrated to provide 5.5 g of a dark-green semisolid. The product was slurried in EtOH (â¼10 mL), and then it was isolated by vacuum filtration and drying under high vacuum to give 3.2 g of <b>18</b> (60% yield) as a granular green solid. Analytical HPLC (4 min gradient) retention time = 1.23 min (100.0% HI). LCMS anal. calcd for C<sub>15</sub>H<sub>10</sub>ClNO<sub>2</sub> 271.04, found [M + H] 272. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 8.6 (dd, 1.6, 4.6 Hz, 2H), 7.38â7.23 (m, 6H), 5.18 (s, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) Î´ 171.9, 157.7, 150.4, 137.9, 137.6, 129.7, 128.8, 128.4, 124.3, 123.6, 114.6, 70.6.</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> 4-(4-Chlorophenyl)-5-(pyridin-4-yl)pyridazine-3,6-diol (<b>20</b>)</h3><div class="NLM_p last">Compound <b>18</b> (3 g, 11 mmol) was dissolved in 550 mL of THF, and potassium <i>tert</i>-butoxide (2.5 g, 28 mmol, 2 equiv) was added. Air was bubbled through the solution with vigorous stirring, and the reaction mixture turned from red to dark-green within a few minutes. When starting material had disappeared, as monitored by HPLC, the reaction was quenched via addition of excess (>3 equiv) 1N HCl. The mixture was stirred for 1 h and evaporated to give <b>19</b> as a dark-green oil. The residue was dissolved in 50 mL of ethanol, and 0.35 mL of hydrazine (11 mmol, 1 equiv) was added, followed by 3 mL of conc HCl. The reaction mixture was heated to 72 Â°C for 18 h and, after cooling, the mixture was evaporated to give 4.9 g of <b>20</b> as a red foam that was used as-is in the next step.</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> 6-Chloro-5-(4-chlorophenyl)-4-(pyridin-4-yl)pyridazin-3(2<i>H</i>)-one (<b>21</b>, As a Mixture of Isomers)</h3><div class="NLM_p last">To a solution of compound <b>9</b> (11 g, 32.7 mmol) in 100 mL of acetonitrile was added 100 mL of 1N NaOH (aq). The mixture was heated at 65 Â°C for 2 h, and the reaction was quenched via addition of 1N HCl to pH 6. A precipitate formed that was collected and suction dried to give 7.8 g (75%) of a beige solid as a 8:1 mixture of regioisomers. Analytical HPLC (4 min gradient) retention time = 2.07 min (88.3% HI). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>CN) Î´ major isomer: 8.60 (d, <i>J</i> = 6.8 Hz, 2H), 7.78 (d, <i>J</i> = 6.8 Hz, 2H), 7.58â7.36 (m, 2H), 7.22â7.17 (m, 2H), 2.05 (br s, 1H); minor isomer: 8.70 (d, <i>J</i> = 6.8 Hz, 2H), 7.87 (d, <i>J</i> = 6.8 Hz, 2H), 7.36â7.26 (m, 2H), 7.14â7.12 (m, 2H), 2.05 (br s, 1H).</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> 6-Chloro-5-(4-chlorophenyl)-2-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)methyl)-4-(pyridin-4-yl)pyridazin-3(2<i>H</i>)-one (<b>23</b>)</h3><div class="NLM_p last">To a solution of compound <b>21</b> (7.6 g, 24 mmol) in 100 mL of DMF was added K<sub>2</sub>CO<sub>3</sub>, and the mixture was heated to 65 Â°C. To the heated mixture was added a solution of compound <b>22</b> (6.0 g, 29 mmol) in DMF (10 mL) in three portions over 2 h. After 45 min, the mixture was poured into 800 mL of water and 500 mL of EtOAc was added. The layers were extracted, and the organic layer was successively washed with 500 mL each of water and brine. The organic layer was dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and evaporated to give a red oil. The residue was purified via silica gel chromatography to give 7.8 g (66%) of <b>23</b> as beige crystals (the minor regioisomer is removed during silica purification). Analytical HPLC (4 min gradient) retention time = 3.37 min (100.0% HI). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 8.57â8.43 (m, 2H), 7.96 (d, <i>J</i> = 7.9 Hz, 1H), 7.54 (d, <i>J</i> = 7.9 Hz, 1H), 7.35â7.19 (m, 2H), 7.07â6.91 (m, 4H), 5.45 (s, 2H), 2.83 (s, 3H).</div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> 8-(4-Chlorophenyl)-5-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)methyl)-7-(pyridin-4-yl)-[1,2,4]triazolo[4,3-<i>b</i>]pyridazine-3,6(2<i>H</i>,5<i>H</i>)-dione (<b>24</b>)</h3><div class="NLM_p last">To a solution of compound <b>23</b> (6.6 g, 13 mmol) in pyridine (25 mL) was added 6 mL of hydrazine (130 mmol), and the mixture was heated in a microwave at 200 Â°C for 30 min. The reaction mixture was evaporated to give a light-yellow foam that was dissolved in THF (140 mL). To this solution was added 1,1â²-carbonyldiimidazole (2.2 g, 13 mmol), and the solution was heated to 65 Â°C for 1 h. The crude reaction mixture was purified over silica gel to give 5.0 g of compound <b>24</b> as an orange foam (73% from <b>23</b>). Analytical HPLC (4 min gradient) retention time = 2.37 min (100.0% HI). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>CN) Î´ 8.56â8.40 (m, 2H), 7.85 (d, <i>J</i> = 7.8 Hz, 1H), 7.69â7.49 (m, 1H), 7.43â7.32 (m, 2H), 7.32â7.21 (m, 2H), 7.20â7.09 (m, 2H), 7.04 (s, 1H), 5.83 (s, 2H), 2.69 (s, 3H).</div></div><div id="sec4_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> 8-(4-Chlorophenyl)-2-ethyl-5-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)methyl)-7-(pyridin-4-yl)-[1,2,4]triazolo[4,3-<i>b</i>]pyridazine-3,6(2<i>H</i>,5<i>H</i>)-dione (<b>15</b>)</h3><div class="NLM_p last">To a mixture of compound <b>24</b> (5.0 g, 9.8 mmol) and K<sub>2</sub>CO<sub>3</sub> (1.6 g, 12 mmol) in DMF (50 mL) was added a solution of ethyl iodide (0.8 mL) in DMF (3 mL), and the mixture was stirred at room temperature for 3 h. The reaction mixture was diluted with 1 L of water, and the resulting milky solution was extracted with 2 Ã 500 mL of EtOAc. The combined organic layers were washed successively with water, 10% Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub>, and brine. The organic layer was dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and evaporated to give 4.0 g of a brown foam. The material was purified via silica gel chromatography to give 3.6 g of compound <b>15</b> as a yellow foam (67%). Recrystallization of 1.4 g of this material provided 1.2 g (90% recovery) of off-white crystals. Analytical HPLC (4 min gradient) retention time = 2.89 min (100.0% HI). HRMS anal. calcd for C<sub>26</sub>H<sub>21</sub>N<sub>6</sub>O<sub>2</sub>ClF<sub>3</sub> [M + H]: 541.1370, found: 541.1361. <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ ppm 8.49 (d, 2H, <i>J</i> = 4.9 Hz), 7.95 (d, 1H, <i>J</i> = 8.1 Hz), 7.73 (d, 1H, <i>J</i> = 8.1 Hz), 7.44 (d, 2H, <i>J</i> = 8.5 Hz), 7.30 (d, 2H, <i>J</i> = 8.5 Hz), 7.16 (d, 2H, <i>J</i> = 4.9 Hz), 5.72 (s, 2H), 3.80 (q, 2H, <i>J</i> = 7.2 Hz), 2.64 (s, 3H), 1.18 (t, 3H, <i>J</i> = 7.2 Hz). <sup>13</sup>C NMR (150 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ ppm 158.5, 156.6, 149.6, 146.5, 144.5 (q, <i>J</i> = 33.9 Hz), 141.5, 141.6, 136.2, 135.8, 135.6, 135.5, 134.7, 132.2, 131.9, 129.7, 128.9, 125.8, 122.2 (q, <i>J</i> = 274 Hz), 118.7 (q, <i>J</i> = 2 Hz), 45.7, 41.3, 22.3, 14.1. <sup>19</sup>F NMR (376.46 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ ppm â66.68. Elemental Anal. Calcd for C<sub>26</sub>H<sub>20</sub>N<sub>6</sub>O<sub>2</sub>Cl F<sub>3</sub>: C 57.71, H 3.76, N 15.48, Cl 6.53, F 10.50. Found: C 57.73, H 3.69, N 15.53, Cl 6.60, F 11.12.</div></div><div id="sec4_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> 8-(4-Chlorophenyl)-2-ethyl-5-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)methyl)-7-(2-methylpyridin-4-yl)-[1,2,4]triazolo[4,3-<i>b</i>]pyridazine-3,6(2<i>H</i>,5<i>H</i>)-dione (<b>27</b>)</h3><div class="NLM_p last">Compound <b>27</b> was synthesized according to the method of compound <b>15</b>. Analytical HPLC (4 min gradient) retention time = 2.462 min (98% HI), LC-MS anal. calcd for C<sub>27</sub>H<sub>22</sub>ClF<sub>3</sub>N<sub>6</sub>O<sub>2</sub>: 554.1, found [M + H] = 555.2. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 8.34 (d, <i>J</i> = 5.5 Hz, 1H), 7.64â7.42 (m, 2H), 7.24 (d, <i>J</i> = 8.2 Hz, 2H), 7.13 (d, <i>J</i> = 8.8 Hz, 2H), 6.91 (s, 1H), 6.74 (d, <i>J</i> = 4.9 Hz, 1H), 5.86 (s, 2H), 3.85 (q, <i>J</i> = 7.1 Hz, 2H), 2.67 (s, 3H), 2.44 (s, 3H), 1.26 (t, <i>J</i> = 7.1 Hz, 3H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) Î´ 158.5, 158.1, 157.0, 148.9, 146.5, 146.3, 136.5, 136.1, 135.2, 135.0, 133.0, 131.3, 128.9, 128.0, 124.8, 122.3, 118.0, 45.0, 41.8, 24.4, 22.4, 13.8.</div></div><div id="sec4_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> 4-(8-(4-Chlorophenyl)-2-ethyl-5-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)methyl)-3,6-dioxo-2,3,5,6-tetrahydro-[1,2,4]triazolo[4,3-<i>b</i>]pyridazin-7-yl)benzonitrile (<b>28</b>).<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a></h3><div class="NLM_p last">Compound <b>28</b> (35 mg, 80% yield) was isolated as a light-yellow solid. Analytical HPLC (4 min gradient) retention time = 3.67 min (98.7% HI). LCMS anal. calcd C<sub>28</sub>H<sub>20</sub>ClF<sub>3</sub>N<sub>6</sub>O<sub>2</sub>: 564.13, found [M + H] = 565. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.65 (d, <i>J</i> = 7.91 Hz, 1H), 7.57 (d, <i>J</i> = 8.35 Hz, 2H), 7.51 (d, <i>J</i> = 7.91 Hz, 1H), 7.31 (d, <i>J</i> = 8.35 Hz, 2H), 7.22â7.28 (m, 2H), 7.18 (d, <i>J</i> = 8.79 Hz, 2H), 5.93 (s, 2H), 3.92 (q, <i>J</i> = 7.18 Hz, 2H), 2.74 (s, 3H), 1.34 (t, <i>J</i> = 7.25 Hz, 3H).</div></div><div id="sec4_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> 4-(8-(4-Chlorophenyl)-2-ethyl-5-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)methyl)-3,6-dioxo-2,3,5,6-tetrahydro-[1,2,4]triazolo[4,3-<i>b</i>]pyridazin-7-yl)-2-methylbenzonitrile (<b>29</b>).<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a></h3><div class="NLM_p last">Analytical HPLC (4 min gradient) retention time = 3.79 min (98.7% HI). LCMS anal. calcd C<sub>29</sub>H<sub>22</sub>ClF<sub>3</sub>N<sub>6</sub>O<sub>2</sub>: 578.14, found [M + H] = 579. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ ppm 7.63 (d, <i>J</i> = 8.1 Hz, 1H), 7.58â7.42 (m, 2H), 7.38â7.28 (m, 2H), 7.22â7.11 (m, 3H), 6.99 (d, <i>J</i> = 7.1 Hz, 1H), 5.93 (s, 2H), 3.92 (q, <i>J</i> = 7.3 Hz, 2H), 2.74 (s, 3H), 2.47 (s, 3H), 1.33 (t, <i>J</i> = 7.2 Hz, 3H).</div></div><div id="sec4_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> 4-(8-(4-Chlorophenyl)-2-ethyl-5-((2-ethyl-6-(trifluoromethyl)pyridin-3-yl)methyl)-3,6-dioxo-2,3,5,6-tetrahydro-[1,2,4]triazolo[4,3-<i>b</i>]pyridazin-7-yl)benzonitrile (<b>30</b>).<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a></h3><div class="NLM_p last">Compound <b>30</b> was isolated in 47% yield as a light-yellow solid. Analytical HPLC (4 min gradient) retention time = 3.82 min (98.6% HI). LCMS anal. calcd C<sub>29</sub>H<sub>22</sub>ClF<sub>3</sub>N<sub>6</sub>O<sub>2</sub>: 578.14, found [M + H] = 579. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.61 (d, <i>J</i> = 7.91 Hz, 1H), 7.57 (d, <i>J</i> = 8.79 Hz, 2H), 7.49 (d, <i>J</i> = 7.91 Hz, 1H), 7.31 (d, <i>J</i> = 8.79 Hz, 2H), 7.23â7.28 (m, 2H), 7.18 (d, <i>J</i> = 8.79 Hz, 2H), 5.98 (s, 2H), 3.93 (q, <i>J</i> = 7.18 Hz, 2H), 3.03 (q, <i>J</i> = 7.47 Hz, 2H), 1.35 (td, <i>J</i> = 7.31, 12.63 Hz, 6H).</div></div><div id="sec4_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> 4-(8-(4-Chlorophenyl)-2-isopropyl-5-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)methyl)-3,6-dioxo-2,3,5,6-tetrahydro-[1,2,4]triazolo[4,3-<i>b</i>]pyridazin-7-yl)benzonitrile (<b>31</b>).<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a></h3><div class="NLM_p last">Compound <b>31</b> was isolated in 66% yield as a light-yellow solid. Analytical HPLC (4 min gradient) retention time = 3.81 min (95.6% HI). LCMS anal. calcd C<sub>29</sub>H<sub>22</sub>ClF<sub>3</sub>N<sub>6</sub>O<sub>2</sub>: 578.14, found [M + H] = 579. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.66 (d, <i>J</i> = 8.35 Hz, 1H), 7.57 (d, <i>J</i> = 8.35 Hz, 2H), 7.51 (d, <i>J</i> = 8.35 Hz, 1H), 7.30 (d, <i>J</i> = 8.79 Hz, 2H), 7.23â7.27 (m, 2H), 7.13â7.21 (m, 2H), 5.93 (s, 2H), 4.53 (quin, <i>J</i> = 6.70 Hz, 1H), 2.74 (s, 3H), 1.35 (d, <i>J</i> = 7.03 Hz, 6H).</div></div><div id="sec4_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> 4-(8-(4-Chlorophenyl)-5-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)methyl)-3,6-dioxo-2-propyl-2,3,5,6-tetrahydro-[1,2,4]triazolo[4,3-<i>b</i>]pyridazin-7-yl)benzonitrile (<b>32</b>).<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a></h3><div class="NLM_p last">Compound <b>32</b> was isolated in 45% yield as a light-yellow solid. Analytical HPLC (4 min gradient) retention time = 3.82 min (100% HI). LCMS anal. calcd C<sub>29</sub>H<sub>22</sub>ClF<sub>3</sub>N<sub>6</sub>O<sub>2</sub>: 578.14, found [M + H] = 579. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.64 (d, <i>J</i> = 7.91 Hz, 1H), 7.57 (d, <i>J</i> = 8.35 Hz, 2H), 7.50 (d, <i>J</i> = 7.91 Hz, 1H), 7.31 (d, <i>J</i> = 8.79 Hz, 2H), 7.24â7.28 (m, 2H), 7.17 (d, <i>J</i> = 8.35 Hz, 2H), 5.94 (s, 2H), 3.78â3.87 (m, 2H), 2.74 (s, 3H), 1.76 (sxt, <i>J</i> = 7.38 Hz, 2H), 0.91 (t, <i>J</i> = 7.47 Hz, 3H).</div></div><div id="sec4_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> 4-(8-(4-Chlorophenyl)-2-ethyl-5-(4-methylbenzyl)-3,6-dioxo-2,3,5,6-tetrahydro-[1,2,4]triazolo[4,3-<i>b</i>]pyridazin-7-yl)benzonitrile (<b>33</b>).<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a></h3><div class="NLM_p last">Compound <b>33</b> (40 mg, 100%) was isolated as a yellow solid. Analytical HPLC (4 min gradient) retention time = 3.90 min (97.5% HI). LCMS anal. calcd for C<sub>28</sub>H<sub>22</sub>ClN<sub>5</sub>O<sub>2</sub>: 495.1, found [M + H] 496.4. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>CN) Î´ ppm 7.64â7.57 (m, 2H), 7.34 (d, <i>J</i> = 7.9 Hz, 2H), 7.32â7.26 (m, 4H), 7.21â7.13 (m, 4H), 5.80 (s, 2H), 3.84 (q, <i>J</i> = 7.2 Hz, 2H), 2.30 (s, 3H), 1.29â1.19 (m, 3H).</div></div><div id="sec4_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> 4-(2-Ethyl-5-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)methyl)-3,6-dioxo-8-(<i>p</i>-tolyl)-2,3,5,6-tetrahydro-[1,2,4]triazolo[4,3-<i>b</i>]pyridazin-7-yl)benzonitrile (<b>34</b>).<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a></h3><div class="NLM_p last">Compound <b>34</b> was isolated in 50% yield as a light-yellow solid. Analytical HPLC (4 min gradient) retention time = 3.64 min (96.7% HI). LCMS anal. calcd for C<sub>29</sub>H<sub>23</sub>F<sub>3</sub>N<sub>6</sub>O<sub>2</sub>: 544.18, found [M + H] 545. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.65 (d, <i>J</i> = 7.91 Hz, 1H), 7.54 (d, <i>J</i> = 8.35 Hz, 2H), 7.51 (d, <i>J</i> = 7.91 Hz, 1H), 7.20â7.31 (m, 2H), 7.12 (s, 4H), 5.93 (s, 2H), 3.92 (q, <i>J</i> = 7.03 Hz, 2H), 2.74 (s, 3H), 2.35 (s, 3H), 1.33 (t, <i>J</i> = 7.03 Hz, 3H).</div></div><div id="sec4_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> 4-(8-(4-Chlorophenyl)-5-(4-cyanobenzyl)-2-ethyl-3,6-dioxo-2,3,5,6-tetrahydro-[1,2,4]triazolo[4,3-<i>b</i>]pyridazin-7-yl)benzonitrile (<b>35</b>).<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a></h3><div class="NLM_p last">Compound <b>35</b> (70 mg, 52%) was isolated as a yellow solid. Analytical HPLC (4 min gradient) retention time = 3.55 min (98.3% HI). LC-MS anal. calcd for C<sub>28</sub>H<sub>19</sub>ClN<sub>6</sub>O<sub>2</sub>: 506.1, found [M + H] 507.2. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>CN) Î´ ppm 7.79â7.69 (m, 2H), 7.65â7.56 (m, 4H), 7.36â7.26 (m, 4H), 7.24â7.15 (m, 2H), 5.85 (s, 2H), 3.84 (q, <i>J</i> = 7.3 Hz, 2H), 1.31â1.19 (m, 3H).</div></div><div id="sec4_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> 8-(4-Chlorophenyl)-2-ethyl-7-(6-(hydroxymethyl)pyridin-3-yl)-5-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)methyl)-[1,2,4]triazolo[4,3-<i>b</i>]pyridazine-3,6(2<i>H</i>,5<i>H</i>)-dione (<b>36</b>)</h3><div class="NLM_p last">To a stirred solution of 8-(4-chlorophenyl)-2-ethyl-5-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)methyl)-7-(6-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-<i>b</i>]pyridazine-3,6(2<i>H</i>,5<i>H</i>)-dione<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> (140 mg, 0.24 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (2 mL) was added mCPBA (65 mg of 77% mCPBA, 0.29 mmol) at room temperature. After stirring for 1 h, the solution was diluted with ethyl acetate and the organic layer was extracted with satd aq NaHCO<sub>3</sub>. The organic layer was separated and dried (MgSO<sub>4</sub>). The dried organic layer was filtered and concentrated to give a colorless foam that was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (2 mL), and trifluoroacetic anhydride (2 mL) was added. The vessel was sealed and heated to 50 Â°C for 2 h. The reaction mixture was cooled to room temperature and was evaporated to an oil. The residue was purified via preparative RP-HPLC; product-containing fractions were evaporated and redissolved in CH<sub>2</sub>Cl<sub>2</sub> and water that was adjusted to pH 8 with solid NaHCO<sub>3</sub>. The layers were extracted and the organic layer was dried (MgSO<sub>4</sub>), filtered, and evaporated to give 56 mg (36%) of compound <b>36</b> as a yellow solid. Analytical HPLC (8 min gradient) retention time = 4.0 min (100% HI). anal. calcd for C<sub>27</sub>H<sub>22</sub>ClF<sub>3</sub>N<sub>6</sub>O<sub>3</sub> 570.14, found [M + H] 571.5. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 8.26 (d, 1H, <i>J</i> = 2.2 Hz), 7.64 (d, 1H, <i>J</i> = 7.7), 7.55 (dd, 1H, <i>J</i> = 2.2, 8.2), 7.50 (d, 1H, <i>J</i> = 7.7), 7.33â7.20 (m, 6H), 5.94 (s, 2H), 4.73 (s, 2H), 3.93 (q, 2H, <i>J</i> = 7.1), 2.74 (s, 3H), 1.33 (t, 3H, <i>J</i> = 7.1 Hz). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) Î´ 159.4, 158.6, 156.9, 149.9, 146.4, 139.1, 136.4, 135.9, 135.3, 135.0, 133.0, 131.5, 130.2, 129.0, 128.2, 127.1, 119.6, 118.0, 64.0, 53.4, 45.0, 41.8, 22.3, 13.7.</div></div><div id="sec4_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> 6-Bromo-4,5-dichloropyridazin-3(2<i>H</i>)-one (<b>38</b>).<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a></h3><div class="NLM_p last">To a solution of 20 g of 4,5-dichloropyridazin-3(2<i>H</i>)-one (121 mmol) in methanol at 70 Â°C was added 5 g of LiOH (121 mmol), followed by slow portionwise addition of bromine (14 mL, 270 mmol). To the heated solution was added 3 g of LiOH until the solution became light-red/orange. The volatile components were removed in vacuo, and the resulting slurry was suspended in 150 mL of water. The solids were collected via filtration, and the filter cake was washed with water and suction dried to give 30 g of a beige solid that was used without further purification.</div></div><div id="sec4_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> 6-Bromo-4,5-dichloro-2-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)methyl)pyridazin-3(2<i>H</i>)-one (<b>39</b>)</h3><div class="NLM_p last">To a heated (70 Â°C) solution of compound <b>38</b> (17 g, 69 mmol) in 100 mL of DMF containing 19 g of K<sub>2</sub>CO<sub>3</sub> (140 mmol) was added a solution of compound <b>22</b> (14 g, 69 mmol) in DMF (100 mL). The solution was heated for 2 h, and the mixture was cooled to room temperature. The resulting solution was diluted into 1.5 L of water. The mixture was extracted with 2 Ã 600 mL of ethyl acetate. The combined organic layers were washed with brine, and then it was dried (MgSO<sub>4</sub>), filtered, and evaporated to give 25 g of a red solid that was used without further purification.</div></div><div id="sec4_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> 6-Bromo-5-chloro-4-methoxy-2-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)methyl)pyridazin-3(2<i>H</i>)-one (<b>40</b>)</h3><div class="NLM_p last">The residue (25 g of crude compound <b>39</b>) was dissolved in NaOMe/MeOH (6.5 g of a 25% w/w solution, 30 mmol) at room temperature. After 15 min, the mixture was diluted into 500 mL of EtOAc/water. The layers were extracted, and the organic layer was washed with brine. The organic layer was separated and dried (MgSO<sub>4</sub>), filtered, and evaporated to give a red oil that was purified via silica gel chromatography to give 4.0 g (35%) compound <b>40</b> as a white solid. Analytical HPLC (4 min gradient) retention time = 3.66 min (97.6% HI). LCMS anal. calcd for C<sub>13</sub>H<sub>10</sub>BrClF<sub>3</sub>N<sub>3</sub>O<sub>2</sub>: 411, 413, 415, found [M + H] = 412, 414, 416. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.7 (d, 8.0 Hz, 1H), 7.5 (d, 8.0 Hz, 1H), 5.3 (s, 2H), 4.31 (s, 3H), 2.75 (s, 3H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) Î´ 158.2, 155.8, 152.1, 147.3, 138.0, 132.0, 129.8, 125.7, 123.0 (app q, CF<sub>3</sub>), 118.1 (d, 2.8 Hz), 61.1, 52.1, 22.5.</div></div><div id="sec4_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> <i>tert</i>-Butyl 2-(4-Chloro-5-methoxy-1-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)methyl)-6-oxo-1,6-dihydropyridazin-3-yl)hydrazinecarboxylate (<b>41</b>)</h3><div class="NLM_p last">To an argon flushed vessel containing 3.7 g of compound <b>40</b> (9 mmol), boc-hydrazine (4.7 g, 36 mmol), and cesium carbonate (3.5 g, 11 mmol) in toluene (45 mL) was added Pd(dppf)Cl<sub>2</sub>-methylene chloride complex (0.37 g, 0.45 mmol), and the mixture was heated at reflux for 4 h. The cooled mixture was diluted with 200 mL each of ethyl acetate and water. The layers were extracted, and the organic layer was washed successively with 1N HCl and brine. The organic layer was dried (MgSO<sub>4</sub>), and the mixture was filtered and evaporated to give a red oil that was purified via silica gel chromatography to give 3.2 g (77%) of compound <b>41</b> as an orange foam. Analytical HPLC (4 min gradient) retention time = 3.21 min (91.3% HI). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 7.6 (d, 7.7 Hz, 1H), 7.44 (d, 8.0 Hz, 1H), 6.47 (br s, 1H), 5.24 (s, 2H), 4.29 (s, 3H), 2.74 (s, 3H), 1.48 (m, 9H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) Î´ 157.8, 155.6, 155.4, 151.8, 146.7, 144.5, 137.4, 133.1, 118.0, 81.8, 60.7, 51.1, 28.2, 28.0, 22.4.</div></div><div id="sec4_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> <i>tert</i>-Butyl 2-(4-(4-Chlorophenyl)-5-methoxy-1-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)methyl)-6-oxo-1,6-dihydropyridazin-3-yl)hydrazinecarboxylate (<b>42</b>)</h3><div class="NLM_p last">To a solution of compound <b>41</b> (1.5 g, 3.23 mmol) in 16 mL of toluene was added 0.76 g of 4-chlorophenyl boronic acid (4.9 mmol) and 1.9 mL of 2 M Na<sub>2</sub>CO<sub>3</sub> (3.9 mmol). The mixture was degassed via vacuum/Ar purge sequence three times, and Pd(PPh<sub>3</sub>)<sub>4</sub> (0.19 g, 0.16 mmol) was added. The resulting mixture was heated at 110 C for 85 min. After cooling to room temperature, the mixture was diluted with 300 mL each of ethyl acetate/water, and the layers were extracted. The organic layer was washed with brine, then it was dried (MgSO<sub>4</sub>), filtered, and evaporated. The residue was purified via silica gel chromatography to give 1.8 g of compound <b>42</b> as a beige solid. Analytical HPLC (4 min gradient) retention time = 1.90 min (94.1% HI). LCMS anal. calcd for C<sub>24</sub>H<sub>25</sub>ClF<sub>3</sub>N<sub>5</sub>O<sub>4</sub> 539, found [M + H] 540. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.73 (d, 8 Hz, 1H), 7.49â7.46 (m, 4H), 7.33 (d, 7.4 Hz, 1H), 6.1 (br s, 1H), 5.5 (d, 4.1 Hz, 1H), 5.3 (s, 2H), 4.0 (s, 3H), 2.8 (s, 3H), 1.48â1.39 (m, 9H).</div></div><div id="sec4_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> 8-(4-Chlorophenyl)-7-methoxy-5-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)methyl)-[1,2,4]triazolo[4,3-<i>b</i>]pyridazine-3,6(2<i>H</i>,5<i>H</i>)-dione (<b>43</b>)</h3><div class="NLM_p last">Compound <b>42</b> (1.8 g, 3.3 mmol) was dissolved in 16 mL of CH<sub>2</sub>Cl<sub>2</sub>, and 2 mL of TFA was added. After stirring at room temperature for 4.5 h, the mixture was evaporated to dryness to give an orange oil. The residue was dissolved in 100 mL of CH<sub>2</sub>Cl<sub>2</sub>, and the mixture was extracted successively with 1N aq NaOH and brine. The organic layer was dried (MgSO<sub>4</sub>), filtered, and evaporated to a yellow foam. The solids were dissolved in 16 mL of CH<sub>2</sub>Cl<sub>2</sub>, and triphosgene (3 g, 10 mmol) was added. The slurry was further diluted with 1 mL of CH<sub>2</sub>Cl<sub>2</sub> to re-establish stirring, and 0.3 g of triphosgene was added. After 2 h, the mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub> and water, and the layers were extracted. The organic layer was washed with brine, and then it was dried (MgSO<sub>4</sub>), filtered, and evaporated to give 1.2 g of compound <b>42</b> as a white solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>CN) Î´ 10.2 (s, 1H), 7.75 (d, 8.0 Hz, 1H), 7.65â7.54 (m, 5H), 5.78 (s, 2H), 3.89 (s, 3H), 2.69 (s, 3H). <sup>13</sup>C NMR (125 MHz, CD<sub>3</sub>CN) Î´ 162.1, 161.9, 153.4, 140.3, 136.9, 133.7, 132.6, 128.5, 66.1, 50.2, 26.8.</div></div><div id="sec4_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> 8-(4-Chlorophenyl)-2-ethyl-5-((2-methyl-6-(trifluoromethyl)pyridin-3-yl)methyl)-7-(2-methylpyrimidin-5-yl)-[1,2,4]triazolo[4,3-<i>b</i>]pyridazine-3,6(2<i>H</i>,5<i>H</i>)-dione (<b>46</b>)</h3><div class="NLM_p last">To a solution of compound <b>43</b> (1.0 g 2 mmol) in 2 mL of CH<sub>2</sub>Cl<sub>2</sub> at â40 Â°C was added 2 mL of 1N BBr<sub>3</sub> in CH<sub>2</sub>Cl<sub>2</sub> (2 mmol). After 15 min, the mixture was diluted with 100 mL of CH<sub>2</sub>Cl<sub>2</sub> and the mixture was extracted with an aq soln of Rochelleâs salt. The layers were extracted, and the organic layer was washed with brine. The organic layer was dried (MgSO<sub>4</sub>), and then it was filtered and evaporated to give 0.62 g of a brown oil. The residue was dissolved in 6.5 mL of CH<sub>2</sub>Cl<sub>2</sub> at 0 Â°C, and to this solution was added triethylamine (0.36 mL, 2.6 mmol) and triflic anhydride (0.33 mL, 1.9 mmol). After 15 min, the mixture was diluted into 50 mL of CH<sub>2</sub>Cl<sub>2</sub> and 50 mL of 0.1 N aq HCl. The layers were extracted, and the organic layer was washed with brine. The organic layer was dried (MgSO<sub>4</sub>), and it was filtered and evaporated to give 0.7 g of compound <b>45</b> as a red oil that was used as-is in the next step. Compound <b>45</b> (0.15 g, 0.24 mmol), 2-methylpyrimidine-5-boronic acid (0.05 g, 0.36 mmol), Pd(dppf)Cl<sub>2</sub>âCH<sub>2</sub>Cl<sub>2</sub> complex (0.04 g, 0.05 mmol), and K<sub>3</sub>PO<sub>4</sub> (0.16 g, 0.73 mmol) were placed in a flask that was then evacuated and purged with argon three times. To the vessel was added 1.2 mL of THF, and the mixture was heated at 80 Â°C for 3 h. The mixture was allowed to stand at room temperature overnight, followed by dilution with 50 mL each of ethyl acetate and water. The layers were extracted, and the organic layer was washed with brine. The organic layer was dried (MgSO<sub>4</sub>), and then it was filtered and evaporated to give a red oil. The residue was purified via silica gel chromatography (using silica that had been pretreated with 2% triethylamine/hexanes) to give 0.03 g of the title compound as a light-yellow solid. Analytical HPLC (4 min gradient) retention time = 3.42 min (100% HI). LCMS Anal. calcd for C<sub>26</sub>H<sub>21</sub>N<sub>7</sub>O<sub>2</sub>F<sub>3</sub>Cl 555.14, found 556.2 [M + H]. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ ppm 8.45 (s, 2H), 7.94 (d, 1H, <i>J</i> = 8.0 Hz), 7.72 (d, 1H, <i>J</i> = 8.0 Hz), 7.50 (d, 2H, <i>J</i> =  8.8 Hz), 7.37 (d, 2H, <i>J</i> = 8.6 Hz), 5.75 (s, 2H), 3.81 (q, 2H, <i>J</i> = 7.3 Hz), 2.65 (s, 3H), 2.57 (s, 3H), 1.18 (t, 3H, <i>J</i> = 7.2 Hz). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) Î´ ppm 166.4, 158.3, 157.9, 156.1, 145.9, 144.0 (q, <i>J</i> = 33.6 Hz), 135.6, 135.4, 135.1, 134.8, 134.3, 131.9, 129.1, 128.5, 127.9, 124.3, 121.6 (q, <i>J</i> = 273.6), 118.2 (d, <i>J</i> = 3.1 Hz), 45.2, 40.8, 25.3, 21.7, 13.5. <sup>19</sup>F NMR (471 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ ppm â66.10 (br s, 3 F). Elemental analysis: Anal. calcd for C<sub>26</sub>H<sub>21</sub>N<sub>7</sub>O<sub>2</sub>F<sub>3</sub>Cl C 56.17, H 3.81, N 17.64, Cl 6.38, F 10.25. Found: C 56.01, H 4.01, N 17.24, Cl 6.16, F 10.25.</div></div><div id="sec4_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> In Vitro CB1 Binding Assay</h3><div class="NLM_p">The source of CB1 receptor was a membrane preparation from Chinese hamster ovary (CHO) cells overexpressing recombinant human CB1. This CHOâCB1 cell line was in-licensed from Euroscreen (cell line EC-110-C) and expresses a high level of CB1 receptor. Compound <b>46</b> and other test compounds were serially diluted in DMSO and added 1:100 to 96 well microtiter plates containing 3 Î¼g of CHOâCB1 membrane protein and 2â5 nM of the cannabinoid small molecule agonist, [<sup>3</sup>H]-CP-55940, or the CB1 selective small molecule antagonist, [<sup>3</sup>H]-rimonabant, in a binding buffer (25 mM HEPES (pH 7.4), 150 mM NaCl, 1 mM EDTA, 2 mM MgCl<sub>2</sub>, 0.25% BSA, 1 mM leupeptin). Incubations were carried out to steady state for 3 h at room temperature for [<sup>3</sup>H]-CP-55940 or 1.5 h for [<sup>3</sup>H]-rimonabant. Binding reactions were terminated by rapid vacuum filtration through GF/B filter plates which were washed with 1.6 mL of 1.8 mM Na<sub>2</sub>HPO<sub>4</sub>, 0.9 mM NaH<sub>2</sub>PO<sub>4</sub> (pH 7.4), 32.5 mM NaCl, with 0.025% Tween 20, dried, and 0.05 mL of Microscint 20 was added to each well and radioactivity quantified on a Packard TopCount scintillation counter. Nonspecific binding was determined by the addition of 1â10 Î¼M of unlabeled CP-55940 or rimonabant. Specific binding CPM were calculated by subtracting nonspecific binding from total binding Specific CPM were converted into % inhibition values, and IC<sub>50</sub> values were determined by nonlinear regression curve fitting carried out in Excel Fit. IC<sub>50</sub> values were converted into <i>K</i><sub>i</sub> values employing the ChengâPrusoff correction using the parameters of radioligand concentration and the <i>K</i><sub>d</sub> values determined for each radioligand. <i>K</i><sub>i</sub> values are reported as the average of at least three determinations with calculated standard deviations. Rimonabant was included in all radioligand binding experiments as an internal reference. Saturation (Scatchard) analyses were carried out to determine the dissociation constant, <i>K</i><sub>d</sub> of the radioligands.</div><div class="NLM_p last">The <i>K</i><sub>d</sub> and <i>B</i><sub>max</sub> values determined for the two radioligands in membranes from a CHO-huCB1 cell line from Euroscreen are as follows: [<sup>3</sup>H]-CP-55940, <i>K</i><sub>d</sub> = 6.8 nM, <i>B</i><sub>max</sub> = 18 pmol/mg protein; [<sup>3</sup>H]-rimonabant, <i>K</i><sub>d</sub> = 2.2 nM, <i>B</i><sub>max</sub> = 5 2 pmol/mg protein. The <i>K</i><sub>d</sub> values obtained with both radioligands are similar to those reported in the literature.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i51"><a href="/doi/suppl/10.1021/jm4010835">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35044" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35044" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Experimental procedures for the synthesis of compounds <b>47</b>â<b>49</b> and <b>S1</b>â<b>S6</b>, methods for in vitro and in vivo biological studies, and data used to generate graphs in Figures <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>A,B and Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a> may be found in the Supporting Information section. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm4010835/suppl_file/jm4010835_si_001.pdf">jm4010835_si_001.pdf (343.31 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm4010835" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33755" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33755" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bruce A. Ellsworth</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers
Squibb, Co., P.O. Box 5400, Princeton, New Jersey 08543-5400, United States</span>;Â 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#e1a393948284cfa48d8d92968e939589a1a3acb2cf828e8c"><span class="__cf_email__" data-cfemail="c88ababdabade68da4a4bbbfa7babca0888a859be6aba7a5">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Philip M. Sher</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers
Squibb, Co., P.O. Box 5400, Princeton, New Jersey 08543-5400, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ximao Wu</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers
Squibb, Co., P.O. Box 5400, Princeton, New Jersey 08543-5400, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gang Wu</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers
Squibb, Co., P.O. Box 5400, Princeton, New Jersey 08543-5400, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Richard B. Sulsky</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers
Squibb, Co., P.O. Box 5400, Princeton, New Jersey 08543-5400, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhengxiang Gu</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers
Squibb, Co., P.O. Box 5400, Princeton, New Jersey 08543-5400, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Natesan Murugesan</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers
Squibb, Co., P.O. Box 5400, Princeton, New Jersey 08543-5400, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yeheng Zhu</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers
Squibb, Co., P.O. Box 5400, Princeton, New Jersey 08543-5400, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Guixue Yu</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers
Squibb, Co., P.O. Box 5400, Princeton, New Jersey 08543-5400, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Doree F. Sitkoff</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers
Squibb, Co., P.O. Box 5400, Princeton, New Jersey 08543-5400, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kenneth E. Carlson</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers
Squibb, Co., P.O. Box 5400, Princeton, New Jersey 08543-5400, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Liya Kang</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers
Squibb, Co., P.O. Box 5400, Princeton, New Jersey 08543-5400, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yifan Yang</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers
Squibb, Co., P.O. Box 5400, Princeton, New Jersey 08543-5400, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ning Lee</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers
Squibb, Co., P.O. Box 5400, Princeton, New Jersey 08543-5400, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rose A. Baska</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers
Squibb, Co., P.O. Box 5400, Princeton, New Jersey 08543-5400, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">William J. Keim</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers
Squibb, Co., P.O. Box 5400, Princeton, New Jersey 08543-5400, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mary Jane Cullen</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers
Squibb, Co., P.O. Box 5400, Princeton, New Jersey 08543-5400, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anthony V. Azzara</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers
Squibb, Co., P.O. Box 5400, Princeton, New Jersey 08543-5400, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eva Zuvich</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers
Squibb, Co., P.O. Box 5400, Princeton, New Jersey 08543-5400, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael A. Thomas</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers
Squibb, Co., P.O. Box 5400, Princeton, New Jersey 08543-5400, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kenneth W. Rohrbach</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers
Squibb, Co., P.O. Box 5400, Princeton, New Jersey 08543-5400, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James J. Devenny</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers
Squibb, Co., P.O. Box 5400, Princeton, New Jersey 08543-5400, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Helen E. Godonis</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers
Squibb, Co., P.O. Box 5400, Princeton, New Jersey 08543-5400, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Susan J. Harvey</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers
Squibb, Co., P.O. Box 5400, Princeton, New Jersey 08543-5400, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brian J. Murphy</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers
Squibb, Co., P.O. Box 5400, Princeton, New Jersey 08543-5400, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gerry G. Everlof</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers
Squibb, Co., P.O. Box 5400, Princeton, New Jersey 08543-5400, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul I. Stetsko</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers
Squibb, Co., P.O. Box 5400, Princeton, New Jersey 08543-5400, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Olafur Gudmundsson</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers
Squibb, Co., P.O. Box 5400, Princeton, New Jersey 08543-5400, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Susan Johnghar</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers
Squibb, Co., P.O. Box 5400, Princeton, New Jersey 08543-5400, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Asoka Ranasinghe</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers
Squibb, Co., P.O. Box 5400, Princeton, New Jersey 08543-5400, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kamelia Behnia</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers
Squibb, Co., P.O. Box 5400, Princeton, New Jersey 08543-5400, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mary Ann Pelleymounter</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers
Squibb, Co., P.O. Box 5400, Princeton, New Jersey 08543-5400, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">William R. Ewing</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers
Squibb, Co., P.O. Box 5400, Princeton, New Jersey 08543-5400, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d674e4103-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i52">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13275" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13275" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Jeffrey Robl, Ph.D., for helpful suggestions in the preparation of this manuscript.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i53" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i53"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i54" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i54"> Abbreviations Used</h2><tr><td class="NLM_term">CB1</td><td class="NLM_def"><p class="first last">cannabinoid receptor 1</p></td></tr><tr><td class="NLM_term"><i>h</i>CB1</td><td class="NLM_def"><p class="first last">human CB1 receptor</p></td></tr><tr><td class="NLM_term">GPCR</td><td class="NLM_def"><p class="first last">G-protein coupled receptor</p></td></tr><tr><td class="NLM_term">2-AG</td><td class="NLM_def"><p class="first last">2-arachidonoylglycerol</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">HTS</td><td class="NLM_def"><p class="first last">high-throughput screening</p></td></tr><tr><td class="NLM_term">TZP</td><td class="NLM_def"><p class="first last">triazolopyridazine</p></td></tr><tr><td class="NLM_term">TZP-dione</td><td class="NLM_def"><p class="first last">triazolopyridazin-dione</p></td></tr><tr><td class="NLM_term">MED</td><td class="NLM_def"><p class="first last">minimally efficacious dose</p></td></tr><tr><td class="NLM_term">Cl</td><td class="NLM_def"><p class="first last">clearance</p></td></tr><tr><td class="NLM_term">CYP</td><td class="NLM_def"><p class="first last">cytochrome P450</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i55">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26427" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26427" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 34 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Piomelli, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giuffrida, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calignano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez de Fonseca, F.</span><span> </span><span class="NLM_article-title">The Endocannabinoid System as a Target for Therapeutic Drugs</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">218</span><span class="NLM_x">â</span> <span class="NLM_lpage">224</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2000&pages=218-224&author=D.+Piomelliauthor=A.+Giuffridaauthor=A.+Calignanoauthor=F.+Rodriguez+de+Fonseca&title=The+Endocannabinoid+System+as+a+Target+for+Therapeutic+Drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPiomelli%26aufirst%3DD.%26aulast%3DGiuffrida%26aufirst%3DA.%26aulast%3DCalignano%26aufirst%3DA.%26aulast%3DRodriguez%2Bde%2BFonseca%26aufirst%3DF.%26atitle%3DThe%2520Endocannabinoid%2520System%2520as%2520a%2520Target%2520for%2520Therapeutic%2520Drugs%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2000%26volume%3D21%26spage%3D218%26epage%3D224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Rinaldi-Carmona, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barth, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heaulme, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shire, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calandra, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Congy, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maruani, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neliat, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caput, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrara, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soubrie, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breliere, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Fur, G.</span><span> </span><span class="NLM_article-title">SR141716A, a Potent and Selective Antagonist of the Brain Cannabinoid Receptor</span> <span class="citation_source-journal">FEBS Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">350</span><span class="NLM_x">, </span> <span class="NLM_fpage">240</span><span class="NLM_x">â</span> <span class="NLM_lpage">244</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Fjm4010835&amp;key=10.1016%2F0014-5793%2894%2900773-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Fjm4010835&amp;key=8070571" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Fjm4010835&amp;key=1%3ACAS%3A528%3ADyaK2cXmsVKjsrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=1994&pages=240-244&author=M.+Rinaldi-Carmonaauthor=F.+Barthauthor=M.+Heaulmeauthor=D.+Shireauthor=B.+Calandraauthor=C.+Congyauthor=S.+Martinezauthor=J.+Maruaniauthor=G.+Neliatauthor=D.+Caputauthor=P.+Ferraraauthor=P.+Soubrieauthor=J.+C.+Breliereauthor=G.+Le+Fur&title=SR141716A%2C+a+Potent+and+Selective+Antagonist+of+the+Brain+Cannabinoid+Receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">SR141716A, a potent and selective antagonist of the brain cannabinoid receptor</span></div><div class="casAuthors">Rinaldi-Carmona, Murielle; Barth, Francis; Heaulme, Michel; Shire, David; Calandra, Bernard; Congy, Christian; Martinez, Serge; Maruani, Jeanne; Neliat, Gervais; et al.</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">350</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">240-4</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    </div><div class="casAbstract">SR141716A is the first selective and orally active antagonist of the brain cannabinoid receptor.  This compd. displays nanomolar affinity for the central cannabinoid receptor but is not active on the peripheral cannabinoid receptor.  In vitro, SR141716A antagonizes the inhibitory effects of cannabinoid receptor agonists on both mouse vas deferens contractions and adenylyl cyclase activity in rat brain membranes.  After i.p. or oral administration, SR141716A antagonizes classical pharmacol. and behavioral effects of cannabinoid receptor agonists.  This compd. should prove to be a powerful tool for investigating the in vivo functions of the anandamide/cannabinoid system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLJ59LaZb2cbVg90H21EOLACvtfcHk0lg-i9hDfX1ZEw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXmsVKjsrw%253D&md5=1eebdfec28d2dde64729cddb859aa6c8</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1016%2F0014-5793%2894%2900773-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-5793%252894%252900773-X%26sid%3Dliteratum%253Aachs%26aulast%3DRinaldi-Carmona%26aufirst%3DM.%26aulast%3DBarth%26aufirst%3DF.%26aulast%3DHeaulme%26aufirst%3DM.%26aulast%3DShire%26aufirst%3DD.%26aulast%3DCalandra%26aufirst%3DB.%26aulast%3DCongy%26aufirst%3DC.%26aulast%3DMartinez%26aufirst%3DS.%26aulast%3DMaruani%26aufirst%3DJ.%26aulast%3DNeliat%26aufirst%3DG.%26aulast%3DCaput%26aufirst%3DD.%26aulast%3DFerrara%26aufirst%3DP.%26aulast%3DSoubrie%26aufirst%3DP.%26aulast%3DBreliere%26aufirst%3DJ.%2BC.%26aulast%3DLe%2BFur%26aufirst%3DG.%26atitle%3DSR141716A%252C%2520a%2520Potent%2520and%2520Selective%2520Antagonist%2520of%2520the%2520Brain%2520Cannabinoid%2520Receptor%26jtitle%3DFEBS%2520Lett.%26date%3D1994%26volume%3D350%26spage%3D240%26epage%3D244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Mukhopadhyay, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howlett, A. C.</span><span> </span><span class="NLM_article-title">Chemically Distinct Ligands Promote Differential CB<sub>1</sub> Cannabinoid Receptor-Gi Protein Interactions</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">2016</span><span class="NLM_x">â</span> <span class="NLM_lpage">2024</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Fjm4010835&amp;key=10.1124%2Fmol.104.003558" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Fjm4010835&amp;key=15749995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Fjm4010835&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkvFGis74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2005&pages=2016-2024&author=S.+Mukhopadhyayauthor=A.+C.+Howlett&title=Chemically+Distinct+Ligands+Promote+Differential+CB1+Cannabinoid+Receptor-Gi+Protein+Interactions"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">Chemically distinct ligands promote differential CB1 cannabinoid receptor-Gi protein interactions</span></div><div class="casAuthors">Mukhopadhyay, Somnath; Howlett, Allyn C.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2016-2024</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">To understand how structurally distinct ligands regulate CB1 receptor interactions with Gi1, Gi2, and Gi3, the authors quantified the GÎ±i and Î²Î³ proteins that coimmunoppt. with the CB1 receptor from a detergent ext. of N18TG2 membranes in the presence of ligands.  A mixt. of A, R, GGDP (or G-), and ARGGDP (or ARG-) complexes was obsd. in the presence of aminoalkylindole (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone (WIN 55,212-2) for all three RGÎ±i complexes, cannabinoid desacetyllevonantradol for GÎ±i1 and GÎ±i2, and eicosanoid (R)-methanandamide for GÎ±i3.  Desacetyllevonantradol maintained RGÎ±i3 complexes and (R)-methanandamide maintained RGÎ±i1 and RGÎ±i2 complexes even in the presence of a nonhydrolyzable GTP analog.  The biaryl pyrazole antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboximide hydrochloride (SR141716) maintained all three RGÎ±i complexes.  GÎ² proteins, and to a certain extent GÎ³2, exhibited the same assocn./dissocn. pattern as the GÎ± proteins.  A GDP analog had no influence on any of these assocn./dissocn. reactions and failed to promote sequestration of G proteins.  These results can be explained by invoking the existence of an inverse agonist-supported inactive state in the ternary complex equil. model.  WIN 55,212-2 behaves as an agonist for all three Gi subtypes; SR141716 behaves as an inverse agonist for all three Gi subtypes; desacetyllevonantradol behaves as an agonist for Gi1 and Gi2, and an inverse agonist at Gi3; and (R)-methanandamide behaves as an inverse agonist at Gi1 and Gi2, and an agonist at Gi3.  These ligand-selective G protein responses imply that multiple conformations of the receptor could be evoked by ligands to regulate individual G proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNEsjFuiX8nLVg90H21EOLACvtfcHk0lg-i9hDfX1ZEw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkvFGis74%253D&md5=953abf18a6cfad444972bd9e71499ea7</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1124%2Fmol.104.003558&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.104.003558%26sid%3Dliteratum%253Aachs%26aulast%3DMukhopadhyay%26aufirst%3DS.%26aulast%3DHowlett%26aufirst%3DA.%2BC.%26atitle%3DChemically%2520Distinct%2520Ligands%2520Promote%2520Differential%2520CB1%2520Cannabinoid%2520Receptor-Gi%2520Protein%2520Interactions%26jtitle%3DMol.%2520Pharmacol.%26date%3D2005%26volume%3D67%26spage%3D2016%26epage%3D2024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Pi-Sunyer, F. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aronne, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heshmati, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenstock, J.</span><span> </span><span class="NLM_article-title">Effect of Rimonabant, a Cannabinoid-1 Receptor Blocker, on Weight and Cardiometabolic Risk Factors in Overweight or Obese Patients</span> <span class="citation_source-journal">JAMA, J. Am. Med. Assoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">295</span><span class="NLM_x">, </span> <span class="NLM_fpage">761</span><span class="NLM_x">â</span> <span class="NLM_lpage">775</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=295&publication_year=2006&pages=761-775&author=F.+X.+Pi-Sunyerauthor=L.+J.+Aronneauthor=H.+M.+Heshmatiauthor=J.+Devinauthor=J.+Rosenstock&title=Effect+of+Rimonabant%2C+a+Cannabinoid-1+Receptor+Blocker%2C+on+Weight+and+Cardiometabolic+Risk+Factors+in+Overweight+or+Obese+Patients"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPi-Sunyer%26aufirst%3DF.%2BX.%26aulast%3DAronne%26aufirst%3DL.%2BJ.%26aulast%3DHeshmati%26aufirst%3DH.%2BM.%26aulast%3DDevin%26aufirst%3DJ.%26aulast%3DRosenstock%26aufirst%3DJ.%26atitle%3DEffect%2520of%2520Rimonabant%252C%2520a%2520Cannabinoid-1%2520Receptor%2520Blocker%252C%2520on%2520Weight%2520and%2520Cardiometabolic%2520Risk%2520Factors%2520in%2520Overweight%2520or%2520Obese%2520Patients%26jtitle%3DJAMA%252C%2520J.%2520Am.%2520Med.%2520Assoc.%26date%3D2006%26volume%3D295%26spage%3D761%26epage%3D775" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit3b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Van Gaal, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rissanen, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheen, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ziegler, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">RÃ¶ssner, S.</span><span> </span><span class="NLM_article-title">Effects of the Cannabinoid-1 Receptor Blocker Rimonabant on Weight Reduction and Cardiovascular Risk Factors in Overweight Patients: 1-Year Experience from the RIO-Europe Study</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">365</span><span class="NLM_x">, </span> <span class="NLM_fpage">1389</span><span class="NLM_x">â</span> <span class="NLM_lpage">1397</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=16&amp;doi=10.1021%2Fjm4010835&amp;key=10.1016%2FS0140-6736%2805%2966374-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=8&amp;doi=10.1021%2Fjm4010835&amp;key=15836887" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=32&amp;doi=10.1021%2Fjm4010835&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjsVegtbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=365&publication_year=2005&pages=1389-1397&author=L.+F.+Van+Gaalauthor=A.+M.+Rissanenauthor=A.+J.+Scheenauthor=O.+Zieglerauthor=S.+R%C3%B6ssner&title=Effects+of+the+Cannabinoid-1+Receptor+Blocker+Rimonabant+on+Weight+Reduction+and+Cardiovascular+Risk+Factors+in+Overweight+Patients%3A+1-Year+Experience+from+the+RIO-Europe+Study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3bR"><div class="casContent"><span class="casTitleNuber">3b</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study</span></div><div class="casAuthors">Van Gaal, Luc F.; Rissanen, Aila M.; Scheen, Andre J.; Ziegler, Olivier; Roessner, Stephan</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">365</span>
        (<span class="NLM_cas:issue">9468</span>),
    <span class="NLM_cas:pages">1389-1397</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Background: In animal models, cannabinoid-1 receptor (CB1) blockade produces a lean phenotype, with resistance to diet-induced obesity and assocd. dyslipidemia.  We assessed the effect of rimonabant, a selective CB1 blocker, on bodyweight and cardiovascular risk factors in overweight or obese patients.  Methods: patients with body-mass index 30 kg/m2 or greater, or body-mass index greater than 27 kg/m2 with treated or untreated dyslipidemia, hypertension, or both, were randomized to receive double-blind treatment with placebo, 5 mg rimonabant, or 20 mg rimonabant once daily in addn. to a mild hypocaloric diet (600 kcal/day deficit).  The primary efficacy endpoint was wt. change from baseline after 1 yr of treatment in the intention-to-treat population.  Findings: Wt. loss at 1 yr was significantly greater in patients treated with rimonabant 5 mg (mean -3Â·4 kg [SD 5Â·7]; p=0Â·002 vs placebo) and 20 mg (-6Â·6 kg [7Â·2]; p<0Â·001 vs placebo) compared with placebo (-1Â·8 kg [6Â·4]).  Significantly more patients treated with rimonabant 20 mg than placebo achieved wt. loss of 5% or greater (p<0Â·001) and 10% or greater (p<0Â·001).  Rimonabant 20 mg produced significantly greater improvements than placebo in waist circumference, HDL-cholesterol, triglycerides, and insulin resistance, and prevalence of the metabolic syndrome.  The effects of rimonabant 5 mg were of less clin. significance.  Rimonabant was generally well tolerated with mild and transient side effects.  Interpretation: CB1 blockade with rimonabant 20 mg, combined with a hypocaloric diet over 1 yr, promoted significant decrease of bodyweight and waist circumference, and improvement in cardiovascular risk factors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJDfvQ1f24LLVg90H21EOLACvtfcHk0lg-i9hDfX1ZEw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjsVegtbo%253D&md5=99a1c3a9978bc97be839c2284db5c385</span></div><a href="/servlet/linkout?suffix=cit3b&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2805%2966374-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252805%252966374-X%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BGaal%26aufirst%3DL.%2BF.%26aulast%3DRissanen%26aufirst%3DA.%2BM.%26aulast%3DScheen%26aufirst%3DA.%2BJ.%26aulast%3DZiegler%26aufirst%3DO.%26aulast%3DR%25C3%25B6ssner%26aufirst%3DS.%26atitle%3DEffects%2520of%2520the%2520Cannabinoid-1%2520Receptor%2520Blocker%2520Rimonabant%2520on%2520Weight%2520Reduction%2520and%2520Cardiovascular%2520Risk%2520Factors%2520in%2520Overweight%2520Patients%253A%25201-Year%2520Experience%2520from%2520the%2520RIO-Europe%2520Study%26jtitle%3DLancet%26date%3D2005%26volume%3D365%26spage%3D1389%26epage%3D1397" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit3c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Bellocchio, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mancini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vicennati, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasquali, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pagotto, U.</span><span> </span><span class="NLM_article-title">Cannabinoid Recptors as Therapeutic Targets for Obesity and Metabolic Diseases</span> <span class="citation_source-journal">Curr. Opin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">586</span><span class="NLM_x">â</span> <span class="NLM_lpage">591</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3c&amp;dbid=16&amp;doi=10.1021%2Fjm4010835&amp;key=10.1016%2Fj.coph.2006.09.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3c&amp;dbid=8&amp;doi=10.1021%2Fjm4010835&amp;key=17027338" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3c&amp;dbid=32&amp;doi=10.1021%2Fjm4010835&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFKmt7fO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=586-591&author=L.+Bellocchioauthor=G.+Manciniauthor=V.+Vicennatiauthor=R.+Pasqualiauthor=U.+Pagotto&title=Cannabinoid+Recptors+as+Therapeutic+Targets+for+Obesity+and+Metabolic+Diseases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3cR"><div class="casContent"><span class="casTitleNuber">3c</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid receptors as therapeutic targets for obesity and metabolic diseases</span></div><div class="casAuthors">Bellocchio, Luigi; Mancini, Giacomo; Vicennati, Valentina; Pasquali, Renato; Pagotto, Uberto</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">586-591</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  One of the most interesting pharmacol. targets proposed in the past ten years for fighting obesity and related metabolic disorders is the endocannabinoid system.  The role of the endocannabinoid system is crucial in regulating the rewarding properties of food, in controlling energy balance by acting at the hypothalamic circuitries involved in food intake, and in peripheral metab. by influencing adipocytes, hepatocytes, myocytes and pancreatic endocrine cells.  Obesity seems to be a condition assocd. with a pathol. overactivation of the endocannabinoid system; therefore, restoring a normal endocannabinoid tone by antagonizing the cannabinoid receptor type 1 (CB1) could help arrest both the development and the maintenance of obesity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0eSr9DU5F-bVg90H21EOLACvtfcHk0liiRe9NP4mV5A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFKmt7fO&md5=2aa553d9332e761be69b53134ad1d7ba</span></div><a href="/servlet/linkout?suffix=cit3c&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2006.09.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2006.09.001%26sid%3Dliteratum%253Aachs%26aulast%3DBellocchio%26aufirst%3DL.%26aulast%3DMancini%26aufirst%3DG.%26aulast%3DVicennati%26aufirst%3DV.%26aulast%3DPasquali%26aufirst%3DR.%26aulast%3DPagotto%26aufirst%3DU.%26atitle%3DCannabinoid%2520Recptors%2520as%2520Therapeutic%2520Targets%2520for%2520Obesity%2520and%2520Metabolic%2520Diseases%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2006%26volume%3D6%26spage%3D586%26epage%3D591" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Walthion, N.</span><div class="note"><p class="first last">European Medicines Agency Press Release EMEA/39457/2009, January 30, 2009; and, European Medicines Agency Press Release EMEA/537153/2008, October 23, 2008.</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Walthion%2C+N.European+Medicines+Agency+Press+Release+EMEA%2F39457%2F2009%2C+January+30%2C+2009%3B+and%2C+European+Medicines+Agency+Press+Release+EMEA%2F537153%2F2008%2C+October+23%2C+2008."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DWalthion%26aufirst%3DN." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Seltzman, H. H.</span><span> </span><span class="NLM_article-title">Recent CB1 Cannabinoid Receptor Antagonists and Inverse Agonists</span> <span class="citation_source-journal">Drug Dev. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">601</span><span class="NLM_x">â</span> <span class="NLM_lpage">615</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm4010835&amp;key=10.1002%2Fddr.20338" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm4010835&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGrtrjP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2009&pages=601-615&issue=8&author=H.+H.+Seltzman&title=Recent+CB1+Cannabinoid+Receptor+Antagonists+and+Inverse+Agonists"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Recent CB1 cannabinoid receptor antagonists and inverse agonists</span></div><div class="casAuthors">Seltzman, Herbert H.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Development Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">601-615</span>CODEN:
                <span class="NLM_cas:coden">DDREDK</span>;
        ISSN:<span class="NLM_cas:issn">0272-4391</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">A review.  Antagonists or inverse agonists of the cannabinoid CB1 receptor (CB1R) reported from the 2006-2007 period are reviewed.  The compds. are either variations of the archetypical cannabinoid CB1 inverse agonist rimonabant (SR141716) or are other structures less obviously related to the archetype.  Many of the former class replace the core pyrazole ring of rimonabant with other ring systems to display/arrange the appended binding/activity elements.  A structure-activity relation evolves from bioassays of these compds. that also provides a more detailed understanding of the mol. mechanism of the binding to and stabilization of the active and inactive states of the constitutively active CB1R.  In addn. to diverse variations of the core ring and appended substituents, conformationally constrained analogs with high affinity were revealed, a no. of which do not fit a one-to-one atom correspondence with the putatively active conformations of the rimonabant template and other active analogs.  Diphenylmethyl analogs were a repeated motif in structures where core rings were either absent or played less restrictive roles in structures pursuing higher conformational freedom.  Bicyclic nitrogen heterocyclic ring systems as the central core structures were reported, as were linear structures including Ph ureas and taranabant analogs.  Finally, peptides in the hemopressin class were presented as CB1 antagonists.  Drug Dev Res 70:601-615, 2009. Â© 2009 Wiley-Liss, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6cEqOfdS8ArVg90H21EOLACvtfcHk0liiRe9NP4mV5A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGrtrjP&md5=dc643cd15355ae07cb035b8f717c46af</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1002%2Fddr.20338&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fddr.20338%26sid%3Dliteratum%253Aachs%26aulast%3DSeltzman%26aufirst%3DH.%2BH.%26atitle%3DRecent%2520CB1%2520Cannabinoid%2520Receptor%2520Antagonists%2520and%2520Inverse%2520Agonists%26jtitle%3DDrug%2520Dev.%2520Res.%26date%3D2009%26volume%3D70%26issue%3D8%26spage%3D601%26epage%3D615" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Letourneau, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jokiel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riviello, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, K.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McAleer, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swanson, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohlmeyer, M. H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, M. L.</span><span> </span><span class="NLM_article-title">Identification and Hit-to-lead Optimization of a Novel Class of CB1 Antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">5449</span><span class="NLM_x">â</span> <span class="NLM_lpage">5453</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=5449-5453&author=J.+J.+Letourneauauthor=P.+Jokielauthor=J.+Olsonauthor=C.+M.+Rivielloauthor=K.-K.+Hoauthor=L.+McAleerauthor=J.+Yangauthor=R.+N.+Swansonauthor=J.+Bakerauthor=P.+Cowleyauthor=D.+Edwardsauthor=N.+Wardauthor=M.+H.+J.+Ohlmeyerauthor=M.+L.+Webb&title=Identification+and+Hit-to-lead+Optimization+of+a+Novel+Class+of+CB1+Antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLetourneau%26aufirst%3DJ.%2BJ.%26aulast%3DJokiel%26aufirst%3DP.%26aulast%3DOlson%26aufirst%3DJ.%26aulast%3DRiviello%26aufirst%3DC.%2BM.%26aulast%3DHo%26aufirst%3DK.-K.%26aulast%3DMcAleer%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DSwanson%26aufirst%3DR.%2BN.%26aulast%3DBaker%26aufirst%3DJ.%26aulast%3DCowley%26aufirst%3DP.%26aulast%3DEdwards%26aufirst%3DD.%26aulast%3DWard%26aufirst%3DN.%26aulast%3DOhlmeyer%26aufirst%3DM.%2BH.%2BJ.%26aulast%3DWebb%26aufirst%3DM.%2BL.%26atitle%3DIdentification%2520and%2520Hit-to-lead%2520Optimization%2520of%2520a%2520Novel%2520Class%2520of%2520CB1%2520Antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D5449%26epage%3D5453" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Griffith, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hadcock, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Black, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iredale, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carpino, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DaSilva-Jardine, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Day, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiBrino, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dow, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Landis, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâConnor, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, D. O.</span><span> </span><span class="NLM_article-title">Discovery of 1-[9-(4-Chlorophenyl)-8-(2-chlorophenyl)-9<i>H</i>-purin-6-yl]-4-ethylaminopiperidine-4-carboxylic Acid Amide Hydrochloride (CP-945,598), a Novel, Potent, and Selective Cannabinoid Type 1 Receptor Antagonist</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">234</span><span class="NLM_x">â</span> <span class="NLM_lpage">237</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm8012932" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=234-237&author=D.+A.+Griffithauthor=J.+R.+Hadcockauthor=S.+C.+Blackauthor=P.+A.+Iredaleauthor=P.+A.+Carpinoauthor=P.+DaSilva-Jardineauthor=R.+Dayauthor=J.+DiBrinoauthor=R.+L.+Dowauthor=M.+S.+Landisauthor=R.+E.+O%E2%80%99Connorauthor=D.+O.+Scott&title=Discovery+of+1-%5B9-%284-Chlorophenyl%29-8-%282-chlorophenyl%29-9H-purin-6-yl%5D-4-ethylaminopiperidine-4-carboxylic+Acid+Amide+Hydrochloride+%28CP-945%2C598%29%2C+a+Novel%2C+Potent%2C+and+Selective+Cannabinoid+Type+1+Receptor+Antagonist"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Fjm8012932&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8012932%26sid%3Dliteratum%253Aachs%26aulast%3DGriffith%26aufirst%3DD.%2BA.%26aulast%3DHadcock%26aufirst%3DJ.%2BR.%26aulast%3DBlack%26aufirst%3DS.%2BC.%26aulast%3DIredale%26aufirst%3DP.%2BA.%26aulast%3DCarpino%26aufirst%3DP.%2BA.%26aulast%3DDaSilva-Jardine%26aufirst%3DP.%26aulast%3DDay%26aufirst%3DR.%26aulast%3DDiBrino%26aufirst%3DJ.%26aulast%3DDow%26aufirst%3DR.%2BL.%26aulast%3DLandis%26aufirst%3DM.%2BS.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DR.%2BE.%26aulast%3DScott%26aufirst%3DD.%2BO.%26atitle%3DDiscovery%2520of%25201-%255B9-%25284-Chlorophenyl%2529-8-%25282-chlorophenyl%2529-9H-purin-6-yl%255D-4-ethylaminopiperidine-4-carboxylic%2520Acid%2520Amide%2520Hydrochloride%2520%2528CP-945%252C598%2529%252C%2520a%2520Novel%252C%2520Potent%252C%2520and%2520Selective%2520Cannabinoid%2520Type%25201%2520Receptor%2520Antagonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D234%26epage%3D237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span>Rimonabant: Acomplia EPAR Product Information; European Agency for The Evaluation of Medicinal Products: <span class="NLM_publisher-loc">London</span>,<span class="NLM_x"> </span><span class="NLM_year">2009</span><span class="NLM_x">; </span><a href="http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000666/human_med_000623.jsp&amp;mid=WC0b01ac058001d124" class="extLink">http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000666/human_med_000623.jsp&mid=WC0b01ac058001d124</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Rimonabant%3A+Acomplia+EPAR+Product+Information%3B+European+Agency+for+The+Evaluation+of+Medicinal+Products%3A+London%2C+2009%3B+http%3A%2F%2Fwww.ema.europa.eu%2Fema%2Findex.jsp%3Fcurl%3Dpages%2Fmedicines%2Fhuman%2Fmedicines%2F000666%2Fhuman_med_000623.jsp%26mid%3DWC0b01ac058001d124."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DRimonabant%253A%2520Acomplia%2520EPAR%2520Product%2520Information%26jtitle%3DEuropean%2520Agency%2520for%2520The%2520Evaluation%2520of%2520Medicinal%2520Products%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Addy, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rothenberg, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Majumdar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agrawal, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunbar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cote, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosko, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Dyck, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Lepeleire, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Hoon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Hecken, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Depre, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knops, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottesdiener, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoch, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, J.</span><span> </span><span class="NLM_article-title">Multiple-Dose Pharmacokinetics, Pharmacodynamics, and Safety of Taranabant, a Novel Selective Cannabinoid-1 Receptor Inverse Agonist, in Healthy Male Volunteers</span> <span class="citation_source-journal">J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">734</span><span class="NLM_x">â</span> <span class="NLM_lpage">744</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm4010835&amp;key=10.1177%2F0091270008317591" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm4010835&amp;key=18508950" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm4010835&amp;key=1%3ACAS%3A528%3ADC%252BD1cXns1Kit7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2008&pages=734-744&author=C.+Addyauthor=P.+Rothenbergauthor=S.+Liauthor=A.+Majumdarauthor=N.+Agrawalauthor=H.+Liauthor=L.+Zhongauthor=J.+Yuanauthor=A.+Maesauthor=S.+Dunbarauthor=J.+Coteauthor=K.+Roskoauthor=K.+Van+Dyckauthor=I.+De+Lepeleireauthor=J.+de+Hoonauthor=A.+Van+Heckenauthor=M.+Depreauthor=A.+Knopsauthor=K.+Gottesdienerauthor=A.+Stochauthor=J.+Wagner&title=Multiple-Dose+Pharmacokinetics%2C+Pharmacodynamics%2C+and+Safety+of+Taranabant%2C+a+Novel+Selective+Cannabinoid-1+Receptor+Inverse+Agonist%2C+in+Healthy+Male+Volunteers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteers</span></div><div class="casAuthors">Addy, Carol; Rothenberg, Paul; Li, Susie; Majumdar, Anup; Agrawal, Nancy; Li, Hankun; Zhong, Ling; Yuan, Jinyu; Maes, Andrea; Dunbar, Stephanie; Cote, Josee; Rosko, Kim; Van Dyck, Kristien; De Lepeleire, Inge; de Hoon, Jan; Van Hecken, Anne; Depre, Marleen; Knops, Annemie; Gottesdiener, Keith; Stoch, Aubrey; Wagner, John</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">734-744</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Taranabant is a cannabinoid-1 receptor inverse agonist for the treatment of obesity.  This study evaluated the safety, pharmacokinetics, and pharmacodynamics of taranabant (5, 7.5, 10, or 25 mg once daily for 14 days) in 60 healthy male subjects.  Taranabant was rapidly absorbed, with a median tmax of 1.0 to 2.0 h and a t1/2 of approx. 74 to 104 h.  Moderate accumulation was obsd. in Cmax (1.18- to 1.40-fold) and AUC0-24 h (1.5- to 1.8-fold) over 14 days for the 5-, 7.5-, and 10-mg doses, with an accumulation half-life ranging from 15 to 21 h.  Steady state was reached after 13 days.  After multiple-dose administration, plasma AUC0-24 h and Cmax of taranabant increased dose proportionally (5-10 mg) and increased somewhat less than dose proportionally for 25 mg.  Taranabant was generally well tolerated up to doses of 10 mg and exhibited multiple-dose pharmacokinetics consistent with once-daily dosing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEiSkhEMfIDLVg90H21EOLACvtfcHk0lip1xlgcgEGLA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXns1Kit7Y%253D&md5=0bb78538334e4b3018954d0cf6ec4c0c</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1177%2F0091270008317591&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0091270008317591%26sid%3Dliteratum%253Aachs%26aulast%3DAddy%26aufirst%3DC.%26aulast%3DRothenberg%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DMajumdar%26aufirst%3DA.%26aulast%3DAgrawal%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DZhong%26aufirst%3DL.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DMaes%26aufirst%3DA.%26aulast%3DDunbar%26aufirst%3DS.%26aulast%3DCote%26aufirst%3DJ.%26aulast%3DRosko%26aufirst%3DK.%26aulast%3DVan%2BDyck%26aufirst%3DK.%26aulast%3DDe%2BLepeleire%26aufirst%3DI.%26aulast%3Dde%2BHoon%26aufirst%3DJ.%26aulast%3DVan%2BHecken%26aufirst%3DA.%26aulast%3DDepre%26aufirst%3DM.%26aulast%3DKnops%26aufirst%3DA.%26aulast%3DGottesdiener%26aufirst%3DK.%26aulast%3DStoch%26aufirst%3DA.%26aulast%3DWagner%26aufirst%3DJ.%26atitle%3DMultiple-Dose%2520Pharmacokinetics%252C%2520Pharmacodynamics%252C%2520and%2520Safety%2520of%2520Taranabant%252C%2520a%2520Novel%2520Selective%2520Cannabinoid-1%2520Receptor%2520Inverse%2520Agonist%252C%2520in%2520Healthy%2520Male%2520Volunteers%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2008%26volume%3D48%26spage%3D734%26epage%3D744" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Miao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liras, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prakash, C.</span><span> </span><span class="NLM_article-title">Excretion, Metabolism, and Pharmacokinetics of 1-(8-(2-Chlorophenyl)-9-(4-chlorophenyl)-9<i>H</i>-purin-6-yl)-4-(ethylamino)piperidine-4-carboxamide, a Selective Cannabinoid Receptor Antagonist, in Healthy Male Volunteers</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">568</span><span class="NLM_x">â</span> <span class="NLM_lpage">578</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=568-578&issue=3&author=Z.+Miaoauthor=H.+Sunauthor=J.+Lirasauthor=C.+Prakash&title=Excretion%2C+Metabolism%2C+and+Pharmacokinetics+of+1-%288-%282-Chlorophenyl%29-9-%284-chlorophenyl%29-9H-purin-6-yl%29-4-%28ethylamino%29piperidine-4-carboxamide%2C+a+Selective+Cannabinoid+Receptor+Antagonist%2C+in+Healthy+Male+Volunteers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMiao%26aufirst%3DZ.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DLiras%26aufirst%3DJ.%26aulast%3DPrakash%26aufirst%3DC.%26atitle%3DExcretion%252C%2520Metabolism%252C%2520and%2520Pharmacokinetics%2520of%25201-%25288-%25282-Chlorophenyl%2529-9-%25284-chlorophenyl%2529-9H-purin-6-yl%2529-4-%2528ethylamino%2529piperidine-4-carboxamide%252C%2520a%2520Selective%2520Cannabinoid%2520Receptor%2520Antagonist%252C%2520in%2520Healthy%2520Male%2520Volunteers%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2012%26volume%3D40%26issue%3D3%26spage%3D568%26epage%3D578" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Greenblatt, D. J.</span><span> </span><span class="NLM_article-title">Elimination Half-life of Drugs: Value and Limitations</span> <span class="citation_source-journal">Annu. Rev. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">421</span><span class="NLM_x">â</span> <span class="NLM_lpage">427</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1985&pages=421-427&author=D.+J.+Greenblatt&title=Elimination+Half-life+of+Drugs%3A+Value+and+Limitations"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGreenblatt%26aufirst%3DD.%2BJ.%26atitle%3DElimination%2520Half-life%2520of%2520Drugs%253A%2520Value%2520and%2520Limitations%26jtitle%3DAnnu.%2520Rev.%2520Med.%26date%3D1985%26volume%3D36%26spage%3D421%26epage%3D427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Welling, P. G.</span> <span class="citation_source-book">Pharmacokinetics</span>; <span class="NLM_series">ACS Monograph 185</span>; <span class="NLM_publisher-name">American Chemical Society</span>: <span class="NLM_publisher-loc">Washington, DC</span>,<span class="NLM_x"> </span><span class="NLM_year">1986</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">187</span><span class="NLM_x">â</span> <span class="NLM_lpage">200</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1986&pages=187-200&author=P.+G.+Welling&title=Pharmacokinetics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DWelling%26aufirst%3DP.%2BG.%26btitle%3DPharmacokinetics%26pub%3DAmerican%2520Chemical%2520Society%26date%3D1986%26spage%3D187%26epage%3D200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Salzman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shader, R. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenblatt, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harmatz, J. S.</span><span> </span><span class="NLM_article-title">Long v Short Half-life Benzodiazepines in the Elderly</span> <span class="citation_source-journal">Arch. Gen. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1983</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">293</span><span class="NLM_x">â</span> <span class="NLM_lpage">297</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm4010835&amp;key=10.1001%2Farchpsyc.1983.01790030063008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm4010835&amp;key=1%3ACAS%3A280%3ADyaL3s7lt1WhsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1983&pages=293-297&author=C.+Salzmanauthor=R.+I.+Shaderauthor=D.+J.+Greenblattauthor=J.+S.+Harmatz&title=Long+v+Short+Half-life+Benzodiazepines+in+the+Elderly"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Long v short half-life benzodiazepines in the elderly. Kinetics and clinical effects of diazepam and oxazepam</span></div><div class="casAuthors">Salzman C; Shader R I; Greenblatt D J; Harmatz J S</div><div class="citationInfo"><span class="NLM_cas:title">Archives of general psychiatry</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">293-7</span>
        ISSN:<span class="NLM_cas:issn">0003-990X</span>.
    </div><div class="casAbstract">Oxazepam and diazepam were compared in healthy elderly volunteers.  Absorption of diazepam was faster than oxazepam and onset of clinical effects were more profound.  Diazepam accumulation was extensive, washout was slow and active compounds were present two weeks after the last dose.  Oxazepam accumulation was significantly less and elimination significantly faster than diazepam.  There was no difference between oxazepam and diazepam in sedation or fatigue during the drug treatment, but sedative effects persisted for two weeks after diazepam therapy was discontinued.  Sedation rapidly returned to baseline in the oxazepam group.  Thus, the differing pharmacokinetic profiles of diazepam and oxazepam have clinical consequences during multiple dosage in the elderly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRH_nfYZaaMgJNiNltV31zlfW6udTcc2eaRvqiFQtRp97ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL3s7lt1WhsA%253D%253D&md5=22583995d29a795a6e352e1e736cb363</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1001%2Farchpsyc.1983.01790030063008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchpsyc.1983.01790030063008%26sid%3Dliteratum%253Aachs%26aulast%3DSalzman%26aufirst%3DC.%26aulast%3DShader%26aufirst%3DR.%2BI.%26aulast%3DGreenblatt%26aufirst%3DD.%2BJ.%26aulast%3DHarmatz%26aufirst%3DJ.%2BS.%26atitle%3DLong%2520v%2520Short%2520Half-life%2520Benzodiazepines%2520in%2520the%2520Elderly%26jtitle%3DArch.%2520Gen.%2520Psychiatry%26date%3D1983%26volume%3D40%26spage%3D293%26epage%3D297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Ellsworth, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pendri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerritz, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlson, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baska, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burford, N. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cullen, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnghar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behnia, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pelleymounter, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Washburn, W. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ewing, W. R.</span><span> </span><span class="NLM_article-title">Discovery of Pyrazine Carboxamide CB1 Antagonists: The Introduction of a Hydroxyl Group Improves the Pharmaceutical Properties and In Vivo Efficacy of the Series</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">3978</span><span class="NLM_x">â</span> <span class="NLM_lpage">3982</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm4010835&amp;key=10.1016%2Fj.bmcl.2007.04.087" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm4010835&amp;key=17513109" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm4010835&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmvVClu7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=3978-3982&author=B.+A.+Ellsworthauthor=Y.+Wangauthor=Y.+Zhuauthor=A.+Pendriauthor=S.+W.+Gerritzauthor=C.+Sunauthor=K.+E.+Carlsonauthor=L.+Kangauthor=R.+A.+Baskaauthor=Y.+Yangauthor=Q.+Huangauthor=N.+T.+Burfordauthor=M.+J.+Cullenauthor=S.+Johngharauthor=K.+Behniaauthor=M.+A.+Pelleymounterauthor=W.+N.+Washburnauthor=W.+R.+Ewing&title=Discovery+of+Pyrazine+Carboxamide+CB1+Antagonists%3A+The+Introduction+of+a+Hydroxyl+Group+Improves+the+Pharmaceutical+Properties+and+In+Vivo+Efficacy+of+the+Series"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of pyrazine carboxamide CB1 antagonists: The introduction of a hydroxyl group improves the pharmaceutical properties and in vivo efficacy of the series</span></div><div class="casAuthors">Ellsworth, Bruce A.; Wang, Ying; Zhu, Yeheng; Pendri, Annapurna; Gerritz, Samuel W.; Sun, Chongqing; Carlson, Kenneth E.; Kang, Liya; Baska, Rose A.; Yang, Yifan; Huang, Qi; Burford, Neil T.; Cullen, Mary Jane; Johnghar, Susan; Behnia, Kamelia; Pelleymounter, Mary Ann; Washburn, William N.; Ewing, William R.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3978-3982</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Structure-activity relationships for a series of pyrazine carboxamide CB1 antagonists are reported.  Pharmaceutical properties of the series are improved via inclusion of hydroxyl-contg. sidechains.  This structural modification sufficiently improved ADME properties of an orally inactive series such that food intake redn. was achieved in rat feeding models.  Compd. 35 (I) elicits a 46% redn. in food intake in ad libitum fed rats 4-h post-dose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqp2iSxEZT2bVg90H21EOLACvtfcHk0lhsBQBSCEEcJw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmvVClu7k%253D&md5=723258b8fb296b9d23ff228d0ce7d15d</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2007.04.087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2007.04.087%26sid%3Dliteratum%253Aachs%26aulast%3DEllsworth%26aufirst%3DB.%2BA.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DPendri%26aufirst%3DA.%26aulast%3DGerritz%26aufirst%3DS.%2BW.%26aulast%3DSun%26aufirst%3DC.%26aulast%3DCarlson%26aufirst%3DK.%2BE.%26aulast%3DKang%26aufirst%3DL.%26aulast%3DBaska%26aufirst%3DR.%2BA.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DBurford%26aufirst%3DN.%2BT.%26aulast%3DCullen%26aufirst%3DM.%2BJ.%26aulast%3DJohnghar%26aufirst%3DS.%26aulast%3DBehnia%26aufirst%3DK.%26aulast%3DPelleymounter%26aufirst%3DM.%2BA.%26aulast%3DWashburn%26aufirst%3DW.%2BN.%26aulast%3DEwing%26aufirst%3DW.%2BR.%26atitle%3DDiscovery%2520of%2520Pyrazine%2520Carboxamide%2520CB1%2520Antagonists%253A%2520The%2520Introduction%2520of%2520a%2520Hydroxyl%2520Group%2520Improves%2520the%2520Pharmaceutical%2520Properties%2520and%2520In%2520Vivo%2520Efficacy%2520of%2520the%2520Series%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D3978%26epage%3D3982" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Meanwell, N. A.</span><span> </span><span class="NLM_article-title">Improving Drug Candidates by Design: A Focus on Physicochemical Properties As a Means of Improving Compound Disposition and Safety</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">1420</span><span class="NLM_x">â</span> <span class="NLM_lpage">1456</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx200211v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm4010835&amp;key=1%3ACAS%3A528%3ADC%252BC3MXptlCitLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2011&pages=1420-1456&issue=9&author=N.+A.+Meanwell&title=Improving+Drug+Candidates+by+Design%3A+A+Focus+on+Physicochemical+Properties+As+a+Means+of+Improving+Compound+Disposition+and+Safety"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Improving Drug Candidates by Design: A Focus on Physicochemical Properties As a Means of Improving Compound Disposition and Safety</span></div><div class="casAuthors">Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1420-1456</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The development of small mol. drug candidates from the discovery phase to a marketed product continues to be a challenging enterprise with very low success rates that have fostered the perception of poor productivity by the pharmaceutical industry.  Although there have been significant advances in preclin. profiling that have improved compd. triaging and altered the underlying reasons for compd. attrition, the failure rates have not appreciably changed.  As part of an effort to more deeply understand the reasons for candidate failure, there has been considerable interest in analyzing the physicochem. properties of marketed drugs for the purpose of comparing with drugs in discovery and development as a means capturing recent trends in drug design.  The scenario that has emerged is one in which contemporary drug discovery is thought to be focused too heavily on advancing candidates with profiles that are most easily satisfied by mols. with increased mol. wt. and higher overall lipophilicity.  The preponderance of mols. expressing these properties is frequently a function of increased arom. ring count when compared with that of the drugs launched in the latter half of the 20th century and may reflect a preoccupation with maximizing target affinity rather than taking a more holistic approach to drug design.  These attributes not only present challenges for formulation and absorption but also may influence the manifestation of toxicity during development.  By providing some definition around the optimal physicochem. properties assocd. with marketed drugs, guidelines for drug design have been developed that are based largely on calcd. parameters and which may readily be applied by medicinal chemists as an aid to understanding candidate quality.  The physicochem. properties of a mol. that are consistent with the potential for good oral absorption were initially defined by Lipinski, with addnl. insights allowing further refinement, while deeper analyses have explored the correlation with metabolic stability and toxicity.  These insights have been augmented by careful analyses of physicochem. aspects of drug-target interactions, with thermodn. profiling indicating that the signature of best-in-class drugs is a dependence on enthalpy to drive binding energetics rather than entropy, which is dependent on lipophilicity.  Optimization of the entropic contribution to the binding energy of a ligand to its target is generally much easier than refining the enthalpic element.  Consequently, in the absence of a fundamental understanding of the thermodn. complexion of an interaction, the design of mols. with increased lipophilicity becomes almost inevitable.  The application of ligand efficiency, a measure of affinity per heavy atom, group efficiency, which assesses affinity in the context of structural changes, and lipophilic ligand efficiency, which relates potency to lipophilicity, offer less sophisticated but practically useful anal. algorithms to assess the quality of drug-target interactions.  These parameters are readily calcd. and can be applied to lead optimization programs in a fashion that helps to maximize potency while minimizing the kind of lipophilic burden that has been dubbed "mol. obesity".  Several recently described lead optimization campaigns provide illustrative, informative, and productive examples of the effect of paying close attention to carefully controlling physicochem. properties by monitoring ligand efficiency and lipophilic ligand efficiency.  However, to be successful during the lead optimization phase, drug candidate identification programs will need to adopt a holistic approach that integrates multiple parameters, many of which will have unique dependencies on both the drug target and the specific chemotype under prosecution.  Nevertheless, there are many important drug targets that necessitate working in space beyond that which has been defined by the retrospective analyses of marketed drugs and which will require adaptation of some of the guideposts that are useful in directing lead optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQrUfIwZiIR7Vg90H21EOLACvtfcHk0lhsBQBSCEEcJw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXptlCitLs%253D&md5=9ddcf6dc81bf8ab0441df5037979ff4e</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Ftx200211v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx200211v%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DImproving%2520Drug%2520Candidates%2520by%2520Design%253A%2520A%2520Focus%2520on%2520Physicochemical%2520Properties%2520As%2520a%2520Means%2520of%2520Improving%2520Compound%2520Disposition%2520and%2520Safety%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2011%26volume%3D24%26issue%3D9%26spage%3D1420%26epage%3D1456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Yu, G.; Ellsworth, B. A.; Mikkilineni, A.; Wu, X.; Wang, Y.; Sitkoff, D.; Gu, Z.; Murugesan, N.; Swartz, S.; Carlson, K. E.; Kang, L.; Yang, Y.; Lee, N.; Baska, R. A.; Huang, Q.; Cullen, M. J.; Zuvich, E.; Thomas, M.; Rohrbach, K.; Devenny, J.; Godonis, H.; Harvey, S.; Johnghar, S.; Behnia, K.; Pelleymounter, M. A.; Ewing, W. R.</span><span> </span><span class="NLM_article-title">Discovery of Di-Aryl Triazolopyridazine Cannabinoid Receptor (CB1) Antagonists</span>. <span class="NLM_conf-name">Fall 2008 ACS National Meeting</span>, <span class="NLM_conf-loc">Philadelphia, PA</span>, <span class="NLM_conf-date">August 17â21, 2008</span>,  <span class="NLM_fpage">MEDI 010</span>, .</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Yu%2C+G.%3B+Ellsworth%2C+B.+A.%3B+Mikkilineni%2C+A.%3B+Wu%2C+X.%3B+Wang%2C+Y.%3B+Sitkoff%2C+D.%3B+Gu%2C+Z.%3B+Murugesan%2C+N.%3B+Swartz%2C+S.%3B+Carlson%2C+K.+E.%3B+Kang%2C+L.%3B+Yang%2C+Y.%3B+Lee%2C+N.%3B+Baska%2C+R.+A.%3B+Huang%2C+Q.%3B+Cullen%2C+M.+J.%3B+Zuvich%2C+E.%3B+Thomas%2C+M.%3B+Rohrbach%2C+K.%3B+Devenny%2C+J.%3B+Godonis%2C+H.%3B+Harvey%2C+S.%3B+Johnghar%2C+S.%3B+Behnia%2C+K.%3B+Pelleymounter%2C+M.+A.%3B+Ewing%2C+W.+R.+Discovery+of+Di-Aryl+Triazolopyridazine+Cannabinoid+Receptor+%28CB1%29+Antagonists.+Fall+2008+ACS+National+Meeting%2C+Philadelphia%2C+PA%2C+August+17%E2%80%9321%2C+2008%2C+MEDI+010%2C+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DG.%26atitle%3DDiscovery%2520of%2520Di-Aryl%2520Triazolopyridazine%2520Cannabinoid%2520Receptor%2520%2528CB1%2529%2520Antagonists%26spage%3DMEDI%2520010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murugesan, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâTanyi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keim, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rohrbach, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnghar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behnia, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pelleymounter, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlson, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ewing, W. R.</span><span> </span><span class="NLM_article-title">Characterization of a novel and selective CB1 antagonist as a radioligand for receptor occupancy studies</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x"> (</span><span class="NLM_issue">22</span><span class="NLM_x">) </span> <span class="NLM_fpage">6856</span><span class="NLM_x">â</span> <span class="NLM_lpage">6860</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=6856-6860&issue=22&author=Y.+Yangauthor=K.+J.+Millerauthor=Y.+Zhuauthor=Y.+Hongauthor=Y.+Tianauthor=N.+Murugesanauthor=Z.+Guauthor=E.+O%E2%80%99Tanyiauthor=W.+J.+Keimauthor=K.+W.+Rohrbachauthor=S.+Johngharauthor=K.+Behniaauthor=M.+A.+Pelleymounterauthor=K.+E.+Carlsonauthor=W.+R.+Ewing&title=Characterization+of+a+novel+and+selective+CB1+antagonist+as+a+radioligand+for+receptor+occupancy+studies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DY.%26aulast%3DMiller%26aufirst%3DK.%2BJ.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DHong%26aufirst%3DY.%26aulast%3DTian%26aufirst%3DY.%26aulast%3DMurugesan%26aufirst%3DN.%26aulast%3DGu%26aufirst%3DZ.%26aulast%3DO%25E2%2580%2599Tanyi%26aufirst%3DE.%26aulast%3DKeim%26aufirst%3DW.%2BJ.%26aulast%3DRohrbach%26aufirst%3DK.%2BW.%26aulast%3DJohnghar%26aufirst%3DS.%26aulast%3DBehnia%26aufirst%3DK.%26aulast%3DPelleymounter%26aufirst%3DM.%2BA.%26aulast%3DCarlson%26aufirst%3DK.%2BE.%26aulast%3DEwing%26aufirst%3DW.%2BR.%26atitle%3DCharacterization%2520of%2520a%2520novel%2520and%2520selective%2520CB1%2520antagonist%2520as%2520a%2520radioligand%2520for%2520receptor%2520occupancy%2520studies%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26issue%3D22%26spage%3D6856%26epage%3D6860" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><div class="note"><p class="first last">The regiochemistry of Grignard addition that we report herein appears to be previously unreported; however, Grignard reagents are found to add to pyridazin-3(2<i>H</i>)-ones as reported in:</p></div><span class="NLM_contrib-group">Verhelst, T.; Verbeeck, S.; Ryabtsova, O.; Depraetere, S.; Maes, B. U. W.</span><span> </span><span class="NLM_article-title">Synthesis of Functionalized Pyridazin-3(2<i>H</i>)-ones via Nucleophilic Substitution of Hydrogen (SnH)</span>.  <span class="citation_source-journal">Org. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">272</span><span class="NLM_x">â</span> <span class="NLM_lpage">275</span>.</span><div class="citationLinks">[<a href="/doi/10.1021/ol102703w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2011&pages=272-275&author=T.+Verhelst&author=S.+Verbeeck&author=O.+Ryabtsova&author=S.+Depraetere&author=B.+U.+W.+Maes&title=Synthesis+of+Functionalized+Pyridazin-3%282H%29-ones+via+Nucleophilic+Substitution+of+Hydrogen+%28SnH%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fol102703w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol102703w%26sid%3Dliteratum%253Aachs%26aulast%3DVerhelst%26aufirst%3DT.%26atitle%3DSynthesis%2520of%2520Functionalized%2520Pyridazin-3%25282H%2529-ones%2520via%2520Nucleophilic%2520Substitution%2520of%2520Hydrogen%2520%2528SnH%2529%26jtitle%3DOrg.%2520Lett.%26date%3D2011%26volume%3D13%26spage%3D272%26epage%3D275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><div class="note"><p class="first last">Experimental log P â<i>e</i> log Pâ was determined by the HPLC method, as described in:</p></div><span class="NLM_contrib-group">Valko, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bevan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, D.</span><span> </span><span class="NLM_article-title">Chromatographic Hydrophobicity Index by Fast-Gradient RP-HPLC: A High-Throughput Alternative to log P/log D</span> <span class="citation_source-journal">Anal. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">2022</span><span class="NLM_x">â</span> <span class="NLM_lpage">2029</span></span><div class="citationLinks">[<a href="/doi/10.1021/ac961242d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm4010835&amp;key=1%3ACAS%3A528%3ADyaK2sXivVertLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=1997&pages=2022-2029&author=K.+Valkoauthor=C.+Bevanauthor=D.+Reynolds&title=Chromatographic+Hydrophobicity+Index+by+Fast-Gradient+RP-HPLC%3A+A+High-Throughput+Alternative+to+log+P%2Flog+D"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Chromatographic Hydrophobicity Index by Fast-Gradient RP-HPLC: A High-Throughput Alternative to Log P/log D</span></div><div class="casAuthors">Valko, Klara; Bevan, Chris; Reynolds, Derek</div><div class="citationInfo"><span class="NLM_cas:title">Analytical Chemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2022-2029</span>CODEN:
                <span class="NLM_cas:coden">ANCHAM</span>;
        ISSN:<span class="NLM_cas:issn">0003-2700</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new chromatog. hydrophobicity index (CHI) is described which can be used as part of a protocol for high-throughput (50-100 compds./day) physicochem. property profiling for rational drug design.  The index is derived from retention times (tR) obsd. in a fast gradient reversed-phase HPLC method.  The isocratic retention factors (log k') were measured for a series of 76 structurally unrelated compds. by using various concns. of acetonitrile in the mobile phase.  By plotting the log k' as a function of the acetonitrile concn., the slope (S) and the intercept (log k'w) values were calcd.  The previously validated index of hydrophobicity Ï0 was calcd. as -log k'w/S.  A good linear correlation was obtained between the gradient retention time values, tR and the isocratically detd. Ï0 values for the 76 compds.  The consts. of this linear correlation can be used to calc. CHI.  For most compds., CHI is between 0 and 100 and in this range it approximates to the percentage (by vol.) of acetonitrile required to achieve an equal distribution of compd. between the mobile and the stationary phases.  CHI values can be measured using acidic, neutral, or slightly basic eluents.  Values corresponding to the neutral form of mols. could be measured for 52 of the compds. and showed good correlation (r = 0.851) to the calcd. octanol/water partition coeff. (c log P) values.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozvQI1B1cnpbVg90H21EOLACvtfcHk0ljO5aBkDU9UNw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXivVertLs%253D&md5=fcbb641105c12dc490d4a20db8fc5032</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fac961242d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fac961242d%26sid%3Dliteratum%253Aachs%26aulast%3DValko%26aufirst%3DK.%26aulast%3DBevan%26aufirst%3DC.%26aulast%3DReynolds%26aufirst%3DD.%26atitle%3DChromatographic%2520Hydrophobicity%2520Index%2520by%2520Fast-Gradient%2520RP-HPLC%253A%2520A%2520High-Throughput%2520Alternative%2520to%2520log%2520P%252Flog%2520D%26jtitle%3DAnal.%2520Chem.%26date%3D1997%26volume%3D69%26spage%3D2022%26epage%3D2029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Rohrbach, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâTanyi, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chi, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taub, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Largent, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, D.</span><span> </span><span class="NLM_article-title">Disconnection Between the Early Onset Anorectic Effects by C75 and Hypothalamic Fatty Acid Synthase Inhibition in Rodents</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">511</span><span class="NLM_x">, </span> <span class="NLM_fpage">31</span><div class="note"><p class="first last">Where indicated, % reduction in food intake is recorded at a shorter timepoint.</p></div></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm4010835&amp;key=10.1016%2Fj.ejphar.2005.01.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm4010835&amp;key=15777777" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm4010835&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitlCjsL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=511&publication_year=2005&pages=31&author=K.+W.+Rohrbachauthor=S.+Hanauthor=J.+Ganauthor=E.+J.+O%E2%80%99Tanyiauthor=H.+Zhangauthor=C.+L.+Chiauthor=R.+Taubauthor=B.+L.+Largentauthor=D.+Cheng&title=Disconnection+Between+the+Early+Onset+Anorectic+Effects+by+C75+and+Hypothalamic+Fatty+Acid+Synthase+Inhibition+in+Rodents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Disconnection between the early onset anorectic effects by C75 and hypothalamic fatty acid synthase inhibition in rodents</span></div><div class="casAuthors">Rohrbach, Kenneth W.; Han, Songping; Gan, Jinping; O'Tanyi, Eva J.; Zhang, Hongwei; Chi, Cecilia L.; Taub, Rebecca; Largent, Brian L.; Cheng, Dong</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">511</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">31-41</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In order to explore the relationship between the anorectic effect of 3-carboxy-4-octyl-2-methylenebutyrolactone (C75) and its pharmacokinetic properties, studies of in vivo and in vitro pharmacol. characterization of C75 were performed in Fischer rats.  In a quant. measurement of food intake, we detd. that appetite suppression by C75 takes place within 4 h.  The C max for C75 of 2.6Â±1.5 Î¼M was reached within 1-4 h after i.p. administration at 30 mg/kg, a drug level that causes complete blockade of food intake.  However, this concn. is substantially lower than the effective concn. used to inhibit rat fatty acid synthase enzyme activity in vitro (IC50: â¼200 Î¼M) and hypothalamic enzyme activity was found not to be inhibited by i.p. administration of C75 at 30 mg/kg.  Instead, a dramatic induction of c-Fos expression was found in area postrema.  Collectively, these data indicate that the anorectic effect of C75 is independent of its inhibition of fatty acid synthase in the hypothalamus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphbCknlWT3JrVg90H21EOLACvtfcHk0ljO5aBkDU9UNw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitlCjsL8%253D&md5=bae875aacd7aa736cb95107bf170c6ab</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2005.01.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2005.01.034%26sid%3Dliteratum%253Aachs%26aulast%3DRohrbach%26aufirst%3DK.%2BW.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DGan%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Tanyi%26aufirst%3DE.%2BJ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DChi%26aufirst%3DC.%2BL.%26aulast%3DTaub%26aufirst%3DR.%26aulast%3DLargent%26aufirst%3DB.%2BL.%26aulast%3DCheng%26aufirst%3DD.%26atitle%3DDisconnection%2520Between%2520the%2520Early%2520Onset%2520Anorectic%2520Effects%2520by%2520C75%2520and%2520Hypothalamic%2520Fatty%2520Acid%2520Synthase%2520Inhibition%2520in%2520Rodents%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2005%26volume%3D511%26spage%3D31" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><div class="note"><p class="first last">For experimental details, see:</p></div><span class="NLM_contrib-group">Sitkoff, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellsworth, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baska, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pendri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malley, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scaringe, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gougoutas, J. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reggio, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ewing, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pelleymounter, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlson, K. E.</span><span> </span><span class="NLM_article-title">Cannabinoid CB<sub>1</sub> Receptor Ligand Binding and Function Examined Through Mutagenesis Studies of F200 and S383</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">651</span><span class="NLM_x"> (</span><span class="NLM_issue">1â3</span><span class="NLM_x">) </span> <span class="NLM_fpage">9</span><span class="NLM_x">â</span> <span class="NLM_lpage">17</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm4010835&amp;key=10.1016%2Fj.ejphar.2010.10.056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm4010835&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1ajsrvJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=651&publication_year=2011&pages=9-17&issue=1%E2%80%933&author=D.+F.+Sitkoffauthor=N.+Leeauthor=B.+A.+Ellsworthauthor=Q.+Huangauthor=L.+Kangauthor=R.+Baskaauthor=Y.+Huangauthor=C.+Sunauthor=A.+Pendriauthor=M.+F.+Malleyauthor=R.+P.+Scaringeauthor=J.+Z.+Gougoutasauthor=P.+H.+Reggioauthor=W.+R.+Ewingauthor=M.+A.+Pelleymounterauthor=K.+E.+Carlson&title=Cannabinoid+CB1+Receptor+Ligand+Binding+and+Function+Examined+Through+Mutagenesis+Studies+of+F200+and+S383"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid CB1 receptor ligand binding and function examined through mutagenesis studies of F200 and S383</span></div><div class="casAuthors">Sitkoff, Doree F.; Lee, Ning; Ellsworth, Bruce A.; Huang, Qi; Kang, Liya; Baska, RoseAnn; Huang, Yanting; Sun, Chongqing; Pendri, Annapurna; Malley, Mary F.; Scaringe, Raymond P.; Gougoutas, Jack Z.; Reggio, Patricia H.; Ewing, William R.; Pelleymounter, Mary Ann; Carlson, Kenneth E.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">651</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">9-17</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The cannabinoid CB1 G protein-coupled receptor has been shown to be a regulator of food consumption and has been studied extensively as a drug target for the treatment of obesity.  To advance understanding of the receptor's three-dimensional structure, we performed mutagenesis studies at human cannabinoid CB1 receptor residues F200 and S383 and measured changes in activity and binding affinity of compds. from two recently discovered active chemotypes, arylsulfonamide agonists and tetrahydroquinoline-based inverse agonists, as well as literature compds.  Our results add support to previous findings that both agonists and inverse agonists show varied patterns of binding at the two mutated residue sites, suggesting multiple subsites for binding to the cannabinoid CB1 receptor for both functional types of ligands.  We addnl. find that an F200L mutation in the receptor largely restores binding affinity to ligands and significantly decreases constitutive activity when compared to F200A, resulting in a receptor phenotype that is closer to the wild-type receptor.  The results downplay the importance of arom. stacking interactions at F200 and suggest that a bulky hydrophobic contact is largely sufficient to provide significant receptor function and binding affinity to cannabinoid CB1 receptor ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoH99h-4jg7VbVg90H21EOLACvtfcHk0ljO5aBkDU9UNw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1ajsrvJ&md5=cd037c4ec201cf09066f9af25c915c40</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2010.10.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2010.10.056%26sid%3Dliteratum%253Aachs%26aulast%3DSitkoff%26aufirst%3DD.%2BF.%26aulast%3DLee%26aufirst%3DN.%26aulast%3DEllsworth%26aufirst%3DB.%2BA.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DKang%26aufirst%3DL.%26aulast%3DBaska%26aufirst%3DR.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DC.%26aulast%3DPendri%26aufirst%3DA.%26aulast%3DMalley%26aufirst%3DM.%2BF.%26aulast%3DScaringe%26aufirst%3DR.%2BP.%26aulast%3DGougoutas%26aufirst%3DJ.%2BZ.%26aulast%3DReggio%26aufirst%3DP.%2BH.%26aulast%3DEwing%26aufirst%3DW.%2BR.%26aulast%3DPelleymounter%26aufirst%3DM.%2BA.%26aulast%3DCarlson%26aufirst%3DK.%2BE.%26atitle%3DCannabinoid%2520CB1%2520Receptor%2520Ligand%2520Binding%2520and%2520Function%2520Examined%2520Through%2520Mutagenesis%2520Studies%2520of%2520F200%2520and%2520S383%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D651%26issue%3D1%25E2%2580%25933%26spage%3D9%26epage%3D17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><div class="note"><p class="first last">Methods and results described in:</p></div><span class="NLM_contrib-group">Azzara, A.; Behnia, K.; Cullen, M. J.; Devenny, J.; Ellsworth, B.; Ewing, W.; Glick, S.; Godonis, H.; Harvey, S.; Keim, W.; Murugesan, N.; Rohrbach, K.; Thomas, M.; Pelleymounter, M. A.</span><span> </span><span class="NLM_article-title">The Novel Cannabinoid-1 Receptor Antagonists BMS-812204 and BMS-811064 Reduce Food Intake and Body Weight in Preclinical Models of Obesity</span>. <span class="NLM_conf-name">Obesity Society 27th Annual Scientific Meeting</span>, <span class="NLM_conf-loc">Washington, DC</span>, <span class="NLM_conf-date">October 24â28, 2009</span>,  <span class="NLM_fpage">Poster 750-P</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Methods+and+results+described+in%3AAzzara%2C+A.%3B+Behnia%2C+K.%3B+Cullen%2C+M.+J.%3B+Devenny%2C+J.%3B+Ellsworth%2C+B.%3B+Ewing%2C+W.%3B+Glick%2C+S.%3B+Godonis%2C+H.%3B+Harvey%2C+S.%3B+Keim%2C+W.%3B+Murugesan%2C+N.%3B+Rohrbach%2C+K.%3B+Thomas%2C+M.%3B+Pelleymounter%2C+M.+A.+The+Novel+Cannabinoid-1+Receptor+Antagonists+BMS-812204+and+BMS-811064+Reduce+Food+Intake+and+Body+Weight+in+Preclinical+Models+of+Obesity.+Obesity+Society+27th+Annual+Scientific+Meeting%2C+Washington%2C+DC%2C+October+24%E2%80%9328%2C+2009%2C+Poster+750-P."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DAzzara%26aufirst%3DA.%26atitle%3DThe%2520Novel%2520Cannabinoid-1%2520Receptor%2520Antagonists%2520BMS-812204%2520and%2520BMS-811064%2520Reduce%2520Food%2520Intake%2520and%2520Body%2520Weight%2520in%2520Preclinical%2520Models%2520of%2520Obesity%26spage%3DPoster%2520750-P" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="note"><p class="first last">Bioavailability was determined from a comparison of exposures from iv vs oral administration of compound; clearance was determined from the terminal time points of the plasma profile upon iv administration. %<i>F</i> in rat, dog, and cynomologous monkey: 50, 40, and 15%, respectively. Clearance in rat, dog, and cynomologous monkey: 10, 12, 31 mL/min/kg. Intravenous elimination half-life in rat, dog, and cynomologous monkey: 5, 38, and 6 h, respectively.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="note"><p class="first last">Compound <b>28</b> displays 3 Î¼g/mL aqueous solubility from an amorphous form and immeasurable solubility from a crystalline form.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Riley, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGinnity, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Austin, R. P.</span><span> </span><span class="NLM_article-title">A Unified Model for Predicting Human Hepatic, Metabolic Clearance from in Vitro Intrinsic Clearance Data in Hepatocytes and Microsomes</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">1304</span><span class="NLM_x">â</span> <span class="NLM_lpage">1311</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm4010835&amp;key=10.1124%2Fdmd.105.004259" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm4010835&amp;key=15932954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm4010835&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpsFamt74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2005&pages=1304-1311&author=R.+J.+Rileyauthor=D.+F.+McGinnityauthor=R.+P.+Austin&title=A+Unified+Model+for+Predicting+Human+Hepatic%2C+Metabolic+Clearance+from+in+Vitro+Intrinsic+Clearance+Data+in+Hepatocytes+and+Microsomes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes</span></div><div class="casAuthors">Riley, Robert J.; McGinnity, D. F.; Austin, R. P.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1304-1311</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The aim of this study was to evaluate a unified method for predicting human in vivo intrinsic clearance (CLint, in vivo) and hepatic clearance (CLh) from in vitro data in hepatocytes and microsomes by applying the unbound fraction in blood (fub) and in vitro incubations (fuinc).  Human CLint, in vivo was projected using in vitro data together with biol. scaling factors and compared with the unbound intrinsic clearance (CLint, ub, in vivo) estd. from clin. data using liver models with and without the various fu terms.  For incubations conducted with fetal calf serum (n = 14), the obsd. CLint, in vivo was modeled well assuming fuinc and fub were equiv.  CLint, ub, in vivo was predicted best using both fub and fuinc for other hepatocyte data (n = 56; r2 = 0.78, p = 3.3Ã10-19, av. fold error = 5.2).  A similar model for CLint, ub, in vivo was established for microsomal data (n = 37; r2 = 0.77, p = 1.2Ã10-12, av. fold error = 6.1).  Using the model for CLint, ub, in vivo (including a further empirical scaling factor), the CLh in humans was also calcd. according to the well stirred liver model for the most extensive dataset.  CLint, in vivo and CLh were both predicted well using in vitro human data from several labs. for acidic, basic, and neutral drugs.  The direct use of this model using only in vitro human data to predict the metabolic component of CLh is attractive, as it does not require extra information from preclin. studies in animals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnrU05rRTm6LVg90H21EOLACvtfcHk0lgSHHKrIZK9aA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpsFamt74%253D&md5=79b80848977739267e4dd0ae82e5cbab</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1124%2Fdmd.105.004259&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.105.004259%26sid%3Dliteratum%253Aachs%26aulast%3DRiley%26aufirst%3DR.%2BJ.%26aulast%3DMcGinnity%26aufirst%3DD.%2BF.%26aulast%3DAustin%26aufirst%3DR.%2BP.%26atitle%3DA%2520Unified%2520Model%2520for%2520Predicting%2520Human%2520Hepatic%252C%2520Metabolic%2520Clearance%2520from%2520in%2520Vitro%2520Intrinsic%2520Clearance%2520Data%2520in%2520Hepatocytes%2520and%2520Microsomes%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2005%26volume%3D33%26spage%3D1304%26epage%3D1311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Parrott, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paquereau, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coassolo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lave, T.</span><span> </span><span class="NLM_article-title">An Evaluation of the Utility of Physiologically Based Models of Pharmacokinetics in Early Drug Discovery</span> <span class="citation_source-journal">J. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">94</span><span class="NLM_x">, </span> <span class="NLM_fpage">2327</span><span class="NLM_x">â</span> <span class="NLM_lpage">2343</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2005&pages=2327-2343&author=N.+Parrottauthor=N.+Paquereauauthor=P.+Coassoloauthor=T.+Lave&title=An+Evaluation+of+the+Utility+of+Physiologically+Based+Models+of+Pharmacokinetics+in+Early+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DParrott%26aufirst%3DN.%26aulast%3DPaquereau%26aufirst%3DN.%26aulast%3DCoassolo%26aufirst%3DP.%26aulast%3DLave%26aufirst%3DT.%26atitle%3DAn%2520Evaluation%2520of%2520the%2520Utility%2520of%2520Physiologically%2520Based%2520Models%2520of%2520Pharmacokinetics%2520in%2520Early%2520Drug%2520Discovery%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2005%26volume%3D94%26spage%3D2327%26epage%3D2343" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Tamaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Komura, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kogayu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamada, S.</span><span> </span><span class="NLM_article-title">Comparative Assessment of Empirical and Physiological Approaches on Predicting Human Clearances</span> <span class="citation_source-journal">J. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">1147</span><span class="NLM_x">â</span> <span class="NLM_lpage">1155</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2011&pages=1147-1155&author=S.+Tamakiauthor=H.+Komuraauthor=M.+Kogayuauthor=S.+Yamada&title=Comparative+Assessment+of+Empirical+and+Physiological+Approaches+on+Predicting+Human+Clearances"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTamaki%26aufirst%3DS.%26aulast%3DKomura%26aufirst%3DH.%26aulast%3DKogayu%26aufirst%3DM.%26aulast%3DYamada%26aufirst%3DS.%26atitle%3DComparative%2520Assessment%2520of%2520Empirical%2520and%2520Physiological%2520Approaches%2520on%2520Predicting%2520Human%2520Clearances%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2011%26volume%3D100%26spage%3D1147%26epage%3D1155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><div class="note"><p class="first last">The physicochemical characteristics of ligands for lipophilic GPCRs have been reviewed in</p></div><span class="NLM_contrib-group">Vieth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutherland, J. J.</span><span> </span><span class="NLM_article-title">Dependence of Molecular Properties on Proteomic Family for Marketed Oral Drugs</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">3451</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0603825" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=3451&author=M.+Viethauthor=J.+J.+Sutherland&title=Dependence+of+Molecular+Properties+on+Proteomic+Family+for+Marketed+Oral+Drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm0603825&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0603825%26sid%3Dliteratum%253Aachs%26aulast%3DVieth%26aufirst%3DM.%26aulast%3DSutherland%26aufirst%3DJ.%2BJ.%26atitle%3DDependence%2520of%2520Molecular%2520Properties%2520on%2520Proteomic%2520Family%2520for%2520Marketed%2520Oral%2520Drugs%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D3451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Masimirembwa, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bredberg, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andersson, T. B.</span><span> </span><span class="NLM_article-title">Metabolic Stability for Drug Discovery and Development</span> <span class="citation_source-journal">Clin. Pharmacokinet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">515</span><span class="NLM_x">â</span> <span class="NLM_lpage">528</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Fjm4010835&amp;key=10.2165%2F00003088-200342060-00002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm4010835&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmtVGmuro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2003&pages=515-528&issue=6&author=C.+M.+Masimirembwaauthor=U.+Bredbergauthor=T.+B.+Andersson&title=Metabolic+Stability+for+Drug+Discovery+and+Development"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic stability for drug discovery and development: Pharmacokinetic and biochemical challenges</span></div><div class="casAuthors">Masimirembwa, Collen M.; Bredberg, Ulf; Andersson, Tommy B.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">515-528</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review.  Metabolic stability refers to the susceptibility of compds. to biotransformation in the context of selecting and/or designing drugs with favorable pharmacokinetic properties.  Metabolic stability results are usually reported as measures of intrinsic clearance, from which secondary pharmacokinetic parameters such as bioavailability and half-life can be calcd. when other data on vol. of distribution and fraction absorbed are available.  Since these parameters are very important in defining the pharmacol. and toxicol. profile of drugs as well as patient compliance, the pharmaceutical industry has a particular interest in optimizing for metabolic stability during the drug discovery and development process.  In the early phases of drug discovery, new chem. entities cannot be administered to humans; hence, predictions of these properties have to be made from in vivo animal, in vitro cellular/subcellular and computational systems.  The utility of these systems to define the metabolic stability of compds. that is predictive of the human situation will be reviewed here.  The timing of performing the studies in the discovery process and the impact of recent advances in research on drug absorption, distribution, metab. and excretion (ADME) will be evaluated with respect to the scope and depth of metabolic stability issues.  Quant. prediction of in vivo clearance from in vitro metab. data has, for many compds., been shown to be poor in retrospective studies.  One explanation for this may be that there are components used in the equations for scaling that are missing or uncertain and should be an area of more research.  For example, as a result of increased biochem. understanding of drug metab., old assumptions (e.g. that the liver is the principal site of first-pass metab.) need revision and new knowledge (e.g. the relationship between transporters and drug metabolizing enzymes) needs to be incorporated into in vitro-in vivo correlation models.  With ADME parameters increasingly being detd. on automated platforms, instead of using results from high throughput screening (HTS) campaigns as simple go/no-go filters, the time saved and the many compds. analyzed using the robots should be invested in careful processing of the data.  A logical step would be to investigate the potential to construct computational models to understand the factors governing metabolic stability.  A rational approach to the use of HTS assays should aim to screen for many properties (e.g. physicochem. parameters, absorption, metab., protein binding, pharmaco-kinetics in animals and pharmacol.) in an integrated manner rather than screen against one property on many compds., since it is likely that the final drug will represent a global av. of these properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMaQNLSmN907Vg90H21EOLACvtfcHk0liIPY4ZBR9I2Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmtVGmuro%253D&md5=c2386c9c2e20ccb3b085fe4a2683eef8</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.2165%2F00003088-200342060-00002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003088-200342060-00002%26sid%3Dliteratum%253Aachs%26aulast%3DMasimirembwa%26aufirst%3DC.%2BM.%26aulast%3DBredberg%26aufirst%3DU.%26aulast%3DAndersson%26aufirst%3DT.%2BB.%26atitle%3DMetabolic%2520Stability%2520for%2520Drug%2520Discovery%2520and%2520Development%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2003%26volume%3D42%26issue%3D6%26spage%3D515%26epage%3D528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Davis-Bruno, K.</span><span> </span><span class="NLM_article-title">Non-clinical Overview: CNS Toxicity with Rimonabant</span>; <span class="NLM_publisher-name">U.S. Food and Drug Administration Center for Drug Evaluation and Research</span>: <span class="NLM_publisher-loc">Silver Spring, MD</span>, <span class="NLM_month">June</span><span class="NLM_day">13</span>,<span class="NLM_x"> </span><span class="NLM_year">2007</span><span class="NLM_x">; </span><a href="http://www.fda.gov/ohrms/dockets/ac/07/slides/2007-4306s1-09-FDA-Bruno.ppt" class="extLink">www.fda.gov/ohrms/dockets/ac/07/slides/2007-4306s1-09-FDA-Bruno.ppt</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=K.+Davis-Bruno&title=Non-clinical+Overview%3A+CNS+Toxicity+with+Rimonabant"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26aulast%3DDavis-Bruno%26aufirst%3DK.%26atitle%3DNon-clinical%2520Overview%253A%2520CNS%2520Toxicity%2520with%2520Rimonabant%26pub%3DU.S.%2520Food%2520and%2520Drug%2520Administration%2520Center%2520for%2520Drug%2520Evaluation%2520and%2520Research%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Okada, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinomura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higashiyama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeuchi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hojo, M.</span><span> </span><span class="NLM_article-title">A Simple and Convenient Synthetic Method for Alpha-Trifluoromethylpyridines</span> <span class="citation_source-journal">Heterocycles</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">129</span><span class="NLM_x">â</span> <span class="NLM_lpage">132</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=1997&pages=129-132&author=E.+Okadaauthor=T.+Kinomuraauthor=Y.+Higashiyamaauthor=H.+Takeuchiauthor=M.+Hojo&title=A+Simple+and+Convenient+Synthetic+Method+for+Alpha-Trifluoromethylpyridines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOkada%26aufirst%3DE.%26aulast%3DKinomura%26aufirst%3DT.%26aulast%3DHigashiyama%26aufirst%3DY.%26aulast%3DTakeuchi%26aufirst%3DH.%26aulast%3DHojo%26aufirst%3DM.%26atitle%3DA%2520Simple%2520and%2520Convenient%2520Synthetic%2520Method%2520for%2520Alpha-Trifluoromethylpyridines%26jtitle%3DHeterocycles%26date%3D1997%26volume%3D46%26spage%3D129%26epage%3D132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><div class="note"><p class="first last">Synthesized according to the method described in:</p></div><span class="NLM_contrib-group">Wu, G.; Sher, P.; Ellsworth, B. A.; Wu, X.; Ewing, W. R.</span> Manuscript in preparation.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Synthesized+according+to+the+method+described+in%3AWu%2C+G.%3B+Sher%2C+P.%3B+Ellsworth%2C+B.+A.%3B+Wu%2C+X.%3B+Ewing%2C+W.+R.+Manuscript+in+preparation."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dunpublished%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DG." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Kazimierczuk, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaminshi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flavio, M.</span><span> </span><span class="NLM_article-title">Studies on Improved Synthesis of 2â²-Deoxyribonucleosides of Pyridazine Derivatives</span> <span class="citation_source-journal">Collect. Czech. Chem. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">889</span><span class="NLM_x">â</span> <span class="NLM_lpage">898</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Fjm4010835&amp;key=10.1135%2Fcccc20060889" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm4010835&amp;key=1%3ACAS%3A528%3ADC%252BD28Xmt1aruro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2006&pages=889-898&issue=6&author=Z.+Kazimierczukauthor=J.+Kaminshiauthor=M.+Flavio&title=Studies+on+Improved+Synthesis+of+2%E2%80%B2-Deoxyribonucleosides+of+Pyridazine+Derivatives"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Studies on improved synthesis of 2'-deoxyribonucleosides of pyridazine derivatives</span></div><div class="casAuthors">Kazimierczuk, Zygmunt; Kaminski, Jaroslaw; Meggio, Flavio</div><div class="citationInfo"><span class="NLM_cas:title">Collection of Czechoslovak Chemical Communications</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">889-898</span>CODEN:
                <span class="NLM_cas:coden">CCCCAK</span>;
        ISSN:<span class="NLM_cas:issn">0010-0765</span>.
    
            (<span class="NLM_cas:orgname">Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic</span>)
        </div><div class="casAbstract">A no. of 2'-deoxyribonucleosides of halogenated pyridazine derivs. were prepd. by glycosylation of their resp. potassium or DBU salts in acetone.  The reaction yielded predominantly Î²-anomers that could be purified by simple crystn. or column chromatog.  Of the studied pyridazines and deoxynucleosides, only 4-bromo-6-chloro-pyridazin-3-one and 6-chloro-2-(2'-deoxyribofuranosyl)pyridazin-3-one showed modest inhibition of CK2 kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUzc-31Z0fgrVg90H21EOLACvtfcHk0liIPY4ZBR9I2Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xmt1aruro%253D&md5=8d533bf31bc79b7c09d5b9b1d9fc3b39</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1135%2Fcccc20060889&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1135%252Fcccc20060889%26sid%3Dliteratum%253Aachs%26aulast%3DKazimierczuk%26aufirst%3DZ.%26aulast%3DKaminshi%26aufirst%3DJ.%26aulast%3DFlavio%26aufirst%3DM.%26atitle%3DStudies%2520on%2520Improved%2520Synthesis%2520of%25202%25E2%2580%25B2-Deoxyribonucleosides%2520of%2520Pyridazine%2520Derivatives%26jtitle%3DCollect.%2520Czech.%2520Chem.%2520Commun.%26date%3D2006%26volume%3D71%26issue%3D6%26spage%3D889%26epage%3D898" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Howlett, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barth, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonner, T. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cabral, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casellas, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devane, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felder, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herkenham, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mackie, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mechoulam, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pertwee, R. G.</span><span> </span><span class="NLM_article-title">International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors</span> <span class="citation_source-journal">Pharmacol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">161</span><span class="NLM_x">â</span> <span class="NLM_lpage">202</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Fjm4010835&amp;key=10.1124%2Fpr.54.2.161" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Fjm4010835&amp;key=12037135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm4010835&amp;key=1%3ACAS%3A528%3ADC%252BD38XltVOiuro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2002&pages=161-202&author=A.+C.+Howlettauthor=F.+Barthauthor=T.+I.+Bonnerauthor=G.+Cabralauthor=P.+Casellasauthor=W.+A.+Devaneauthor=C.+C.+Felderauthor=M.+Herkenhamauthor=K.+Mackieauthor=B.+R.+Martinauthor=R.+Mechoulamauthor=R.+G.+Pertwee&title=International+Union+of+Pharmacology.+XXVII.+Classification+of+Cannabinoid+Receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">International Union of Pharmacology. XXVII. Classification of cannabinoid receptors</span></div><div class="casAuthors">Howlett, A. C.; Barth, F.; Bonner, T. I.; Cabral, G.; Casellas, P.; Devane, W. A.; Felder, C. C.; Herkenham, M.; Mackie, K.; Martin, B. R.; Mechoulam, R.; Pertwee, R. G.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">161-202</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  Two types of cannabinoid receptor have been discovered so far, CB1 (2.1: CBD:1:CB1:), cloned in 1990, and CB2 (2.1:CBD:2:CB2:), cloned in 1993.  Distinction between these receptors is based on differences in their predicted amino acid sequence, signaling mechanisms, tissue distribution, and sensitivity to certain potent agonists and antagonists that show marked selectivity for one or the other receptor type.  Cannabinoid receptors CB1 and CB2 exhibit 48% amino acid sequence identity.  Both receptor types are coupled through G proteins to adenylyl cyclase and mitogen-activated protein kinase.  CB1 receptors are also coupled through G proteins to several types of calcium and potassium channels.  These receptors exist primarily on central and peripheral neurons, one of their functions being to inhibit neurotransmitter release.  Indeed, endogenous CB1 agonists probably serve as retrograde synaptic messengers.  CB2 receptors are present mainly on immune cells.  Such cells also express CB1 receptors, albeit to a lesser extent, with both receptor types exerting a broad spectrum of immune effects that includes modulation of cytokine release.  Of several endogenous agonists for cannabinoid receptors identified thus far, the most notable are arachidonoylethanolamide, 2-arachidonoylglycerol, and 2-arachidonylglyceryl ether.  It is unclear whether these eicosanoid mols. are the only, or primary, endogenous agonists.  Hence, the authors consider it premature to rename cannabinoid receptors after an endogenous agonist as is recommended by the International Union of Pharmacol. Committee on Receptor Nomenclature and Drug Classification.  Although pharmacol. evidence for the existence of addnl. types of cannabinoid receptor is emerging, other kinds of supporting evidence are still lacking.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeoe-6izzgsrVg90H21EOLACvtfcHk0liSw1ACRWOIVw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltVOiuro%253D&md5=4a8345d34b5724ee3cd999b71956ab54</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1124%2Fpr.54.2.161&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.54.2.161%26sid%3Dliteratum%253Aachs%26aulast%3DHowlett%26aufirst%3DA.%2BC.%26aulast%3DBarth%26aufirst%3DF.%26aulast%3DBonner%26aufirst%3DT.%2BI.%26aulast%3DCabral%26aufirst%3DG.%26aulast%3DCasellas%26aufirst%3DP.%26aulast%3DDevane%26aufirst%3DW.%2BA.%26aulast%3DFelder%26aufirst%3DC.%2BC.%26aulast%3DHerkenham%26aufirst%3DM.%26aulast%3DMackie%26aufirst%3DK.%26aulast%3DMartin%26aufirst%3DB.%2BR.%26aulast%3DMechoulam%26aufirst%3DR.%26aulast%3DPertwee%26aufirst%3DR.%2BG.%26atitle%3DInternational%2520Union%2520of%2520Pharmacology.%2520XXVII.%2520Classification%2520of%2520Cannabinoid%2520Receptors%26jtitle%3DPharmacol.%2520Rev.%26date%3D2002%26volume%3D54%26spage%3D161%26epage%3D202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2a','cit2b'],'ref3':['cit3a','cit3b','cit3c'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':[],'ref24':[],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 7 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hai-Yan  Qian</span>, <span class="hlFld-ContribAuthor ">Zhi-Long  Wang</span>, <span class="hlFld-ContribAuthor ">You-Lu  Pan</span>, <span class="hlFld-ContribAuthor ">Li-Li  Chen</span>, <span class="hlFld-ContribAuthor ">Xin  Xie</span>, and <span class="hlFld-ContribAuthor ">Jian-Zhong  Chen</span>  . </span><span class="cited-content_cbyCitation_article-title">Development of Quinazoline/Pyrimidine-2,4(1H,3H)-diones as Agonists of Cannabinoid Receptor Type 2. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>8 </em>
                                    (6)
                                     , 678-681. <a href="https://doi.org/10.1021/acsmedchemlett.7b00007" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.7b00007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.7b00007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.7b00007%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDevelopment%252Bof%252BQuinazoline%25252FPyrimidine-2%25252C4%2525281H%25252C3H%252529-diones%252Bas%252BAgonists%252Bof%252BCannabinoid%252BReceptor%252BType%252B2%26aulast%3DQian%26aufirst%3DHai-Yan%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D13012017%26date%3D01052017%26date%3D03052017%26date%3D08062017%26date%3D01052017%26volume%3D8%26issue%3D6%26spage%3D678%26epage%3D681" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Claudia  Mugnaini</span>, <span class="hlFld-ContribAuthor ">Antonella  Brizzi</span>, <span class="hlFld-ContribAuthor ">Alessia  Ligresti</span>, <span class="hlFld-ContribAuthor ">Marco  AllarÃ </span>, <span class="hlFld-ContribAuthor ">Stefania  Lamponi</span>, <span class="hlFld-ContribAuthor ">Federica  Vacondio</span>, <span class="hlFld-ContribAuthor ">Claudia  Silva</span>, <span class="hlFld-ContribAuthor ">Marco  Mor</span>, <span class="hlFld-ContribAuthor ">Vincenzo  Di Marzo</span>, and <span class="hlFld-ContribAuthor ">Federico  Corelli</span>  . </span><span class="cited-content_cbyCitation_article-title">Investigations on the 4-Quinolone-3-carboxylic Acid Motif. 7. Synthesis and Pharmacological Evaluation of 4-Quinolone-3-carboxamides and 4-Hydroxy-2-quinolone-3-carboxamides as High Affinity Cannabinoid Receptor 2 (CB2R) Ligands with Improved Aqueous Solubility. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (3)
                                     , 1052-1067. <a href="https://doi.org/10.1021/acs.jmedchem.5b01559" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01559</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b01559%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DInvestigations%252Bon%252Bthe%252B4-Quinolone-3-carboxylic%252BAcid%252BMotif.%252B7.%252BSynthesis%252Band%252BPharmacological%252BEvaluation%252Bof%252B4-Quinolone-3-carboxamides%252Band%252B4-Hydroxy-2-quinolone-3-carboxamides%252Bas%252BHigh%252BAffinity%252BCannabinoid%252BReceptor%252B2%252B%252528CB2R%252529%252BLigands%252Bwith%252BImproved%252BAqueous%252BSolubility%26aulast%3DMugnaini%26aufirst%3DClaudia%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D06102015%26date%3D26012016%26date%3D11022016%26date%3D12012016%26volume%3D59%26issue%3D3%26spage%3D1052%26epage%3D1067" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ranjana  Aggarwal</span>, <span class="hlFld-ContribAuthor ">Mamta</span>, <span class="hlFld-ContribAuthor ">Garima  Sumran</span>, <span class="hlFld-ContribAuthor ">Mari Carmen  Torralba</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and structural studies of 3,6-disubstituted-bis-1,2,4-triazolo-[4,3-b][3â²,4â²-f]pyridazines. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Structure</span><span> <strong>2019,</strong> <em>1185 </em>, 379-391. <a href="https://doi.org/10.1016/j.molstruc.2019.02.082" title="DOI URL">https://doi.org/10.1016/j.molstruc.2019.02.082</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.molstruc.2019.02.082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.molstruc.2019.02.082%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Structure%26atitle%3DSynthesis%252Band%252Bstructural%252Bstudies%252Bof%252B3%25252C6-disubstituted-bis-1%25252C2%25252C4-triazolo-%25255B4%25252C3-b%25255D%25255B3%2525E2%252580%2525B2%25252C4%2525E2%252580%2525B2-f%25255Dpyridazines%26aulast%3DAggarwal%26aufirst%3DRanjana%26date%3D2019%26volume%3D1185%26spage%3D379%26epage%3D391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">P.  HorkÃ½</span>, <span class="hlFld-ContribAuthor ">M.  VorÃ¡ÄovÃ¡</span>, <span class="hlFld-ContribAuthor ">K.  KoneÄnÃ¡</span>, <span class="hlFld-ContribAuthor ">D.  SedlÃ¡k</span>, <span class="hlFld-ContribAuthor ">P.  BartÅ¯nÄk</span>, <span class="hlFld-ContribAuthor ">J.  Vacek</span>, <span class="hlFld-ContribAuthor ">J.  KuneÅ¡</span>, <span class="hlFld-ContribAuthor ">M.  Pour</span>. </span><span class="cited-content_cbyCitation_article-title">Nontoxic combretafuranone analogues with high inÂ vitro antibacterial activity. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>143 </em>, 843-853. <a href="https://doi.org/10.1016/j.ejmech.2017.11.078" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.11.078</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.11.078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.11.078%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNontoxic%252Bcombretafuranone%252Banalogues%252Bwith%252Bhigh%252Bin%2525C2%2525A0vitro%252Bantibacterial%252Bactivity%26aulast%3DHork%25C3%25BD%26aufirst%3DP.%26date%3D2018%26volume%3D143%26spage%3D843%26epage%3D853" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hai-Yan  Qian</span>, <span class="hlFld-ContribAuthor ">Zhi-Long  Wang</span>, <span class="hlFld-ContribAuthor ">Xiao-Yu  Xie</span>, <span class="hlFld-ContribAuthor ">You-Lu  Pan</span>, <span class="hlFld-ContribAuthor ">Gang-Jian  Li</span>, <span class="hlFld-ContribAuthor ">Xin  Xie</span>, <span class="hlFld-ContribAuthor ">Jian-Zhong  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Developing pyridazine-3-carboxamides to be CB2 agonists: The design, synthesis, structure-activity relationships and docking studies. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>137 </em>, 598-611. <a href="https://doi.org/10.1016/j.ejmech.2017.05.060" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.05.060</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.05.060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.05.060%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDeveloping%252Bpyridazine-3-carboxamides%252Bto%252Bbe%252BCB2%252Bagonists%25253A%252BThe%252Bdesign%25252C%252Bsynthesis%25252C%252Bstructure-activity%252Brelationships%252Band%252Bdocking%252Bstudies%26aulast%3DQian%26aufirst%3DHai-Yan%26date%3D2017%26volume%3D137%26spage%3D598%26epage%3D611" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Scott B.  Tran</span>, <span class="hlFld-ContribAuthor ">Brad D.  Maxwell</span>, <span class="hlFld-ContribAuthor ">Richard  Burrell</span>, <span class="hlFld-ContribAuthor ">Samuel J.  Bonacorsi</span>. </span><span class="cited-content_cbyCitation_article-title">The syntheses of isotopically labelled CB-1 antagonists for the treatment of obesity. </span><span class="cited-content_cbyCitation_journal-name">Journal of Labelled Compounds and Radiopharmaceuticals</span><span> <strong>2016,</strong> <em>59 </em>
                                    (14)
                                     , 665-672. <a href="https://doi.org/10.1002/jlcr.3433" title="DOI URL">https://doi.org/10.1002/jlcr.3433</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jlcr.3433&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjlcr.3433%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Labelled%2520Compounds%2520and%2520Radiopharmaceuticals%26atitle%3DThe%252Bsyntheses%252Bof%252Bisotopically%252Blabelled%252BCB-1%252Bantagonists%252Bfor%252Bthe%252Btreatment%252Bof%252Bobesity%26aulast%3DTran%26aufirst%3DScott%2BB.%26date%3D2016%26date%3D2016%26volume%3D59%26issue%3D14%26spage%3D665%26epage%3D672" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Emanuele  Perola</span>, <span class="hlFld-ContribAuthor ">Dean  Stamos</span>, <span class="hlFld-ContribAuthor ">Anne-Laure  Grillot</span>, <span class="hlFld-ContribAuthor ">Steven  Ronkin</span>, <span class="hlFld-ContribAuthor ">Tiansheng  Wang</span>, <span class="hlFld-ContribAuthor ">Arnaud  LeTiran</span>, <span class="hlFld-ContribAuthor ">Qing  Tang</span>, <span class="hlFld-ContribAuthor ">David D.  Deininger</span>, <span class="hlFld-ContribAuthor ">Yusheng  Liao</span>, <span class="hlFld-ContribAuthor ">Shi-Kai  Tian</span>, <span class="hlFld-ContribAuthor ">Joseph E.  Drumm</span>, <span class="hlFld-ContribAuthor ">David P.  Nicolau</span>, <span class="hlFld-ContribAuthor ">Pamela R.  Tessier</span>, <span class="hlFld-ContribAuthor ">Nagraj  Mani</span>, <span class="hlFld-ContribAuthor ">Trudy H.  Grossman</span>, <span class="hlFld-ContribAuthor ">Paul S.  Charifson</span>. </span><span class="cited-content_cbyCitation_article-title">Successful application of serum shift prediction models to the design of dual targeting inhibitors of bacterial gyrase B and topoisomerase IV with improved in vivo efficacy. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2014,</strong> <em>24 </em>
                                    (9)
                                     , 2177-2181. <a href="https://doi.org/10.1016/j.bmcl.2014.03.022" title="DOI URL">https://doi.org/10.1016/j.bmcl.2014.03.022</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2014.03.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2014.03.022%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSuccessful%252Bapplication%252Bof%252Bserum%252Bshift%252Bprediction%252Bmodels%252Bto%252Bthe%252Bdesign%252Bof%252Bdual%252Btargeting%252Binhibitors%252Bof%252Bbacterial%252Bgyrase%252BB%252Band%252Btopoisomerase%252BIV%252Bwith%252Bimproved%252Bin%252Bvivo%252Befficacy%26aulast%3DPerola%26aufirst%3DEmanuele%26date%3D2014%26volume%3D24%26issue%3D9%26spage%3D2177%26epage%3D2181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_null" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/medium/jm-2013-010835_0019.gif" alt="" id="_i1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/large/jm-2013-010835_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4010835&amp;id=f_null"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/medium/jm-2013-010835_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/large/jm-2013-010835_0002.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Evolution of the triazolopyridazine series of CB1 receptor antagonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/large/jm-2013-010835_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4010835&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/medium/jm-2013-010835_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/large/jm-2013-010835_0008.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Methyl Grignard Addition to Triazolopyridazinone <b>3</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/large/jm-2013-010835_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4010835&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/medium/jm-2013-010835_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/large/jm-2013-010835_0003.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. SAR of 4-pyridine positional isomers.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/large/jm-2013-010835_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4010835&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/medium/jm-2013-010835_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/large/jm-2013-010835_0004.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Comparison of proposed binding modes and of <i>h</i>CB1 <i>K</i><sub>i</sub> values for <i>N</i>-2-CF<sub>3</sub>-pyridyl- vs <i>N</i>-5-CF<sub>3</sub>-pyridyl-triazolopyridazinediones <b>7</b> and <b>12</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/large/jm-2013-010835_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4010835&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/medium/jm-2013-010835_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/large/jm-2013-010835_0009.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compound <b>15<sup>a</sup></b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/large/jm-2013-010835_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4010835&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Conditions: (a) KOtBu, DMF, 88%; (b) air, KOtBu, THF; (c) hydrazine hydrate, EtOH, HCl, 32% (2 steps); (d) POCl<sub>3</sub>, 85 Â°C, 72%; (e) NaOH, CH<sub>3</sub>CN, 75%; (f) K<sub>2</sub>CO<sub>3</sub>, DMF, 66%; (g) hydrazine (anhyd) pyridine; (h) 1,1â²-carbonyldiimidazole, THF, 73% (2 steps); (i) EtI, K<sub>2</sub>CO<sub>3</sub>, DMF, 67%.</p></p></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/medium/jm-2013-010835_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/large/jm-2013-010835_0005.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) In vitro metabolism rate (rat liver microsomes (RLM)) vs rat in vivo Cl (mL/min/kg). (B) Unbound RLM Cl (mL/min/kg) vs rat in vivo Cl (mL/min/kg), filtered to show compounds with â¤95% protein binding.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/large/jm-2013-010835_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4010835&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/medium/jm-2013-010835_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/large/jm-2013-010835_0006.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Graph of <i>e</i> log P vs rat plasma protein binding.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/large/jm-2013-010835_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4010835&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/medium/jm-2013-010835_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/large/jm-2013-010835_0007.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Potent CB1 antagonists (<i>h</i>CB1 <i>K</i><sub>i</sub> = 5 nM for both <b>35</b> and <b>36</b>) with lowered log P and shortened half-life relative to compound <b>28</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/large/jm-2013-010835_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4010835&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch3" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/medium/jm-2013-010835_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/large/jm-2013-010835_0010.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Revised Synthesis of TZP-diones to Enable Late Introduction of C7 and C8-Substituents<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-23/jm4010835/production/images/large/jm-2013-010835_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm4010835&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) Br<sub>2</sub>, LiOH, MeOH; (b) <b>22</b>, K<sub>2</sub>CO<sub>3</sub>, DMF, 80% (2 steps); (c) NaOMe, dioxane, 72%; (d) Pd(dppf)Cl<sub>2</sub>, BocNHNH<sub>2</sub>, Cs<sub>2</sub>CO<sub>3</sub>, toluene, 78%; (e) 4-ClPhB(OH)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub>, toluene, 92%; (f) HCl, dioxane; (g) 1,1â²-carbonyldiimidazole, THF, 70% (2 steps); (h) EtI, K<sub>2</sub>CO<sub>3</sub>, DMF, 84%; (i) BBr<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>; (j) Tf<sub>2</sub>O, TEA, CH<sub>2</sub>Cl<sub>2</sub>; (k) Pd(dppf)Cl<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, THF, 2-methylpyrimidinyl-5-boronic acid, 14% (3 steps).</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i55">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01276" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01276" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 34 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Piomelli, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giuffrida, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calignano, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguez de Fonseca, F.</span><span> </span><span class="NLM_article-title">The Endocannabinoid System as a Target for Therapeutic Drugs</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">218</span><span class="NLM_x">â</span> <span class="NLM_lpage">224</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2000&pages=218-224&author=D.+Piomelliauthor=A.+Giuffridaauthor=A.+Calignanoauthor=F.+Rodriguez+de+Fonseca&title=The+Endocannabinoid+System+as+a+Target+for+Therapeutic+Drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPiomelli%26aufirst%3DD.%26aulast%3DGiuffrida%26aufirst%3DA.%26aulast%3DCalignano%26aufirst%3DA.%26aulast%3DRodriguez%2Bde%2BFonseca%26aufirst%3DF.%26atitle%3DThe%2520Endocannabinoid%2520System%2520as%2520a%2520Target%2520for%2520Therapeutic%2520Drugs%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2000%26volume%3D21%26spage%3D218%26epage%3D224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Rinaldi-Carmona, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barth, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heaulme, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shire, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calandra, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Congy, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maruani, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neliat, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caput, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrara, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soubrie, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breliere, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Fur, G.</span><span> </span><span class="NLM_article-title">SR141716A, a Potent and Selective Antagonist of the Brain Cannabinoid Receptor</span> <span class="citation_source-journal">FEBS Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">350</span><span class="NLM_x">, </span> <span class="NLM_fpage">240</span><span class="NLM_x">â</span> <span class="NLM_lpage">244</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Fjm4010835&amp;key=10.1016%2F0014-5793%2894%2900773-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Fjm4010835&amp;key=8070571" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Fjm4010835&amp;key=1%3ACAS%3A528%3ADyaK2cXmsVKjsrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=1994&pages=240-244&author=M.+Rinaldi-Carmonaauthor=F.+Barthauthor=M.+Heaulmeauthor=D.+Shireauthor=B.+Calandraauthor=C.+Congyauthor=S.+Martinezauthor=J.+Maruaniauthor=G.+Neliatauthor=D.+Caputauthor=P.+Ferraraauthor=P.+Soubrieauthor=J.+C.+Breliereauthor=G.+Le+Fur&title=SR141716A%2C+a+Potent+and+Selective+Antagonist+of+the+Brain+Cannabinoid+Receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">SR141716A, a potent and selective antagonist of the brain cannabinoid receptor</span></div><div class="casAuthors">Rinaldi-Carmona, Murielle; Barth, Francis; Heaulme, Michel; Shire, David; Calandra, Bernard; Congy, Christian; Martinez, Serge; Maruani, Jeanne; Neliat, Gervais; et al.</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">350</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">240-4</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    </div><div class="casAbstract">SR141716A is the first selective and orally active antagonist of the brain cannabinoid receptor.  This compd. displays nanomolar affinity for the central cannabinoid receptor but is not active on the peripheral cannabinoid receptor.  In vitro, SR141716A antagonizes the inhibitory effects of cannabinoid receptor agonists on both mouse vas deferens contractions and adenylyl cyclase activity in rat brain membranes.  After i.p. or oral administration, SR141716A antagonizes classical pharmacol. and behavioral effects of cannabinoid receptor agonists.  This compd. should prove to be a powerful tool for investigating the in vivo functions of the anandamide/cannabinoid system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLJ59LaZb2cbVg90H21EOLACvtfcHk0li7fRXnbg-UKQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXmsVKjsrw%253D&md5=1eebdfec28d2dde64729cddb859aa6c8</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1016%2F0014-5793%2894%2900773-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-5793%252894%252900773-X%26sid%3Dliteratum%253Aachs%26aulast%3DRinaldi-Carmona%26aufirst%3DM.%26aulast%3DBarth%26aufirst%3DF.%26aulast%3DHeaulme%26aufirst%3DM.%26aulast%3DShire%26aufirst%3DD.%26aulast%3DCalandra%26aufirst%3DB.%26aulast%3DCongy%26aufirst%3DC.%26aulast%3DMartinez%26aufirst%3DS.%26aulast%3DMaruani%26aufirst%3DJ.%26aulast%3DNeliat%26aufirst%3DG.%26aulast%3DCaput%26aufirst%3DD.%26aulast%3DFerrara%26aufirst%3DP.%26aulast%3DSoubrie%26aufirst%3DP.%26aulast%3DBreliere%26aufirst%3DJ.%2BC.%26aulast%3DLe%2BFur%26aufirst%3DG.%26atitle%3DSR141716A%252C%2520a%2520Potent%2520and%2520Selective%2520Antagonist%2520of%2520the%2520Brain%2520Cannabinoid%2520Receptor%26jtitle%3DFEBS%2520Lett.%26date%3D1994%26volume%3D350%26spage%3D240%26epage%3D244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Mukhopadhyay, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howlett, A. C.</span><span> </span><span class="NLM_article-title">Chemically Distinct Ligands Promote Differential CB<sub>1</sub> Cannabinoid Receptor-Gi Protein Interactions</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">2016</span><span class="NLM_x">â</span> <span class="NLM_lpage">2024</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Fjm4010835&amp;key=10.1124%2Fmol.104.003558" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Fjm4010835&amp;key=15749995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Fjm4010835&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkvFGis74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2005&pages=2016-2024&author=S.+Mukhopadhyayauthor=A.+C.+Howlett&title=Chemically+Distinct+Ligands+Promote+Differential+CB1+Cannabinoid+Receptor-Gi+Protein+Interactions"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">Chemically distinct ligands promote differential CB1 cannabinoid receptor-Gi protein interactions</span></div><div class="casAuthors">Mukhopadhyay, Somnath; Howlett, Allyn C.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2016-2024</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">To understand how structurally distinct ligands regulate CB1 receptor interactions with Gi1, Gi2, and Gi3, the authors quantified the GÎ±i and Î²Î³ proteins that coimmunoppt. with the CB1 receptor from a detergent ext. of N18TG2 membranes in the presence of ligands.  A mixt. of A, R, GGDP (or G-), and ARGGDP (or ARG-) complexes was obsd. in the presence of aminoalkylindole (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone (WIN 55,212-2) for all three RGÎ±i complexes, cannabinoid desacetyllevonantradol for GÎ±i1 and GÎ±i2, and eicosanoid (R)-methanandamide for GÎ±i3.  Desacetyllevonantradol maintained RGÎ±i3 complexes and (R)-methanandamide maintained RGÎ±i1 and RGÎ±i2 complexes even in the presence of a nonhydrolyzable GTP analog.  The biaryl pyrazole antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboximide hydrochloride (SR141716) maintained all three RGÎ±i complexes.  GÎ² proteins, and to a certain extent GÎ³2, exhibited the same assocn./dissocn. pattern as the GÎ± proteins.  A GDP analog had no influence on any of these assocn./dissocn. reactions and failed to promote sequestration of G proteins.  These results can be explained by invoking the existence of an inverse agonist-supported inactive state in the ternary complex equil. model.  WIN 55,212-2 behaves as an agonist for all three Gi subtypes; SR141716 behaves as an inverse agonist for all three Gi subtypes; desacetyllevonantradol behaves as an agonist for Gi1 and Gi2, and an inverse agonist at Gi3; and (R)-methanandamide behaves as an inverse agonist at Gi1 and Gi2, and an agonist at Gi3.  These ligand-selective G protein responses imply that multiple conformations of the receptor could be evoked by ligands to regulate individual G proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNEsjFuiX8nLVg90H21EOLACvtfcHk0li7fRXnbg-UKQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkvFGis74%253D&md5=953abf18a6cfad444972bd9e71499ea7</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1124%2Fmol.104.003558&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.104.003558%26sid%3Dliteratum%253Aachs%26aulast%3DMukhopadhyay%26aufirst%3DS.%26aulast%3DHowlett%26aufirst%3DA.%2BC.%26atitle%3DChemically%2520Distinct%2520Ligands%2520Promote%2520Differential%2520CB1%2520Cannabinoid%2520Receptor-Gi%2520Protein%2520Interactions%26jtitle%3DMol.%2520Pharmacol.%26date%3D2005%26volume%3D67%26spage%3D2016%26epage%3D2024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Pi-Sunyer, F. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aronne, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heshmati, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenstock, J.</span><span> </span><span class="NLM_article-title">Effect of Rimonabant, a Cannabinoid-1 Receptor Blocker, on Weight and Cardiometabolic Risk Factors in Overweight or Obese Patients</span> <span class="citation_source-journal">JAMA, J. Am. Med. Assoc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">295</span><span class="NLM_x">, </span> <span class="NLM_fpage">761</span><span class="NLM_x">â</span> <span class="NLM_lpage">775</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=295&publication_year=2006&pages=761-775&author=F.+X.+Pi-Sunyerauthor=L.+J.+Aronneauthor=H.+M.+Heshmatiauthor=J.+Devinauthor=J.+Rosenstock&title=Effect+of+Rimonabant%2C+a+Cannabinoid-1+Receptor+Blocker%2C+on+Weight+and+Cardiometabolic+Risk+Factors+in+Overweight+or+Obese+Patients"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPi-Sunyer%26aufirst%3DF.%2BX.%26aulast%3DAronne%26aufirst%3DL.%2BJ.%26aulast%3DHeshmati%26aufirst%3DH.%2BM.%26aulast%3DDevin%26aufirst%3DJ.%26aulast%3DRosenstock%26aufirst%3DJ.%26atitle%3DEffect%2520of%2520Rimonabant%252C%2520a%2520Cannabinoid-1%2520Receptor%2520Blocker%252C%2520on%2520Weight%2520and%2520Cardiometabolic%2520Risk%2520Factors%2520in%2520Overweight%2520or%2520Obese%2520Patients%26jtitle%3DJAMA%252C%2520J.%2520Am.%2520Med.%2520Assoc.%26date%3D2006%26volume%3D295%26spage%3D761%26epage%3D775" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit3b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Van Gaal, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rissanen, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheen, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ziegler, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">RÃ¶ssner, S.</span><span> </span><span class="NLM_article-title">Effects of the Cannabinoid-1 Receptor Blocker Rimonabant on Weight Reduction and Cardiovascular Risk Factors in Overweight Patients: 1-Year Experience from the RIO-Europe Study</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">365</span><span class="NLM_x">, </span> <span class="NLM_fpage">1389</span><span class="NLM_x">â</span> <span class="NLM_lpage">1397</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=16&amp;doi=10.1021%2Fjm4010835&amp;key=10.1016%2FS0140-6736%2805%2966374-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=8&amp;doi=10.1021%2Fjm4010835&amp;key=15836887" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3b&amp;dbid=32&amp;doi=10.1021%2Fjm4010835&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjsVegtbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=365&publication_year=2005&pages=1389-1397&author=L.+F.+Van+Gaalauthor=A.+M.+Rissanenauthor=A.+J.+Scheenauthor=O.+Zieglerauthor=S.+R%C3%B6ssner&title=Effects+of+the+Cannabinoid-1+Receptor+Blocker+Rimonabant+on+Weight+Reduction+and+Cardiovascular+Risk+Factors+in+Overweight+Patients%3A+1-Year+Experience+from+the+RIO-Europe+Study"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3bR"><div class="casContent"><span class="casTitleNuber">3b</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study</span></div><div class="casAuthors">Van Gaal, Luc F.; Rissanen, Aila M.; Scheen, Andre J.; Ziegler, Olivier; Roessner, Stephan</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">365</span>
        (<span class="NLM_cas:issue">9468</span>),
    <span class="NLM_cas:pages">1389-1397</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Background: In animal models, cannabinoid-1 receptor (CB1) blockade produces a lean phenotype, with resistance to diet-induced obesity and assocd. dyslipidemia.  We assessed the effect of rimonabant, a selective CB1 blocker, on bodyweight and cardiovascular risk factors in overweight or obese patients.  Methods: patients with body-mass index 30 kg/m2 or greater, or body-mass index greater than 27 kg/m2 with treated or untreated dyslipidemia, hypertension, or both, were randomized to receive double-blind treatment with placebo, 5 mg rimonabant, or 20 mg rimonabant once daily in addn. to a mild hypocaloric diet (600 kcal/day deficit).  The primary efficacy endpoint was wt. change from baseline after 1 yr of treatment in the intention-to-treat population.  Findings: Wt. loss at 1 yr was significantly greater in patients treated with rimonabant 5 mg (mean -3Â·4 kg [SD 5Â·7]; p=0Â·002 vs placebo) and 20 mg (-6Â·6 kg [7Â·2]; p<0Â·001 vs placebo) compared with placebo (-1Â·8 kg [6Â·4]).  Significantly more patients treated with rimonabant 20 mg than placebo achieved wt. loss of 5% or greater (p<0Â·001) and 10% or greater (p<0Â·001).  Rimonabant 20 mg produced significantly greater improvements than placebo in waist circumference, HDL-cholesterol, triglycerides, and insulin resistance, and prevalence of the metabolic syndrome.  The effects of rimonabant 5 mg were of less clin. significance.  Rimonabant was generally well tolerated with mild and transient side effects.  Interpretation: CB1 blockade with rimonabant 20 mg, combined with a hypocaloric diet over 1 yr, promoted significant decrease of bodyweight and waist circumference, and improvement in cardiovascular risk factors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJDfvQ1f24LLVg90H21EOLACvtfcHk0ljJgnt8Bhu1bw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjsVegtbo%253D&md5=99a1c3a9978bc97be839c2284db5c385</span></div><a href="/servlet/linkout?suffix=cit3b&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2805%2966374-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252805%252966374-X%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BGaal%26aufirst%3DL.%2BF.%26aulast%3DRissanen%26aufirst%3DA.%2BM.%26aulast%3DScheen%26aufirst%3DA.%2BJ.%26aulast%3DZiegler%26aufirst%3DO.%26aulast%3DR%25C3%25B6ssner%26aufirst%3DS.%26atitle%3DEffects%2520of%2520the%2520Cannabinoid-1%2520Receptor%2520Blocker%2520Rimonabant%2520on%2520Weight%2520Reduction%2520and%2520Cardiovascular%2520Risk%2520Factors%2520in%2520Overweight%2520Patients%253A%25201-Year%2520Experience%2520from%2520the%2520RIO-Europe%2520Study%26jtitle%3DLancet%26date%3D2005%26volume%3D365%26spage%3D1389%26epage%3D1397" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit3c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Bellocchio, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mancini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vicennati, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pasquali, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pagotto, U.</span><span> </span><span class="NLM_article-title">Cannabinoid Recptors as Therapeutic Targets for Obesity and Metabolic Diseases</span> <span class="citation_source-journal">Curr. Opin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">586</span><span class="NLM_x">â</span> <span class="NLM_lpage">591</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3c&amp;dbid=16&amp;doi=10.1021%2Fjm4010835&amp;key=10.1016%2Fj.coph.2006.09.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3c&amp;dbid=8&amp;doi=10.1021%2Fjm4010835&amp;key=17027338" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3c&amp;dbid=32&amp;doi=10.1021%2Fjm4010835&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFKmt7fO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=586-591&author=L.+Bellocchioauthor=G.+Manciniauthor=V.+Vicennatiauthor=R.+Pasqualiauthor=U.+Pagotto&title=Cannabinoid+Recptors+as+Therapeutic+Targets+for+Obesity+and+Metabolic+Diseases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3cR"><div class="casContent"><span class="casTitleNuber">3c</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid receptors as therapeutic targets for obesity and metabolic diseases</span></div><div class="casAuthors">Bellocchio, Luigi; Mancini, Giacomo; Vicennati, Valentina; Pasquali, Renato; Pagotto, Uberto</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">586-591</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  One of the most interesting pharmacol. targets proposed in the past ten years for fighting obesity and related metabolic disorders is the endocannabinoid system.  The role of the endocannabinoid system is crucial in regulating the rewarding properties of food, in controlling energy balance by acting at the hypothalamic circuitries involved in food intake, and in peripheral metab. by influencing adipocytes, hepatocytes, myocytes and pancreatic endocrine cells.  Obesity seems to be a condition assocd. with a pathol. overactivation of the endocannabinoid system; therefore, restoring a normal endocannabinoid tone by antagonizing the cannabinoid receptor type 1 (CB1) could help arrest both the development and the maintenance of obesity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0eSr9DU5F-bVg90H21EOLACvtfcHk0ljJgnt8Bhu1bw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFKmt7fO&md5=2aa553d9332e761be69b53134ad1d7ba</span></div><a href="/servlet/linkout?suffix=cit3c&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2006.09.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2006.09.001%26sid%3Dliteratum%253Aachs%26aulast%3DBellocchio%26aufirst%3DL.%26aulast%3DMancini%26aufirst%3DG.%26aulast%3DVicennati%26aufirst%3DV.%26aulast%3DPasquali%26aufirst%3DR.%26aulast%3DPagotto%26aufirst%3DU.%26atitle%3DCannabinoid%2520Recptors%2520as%2520Therapeutic%2520Targets%2520for%2520Obesity%2520and%2520Metabolic%2520Diseases%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2006%26volume%3D6%26spage%3D586%26epage%3D591" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Walthion, N.</span><div class="note"><p class="first last">European Medicines Agency Press Release EMEA/39457/2009, January 30, 2009; and, European Medicines Agency Press Release EMEA/537153/2008, October 23, 2008.</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Walthion%2C+N.European+Medicines+Agency+Press+Release+EMEA%2F39457%2F2009%2C+January+30%2C+2009%3B+and%2C+European+Medicines+Agency+Press+Release+EMEA%2F537153%2F2008%2C+October+23%2C+2008."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DWalthion%26aufirst%3DN." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Seltzman, H. H.</span><span> </span><span class="NLM_article-title">Recent CB1 Cannabinoid Receptor Antagonists and Inverse Agonists</span> <span class="citation_source-journal">Drug Dev. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">601</span><span class="NLM_x">â</span> <span class="NLM_lpage">615</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm4010835&amp;key=10.1002%2Fddr.20338" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm4010835&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGrtrjP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2009&pages=601-615&issue=8&author=H.+H.+Seltzman&title=Recent+CB1+Cannabinoid+Receptor+Antagonists+and+Inverse+Agonists"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Recent CB1 cannabinoid receptor antagonists and inverse agonists</span></div><div class="casAuthors">Seltzman, Herbert H.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Development Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">601-615</span>CODEN:
                <span class="NLM_cas:coden">DDREDK</span>;
        ISSN:<span class="NLM_cas:issn">0272-4391</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">A review.  Antagonists or inverse agonists of the cannabinoid CB1 receptor (CB1R) reported from the 2006-2007 period are reviewed.  The compds. are either variations of the archetypical cannabinoid CB1 inverse agonist rimonabant (SR141716) or are other structures less obviously related to the archetype.  Many of the former class replace the core pyrazole ring of rimonabant with other ring systems to display/arrange the appended binding/activity elements.  A structure-activity relation evolves from bioassays of these compds. that also provides a more detailed understanding of the mol. mechanism of the binding to and stabilization of the active and inactive states of the constitutively active CB1R.  In addn. to diverse variations of the core ring and appended substituents, conformationally constrained analogs with high affinity were revealed, a no. of which do not fit a one-to-one atom correspondence with the putatively active conformations of the rimonabant template and other active analogs.  Diphenylmethyl analogs were a repeated motif in structures where core rings were either absent or played less restrictive roles in structures pursuing higher conformational freedom.  Bicyclic nitrogen heterocyclic ring systems as the central core structures were reported, as were linear structures including Ph ureas and taranabant analogs.  Finally, peptides in the hemopressin class were presented as CB1 antagonists.  Drug Dev Res 70:601-615, 2009. Â© 2009 Wiley-Liss, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6cEqOfdS8ArVg90H21EOLACvtfcHk0ljJgnt8Bhu1bw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGrtrjP&md5=dc643cd15355ae07cb035b8f717c46af</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1002%2Fddr.20338&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fddr.20338%26sid%3Dliteratum%253Aachs%26aulast%3DSeltzman%26aufirst%3DH.%2BH.%26atitle%3DRecent%2520CB1%2520Cannabinoid%2520Receptor%2520Antagonists%2520and%2520Inverse%2520Agonists%26jtitle%3DDrug%2520Dev.%2520Res.%26date%3D2009%26volume%3D70%26issue%3D8%26spage%3D601%26epage%3D615" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Letourneau, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jokiel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riviello, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, K.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McAleer, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swanson, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohlmeyer, M. H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, M. L.</span><span> </span><span class="NLM_article-title">Identification and Hit-to-lead Optimization of a Novel Class of CB1 Antagonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">5449</span><span class="NLM_x">â</span> <span class="NLM_lpage">5453</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=5449-5453&author=J.+J.+Letourneauauthor=P.+Jokielauthor=J.+Olsonauthor=C.+M.+Rivielloauthor=K.-K.+Hoauthor=L.+McAleerauthor=J.+Yangauthor=R.+N.+Swansonauthor=J.+Bakerauthor=P.+Cowleyauthor=D.+Edwardsauthor=N.+Wardauthor=M.+H.+J.+Ohlmeyerauthor=M.+L.+Webb&title=Identification+and+Hit-to-lead+Optimization+of+a+Novel+Class+of+CB1+Antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLetourneau%26aufirst%3DJ.%2BJ.%26aulast%3DJokiel%26aufirst%3DP.%26aulast%3DOlson%26aufirst%3DJ.%26aulast%3DRiviello%26aufirst%3DC.%2BM.%26aulast%3DHo%26aufirst%3DK.-K.%26aulast%3DMcAleer%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DSwanson%26aufirst%3DR.%2BN.%26aulast%3DBaker%26aufirst%3DJ.%26aulast%3DCowley%26aufirst%3DP.%26aulast%3DEdwards%26aufirst%3DD.%26aulast%3DWard%26aufirst%3DN.%26aulast%3DOhlmeyer%26aufirst%3DM.%2BH.%2BJ.%26aulast%3DWebb%26aufirst%3DM.%2BL.%26atitle%3DIdentification%2520and%2520Hit-to-lead%2520Optimization%2520of%2520a%2520Novel%2520Class%2520of%2520CB1%2520Antagonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D5449%26epage%3D5453" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Griffith, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hadcock, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Black, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iredale, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carpino, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DaSilva-Jardine, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Day, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiBrino, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dow, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Landis, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâConnor, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, D. O.</span><span> </span><span class="NLM_article-title">Discovery of 1-[9-(4-Chlorophenyl)-8-(2-chlorophenyl)-9<i>H</i>-purin-6-yl]-4-ethylaminopiperidine-4-carboxylic Acid Amide Hydrochloride (CP-945,598), a Novel, Potent, and Selective Cannabinoid Type 1 Receptor Antagonist</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">234</span><span class="NLM_x">â</span> <span class="NLM_lpage">237</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm8012932" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=234-237&author=D.+A.+Griffithauthor=J.+R.+Hadcockauthor=S.+C.+Blackauthor=P.+A.+Iredaleauthor=P.+A.+Carpinoauthor=P.+DaSilva-Jardineauthor=R.+Dayauthor=J.+DiBrinoauthor=R.+L.+Dowauthor=M.+S.+Landisauthor=R.+E.+O%E2%80%99Connorauthor=D.+O.+Scott&title=Discovery+of+1-%5B9-%284-Chlorophenyl%29-8-%282-chlorophenyl%29-9H-purin-6-yl%5D-4-ethylaminopiperidine-4-carboxylic+Acid+Amide+Hydrochloride+%28CP-945%2C598%29%2C+a+Novel%2C+Potent%2C+and+Selective+Cannabinoid+Type+1+Receptor+Antagonist"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Fjm8012932&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8012932%26sid%3Dliteratum%253Aachs%26aulast%3DGriffith%26aufirst%3DD.%2BA.%26aulast%3DHadcock%26aufirst%3DJ.%2BR.%26aulast%3DBlack%26aufirst%3DS.%2BC.%26aulast%3DIredale%26aufirst%3DP.%2BA.%26aulast%3DCarpino%26aufirst%3DP.%2BA.%26aulast%3DDaSilva-Jardine%26aufirst%3DP.%26aulast%3DDay%26aufirst%3DR.%26aulast%3DDiBrino%26aufirst%3DJ.%26aulast%3DDow%26aufirst%3DR.%2BL.%26aulast%3DLandis%26aufirst%3DM.%2BS.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DR.%2BE.%26aulast%3DScott%26aufirst%3DD.%2BO.%26atitle%3DDiscovery%2520of%25201-%255B9-%25284-Chlorophenyl%2529-8-%25282-chlorophenyl%2529-9H-purin-6-yl%255D-4-ethylaminopiperidine-4-carboxylic%2520Acid%2520Amide%2520Hydrochloride%2520%2528CP-945%252C598%2529%252C%2520a%2520Novel%252C%2520Potent%252C%2520and%2520Selective%2520Cannabinoid%2520Type%25201%2520Receptor%2520Antagonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D234%26epage%3D237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span>Rimonabant: Acomplia EPAR Product Information; European Agency for The Evaluation of Medicinal Products: <span class="NLM_publisher-loc">London</span>,<span class="NLM_x"> </span><span class="NLM_year">2009</span><span class="NLM_x">; </span><a href="http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000666/human_med_000623.jsp&amp;mid=WC0b01ac058001d124" class="extLink">http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000666/human_med_000623.jsp&mid=WC0b01ac058001d124</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Rimonabant%3A+Acomplia+EPAR+Product+Information%3B+European+Agency+for+The+Evaluation+of+Medicinal+Products%3A+London%2C+2009%3B+http%3A%2F%2Fwww.ema.europa.eu%2Fema%2Findex.jsp%3Fcurl%3Dpages%2Fmedicines%2Fhuman%2Fmedicines%2F000666%2Fhuman_med_000623.jsp%26mid%3DWC0b01ac058001d124."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DRimonabant%253A%2520Acomplia%2520EPAR%2520Product%2520Information%26jtitle%3DEuropean%2520Agency%2520for%2520The%2520Evaluation%2520of%2520Medicinal%2520Products%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Addy, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rothenberg, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Majumdar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agrawal, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunbar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cote, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosko, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Dyck, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Lepeleire, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Hoon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Hecken, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Depre, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knops, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottesdiener, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoch, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, J.</span><span> </span><span class="NLM_article-title">Multiple-Dose Pharmacokinetics, Pharmacodynamics, and Safety of Taranabant, a Novel Selective Cannabinoid-1 Receptor Inverse Agonist, in Healthy Male Volunteers</span> <span class="citation_source-journal">J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">734</span><span class="NLM_x">â</span> <span class="NLM_lpage">744</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm4010835&amp;key=10.1177%2F0091270008317591" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Fjm4010835&amp;key=18508950" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm4010835&amp;key=1%3ACAS%3A528%3ADC%252BD1cXns1Kit7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2008&pages=734-744&author=C.+Addyauthor=P.+Rothenbergauthor=S.+Liauthor=A.+Majumdarauthor=N.+Agrawalauthor=H.+Liauthor=L.+Zhongauthor=J.+Yuanauthor=A.+Maesauthor=S.+Dunbarauthor=J.+Coteauthor=K.+Roskoauthor=K.+Van+Dyckauthor=I.+De+Lepeleireauthor=J.+de+Hoonauthor=A.+Van+Heckenauthor=M.+Depreauthor=A.+Knopsauthor=K.+Gottesdienerauthor=A.+Stochauthor=J.+Wagner&title=Multiple-Dose+Pharmacokinetics%2C+Pharmacodynamics%2C+and+Safety+of+Taranabant%2C+a+Novel+Selective+Cannabinoid-1+Receptor+Inverse+Agonist%2C+in+Healthy+Male+Volunteers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteers</span></div><div class="casAuthors">Addy, Carol; Rothenberg, Paul; Li, Susie; Majumdar, Anup; Agrawal, Nancy; Li, Hankun; Zhong, Ling; Yuan, Jinyu; Maes, Andrea; Dunbar, Stephanie; Cote, Josee; Rosko, Kim; Van Dyck, Kristien; De Lepeleire, Inge; de Hoon, Jan; Van Hecken, Anne; Depre, Marleen; Knops, Annemie; Gottesdiener, Keith; Stoch, Aubrey; Wagner, John</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">734-744</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Taranabant is a cannabinoid-1 receptor inverse agonist for the treatment of obesity.  This study evaluated the safety, pharmacokinetics, and pharmacodynamics of taranabant (5, 7.5, 10, or 25 mg once daily for 14 days) in 60 healthy male subjects.  Taranabant was rapidly absorbed, with a median tmax of 1.0 to 2.0 h and a t1/2 of approx. 74 to 104 h.  Moderate accumulation was obsd. in Cmax (1.18- to 1.40-fold) and AUC0-24 h (1.5- to 1.8-fold) over 14 days for the 5-, 7.5-, and 10-mg doses, with an accumulation half-life ranging from 15 to 21 h.  Steady state was reached after 13 days.  After multiple-dose administration, plasma AUC0-24 h and Cmax of taranabant increased dose proportionally (5-10 mg) and increased somewhat less than dose proportionally for 25 mg.  Taranabant was generally well tolerated up to doses of 10 mg and exhibited multiple-dose pharmacokinetics consistent with once-daily dosing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEiSkhEMfIDLVg90H21EOLACvtfcHk0lgnLGE2C_SvGw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXns1Kit7Y%253D&md5=0bb78538334e4b3018954d0cf6ec4c0c</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1177%2F0091270008317591&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0091270008317591%26sid%3Dliteratum%253Aachs%26aulast%3DAddy%26aufirst%3DC.%26aulast%3DRothenberg%26aufirst%3DP.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DMajumdar%26aufirst%3DA.%26aulast%3DAgrawal%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DZhong%26aufirst%3DL.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DMaes%26aufirst%3DA.%26aulast%3DDunbar%26aufirst%3DS.%26aulast%3DCote%26aufirst%3DJ.%26aulast%3DRosko%26aufirst%3DK.%26aulast%3DVan%2BDyck%26aufirst%3DK.%26aulast%3DDe%2BLepeleire%26aufirst%3DI.%26aulast%3Dde%2BHoon%26aufirst%3DJ.%26aulast%3DVan%2BHecken%26aufirst%3DA.%26aulast%3DDepre%26aufirst%3DM.%26aulast%3DKnops%26aufirst%3DA.%26aulast%3DGottesdiener%26aufirst%3DK.%26aulast%3DStoch%26aufirst%3DA.%26aulast%3DWagner%26aufirst%3DJ.%26atitle%3DMultiple-Dose%2520Pharmacokinetics%252C%2520Pharmacodynamics%252C%2520and%2520Safety%2520of%2520Taranabant%252C%2520a%2520Novel%2520Selective%2520Cannabinoid-1%2520Receptor%2520Inverse%2520Agonist%252C%2520in%2520Healthy%2520Male%2520Volunteers%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2008%26volume%3D48%26spage%3D734%26epage%3D744" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Miao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liras, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prakash, C.</span><span> </span><span class="NLM_article-title">Excretion, Metabolism, and Pharmacokinetics of 1-(8-(2-Chlorophenyl)-9-(4-chlorophenyl)-9<i>H</i>-purin-6-yl)-4-(ethylamino)piperidine-4-carboxamide, a Selective Cannabinoid Receptor Antagonist, in Healthy Male Volunteers</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">568</span><span class="NLM_x">â</span> <span class="NLM_lpage">578</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=568-578&issue=3&author=Z.+Miaoauthor=H.+Sunauthor=J.+Lirasauthor=C.+Prakash&title=Excretion%2C+Metabolism%2C+and+Pharmacokinetics+of+1-%288-%282-Chlorophenyl%29-9-%284-chlorophenyl%29-9H-purin-6-yl%29-4-%28ethylamino%29piperidine-4-carboxamide%2C+a+Selective+Cannabinoid+Receptor+Antagonist%2C+in+Healthy+Male+Volunteers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMiao%26aufirst%3DZ.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DLiras%26aufirst%3DJ.%26aulast%3DPrakash%26aufirst%3DC.%26atitle%3DExcretion%252C%2520Metabolism%252C%2520and%2520Pharmacokinetics%2520of%25201-%25288-%25282-Chlorophenyl%2529-9-%25284-chlorophenyl%2529-9H-purin-6-yl%2529-4-%2528ethylamino%2529piperidine-4-carboxamide%252C%2520a%2520Selective%2520Cannabinoid%2520Receptor%2520Antagonist%252C%2520in%2520Healthy%2520Male%2520Volunteers%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2012%26volume%3D40%26issue%3D3%26spage%3D568%26epage%3D578" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Greenblatt, D. J.</span><span> </span><span class="NLM_article-title">Elimination Half-life of Drugs: Value and Limitations</span> <span class="citation_source-journal">Annu. Rev. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">421</span><span class="NLM_x">â</span> <span class="NLM_lpage">427</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1985&pages=421-427&author=D.+J.+Greenblatt&title=Elimination+Half-life+of+Drugs%3A+Value+and+Limitations"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGreenblatt%26aufirst%3DD.%2BJ.%26atitle%3DElimination%2520Half-life%2520of%2520Drugs%253A%2520Value%2520and%2520Limitations%26jtitle%3DAnnu.%2520Rev.%2520Med.%26date%3D1985%26volume%3D36%26spage%3D421%26epage%3D427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Welling, P. G.</span> <span class="citation_source-book">Pharmacokinetics</span>; <span class="NLM_series">ACS Monograph 185</span>; <span class="NLM_publisher-name">American Chemical Society</span>: <span class="NLM_publisher-loc">Washington, DC</span>,<span class="NLM_x"> </span><span class="NLM_year">1986</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">187</span><span class="NLM_x">â</span> <span class="NLM_lpage">200</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1986&pages=187-200&author=P.+G.+Welling&title=Pharmacokinetics"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DWelling%26aufirst%3DP.%2BG.%26btitle%3DPharmacokinetics%26pub%3DAmerican%2520Chemical%2520Society%26date%3D1986%26spage%3D187%26epage%3D200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Salzman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shader, R. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenblatt, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harmatz, J. S.</span><span> </span><span class="NLM_article-title">Long v Short Half-life Benzodiazepines in the Elderly</span> <span class="citation_source-journal">Arch. Gen. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1983</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">293</span><span class="NLM_x">â</span> <span class="NLM_lpage">297</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm4010835&amp;key=10.1001%2Farchpsyc.1983.01790030063008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm4010835&amp;key=1%3ACAS%3A280%3ADyaL3s7lt1WhsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1983&pages=293-297&author=C.+Salzmanauthor=R.+I.+Shaderauthor=D.+J.+Greenblattauthor=J.+S.+Harmatz&title=Long+v+Short+Half-life+Benzodiazepines+in+the+Elderly"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Long v short half-life benzodiazepines in the elderly. Kinetics and clinical effects of diazepam and oxazepam</span></div><div class="casAuthors">Salzman C; Shader R I; Greenblatt D J; Harmatz J S</div><div class="citationInfo"><span class="NLM_cas:title">Archives of general psychiatry</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">293-7</span>
        ISSN:<span class="NLM_cas:issn">0003-990X</span>.
    </div><div class="casAbstract">Oxazepam and diazepam were compared in healthy elderly volunteers.  Absorption of diazepam was faster than oxazepam and onset of clinical effects were more profound.  Diazepam accumulation was extensive, washout was slow and active compounds were present two weeks after the last dose.  Oxazepam accumulation was significantly less and elimination significantly faster than diazepam.  There was no difference between oxazepam and diazepam in sedation or fatigue during the drug treatment, but sedative effects persisted for two weeks after diazepam therapy was discontinued.  Sedation rapidly returned to baseline in the oxazepam group.  Thus, the differing pharmacokinetic profiles of diazepam and oxazepam have clinical consequences during multiple dosage in the elderly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRH_nfYZaaMgJNiNltV31zlfW6udTcc2eb-YGhbGtQ74bntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL3s7lt1WhsA%253D%253D&md5=22583995d29a795a6e352e1e736cb363</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1001%2Farchpsyc.1983.01790030063008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchpsyc.1983.01790030063008%26sid%3Dliteratum%253Aachs%26aulast%3DSalzman%26aufirst%3DC.%26aulast%3DShader%26aufirst%3DR.%2BI.%26aulast%3DGreenblatt%26aufirst%3DD.%2BJ.%26aulast%3DHarmatz%26aufirst%3DJ.%2BS.%26atitle%3DLong%2520v%2520Short%2520Half-life%2520Benzodiazepines%2520in%2520the%2520Elderly%26jtitle%3DArch.%2520Gen.%2520Psychiatry%26date%3D1983%26volume%3D40%26spage%3D293%26epage%3D297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Ellsworth, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pendri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerritz, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlson, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baska, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burford, N. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cullen, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnghar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behnia, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pelleymounter, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Washburn, W. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ewing, W. R.</span><span> </span><span class="NLM_article-title">Discovery of Pyrazine Carboxamide CB1 Antagonists: The Introduction of a Hydroxyl Group Improves the Pharmaceutical Properties and In Vivo Efficacy of the Series</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">3978</span><span class="NLM_x">â</span> <span class="NLM_lpage">3982</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm4010835&amp;key=10.1016%2Fj.bmcl.2007.04.087" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm4010835&amp;key=17513109" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm4010835&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmvVClu7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=3978-3982&author=B.+A.+Ellsworthauthor=Y.+Wangauthor=Y.+Zhuauthor=A.+Pendriauthor=S.+W.+Gerritzauthor=C.+Sunauthor=K.+E.+Carlsonauthor=L.+Kangauthor=R.+A.+Baskaauthor=Y.+Yangauthor=Q.+Huangauthor=N.+T.+Burfordauthor=M.+J.+Cullenauthor=S.+Johngharauthor=K.+Behniaauthor=M.+A.+Pelleymounterauthor=W.+N.+Washburnauthor=W.+R.+Ewing&title=Discovery+of+Pyrazine+Carboxamide+CB1+Antagonists%3A+The+Introduction+of+a+Hydroxyl+Group+Improves+the+Pharmaceutical+Properties+and+In+Vivo+Efficacy+of+the+Series"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of pyrazine carboxamide CB1 antagonists: The introduction of a hydroxyl group improves the pharmaceutical properties and in vivo efficacy of the series</span></div><div class="casAuthors">Ellsworth, Bruce A.; Wang, Ying; Zhu, Yeheng; Pendri, Annapurna; Gerritz, Samuel W.; Sun, Chongqing; Carlson, Kenneth E.; Kang, Liya; Baska, Rose A.; Yang, Yifan; Huang, Qi; Burford, Neil T.; Cullen, Mary Jane; Johnghar, Susan; Behnia, Kamelia; Pelleymounter, Mary Ann; Washburn, William N.; Ewing, William R.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3978-3982</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Structure-activity relationships for a series of pyrazine carboxamide CB1 antagonists are reported.  Pharmaceutical properties of the series are improved via inclusion of hydroxyl-contg. sidechains.  This structural modification sufficiently improved ADME properties of an orally inactive series such that food intake redn. was achieved in rat feeding models.  Compd. 35 (I) elicits a 46% redn. in food intake in ad libitum fed rats 4-h post-dose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqp2iSxEZT2bVg90H21EOLACvtfcHk0ljqYlnEIEC94g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmvVClu7k%253D&md5=723258b8fb296b9d23ff228d0ce7d15d</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2007.04.087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2007.04.087%26sid%3Dliteratum%253Aachs%26aulast%3DEllsworth%26aufirst%3DB.%2BA.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DPendri%26aufirst%3DA.%26aulast%3DGerritz%26aufirst%3DS.%2BW.%26aulast%3DSun%26aufirst%3DC.%26aulast%3DCarlson%26aufirst%3DK.%2BE.%26aulast%3DKang%26aufirst%3DL.%26aulast%3DBaska%26aufirst%3DR.%2BA.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DBurford%26aufirst%3DN.%2BT.%26aulast%3DCullen%26aufirst%3DM.%2BJ.%26aulast%3DJohnghar%26aufirst%3DS.%26aulast%3DBehnia%26aufirst%3DK.%26aulast%3DPelleymounter%26aufirst%3DM.%2BA.%26aulast%3DWashburn%26aufirst%3DW.%2BN.%26aulast%3DEwing%26aufirst%3DW.%2BR.%26atitle%3DDiscovery%2520of%2520Pyrazine%2520Carboxamide%2520CB1%2520Antagonists%253A%2520The%2520Introduction%2520of%2520a%2520Hydroxyl%2520Group%2520Improves%2520the%2520Pharmaceutical%2520Properties%2520and%2520In%2520Vivo%2520Efficacy%2520of%2520the%2520Series%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D3978%26epage%3D3982" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Meanwell, N. A.</span><span> </span><span class="NLM_article-title">Improving Drug Candidates by Design: A Focus on Physicochemical Properties As a Means of Improving Compound Disposition and Safety</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">1420</span><span class="NLM_x">â</span> <span class="NLM_lpage">1456</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx200211v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm4010835&amp;key=1%3ACAS%3A528%3ADC%252BC3MXptlCitLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2011&pages=1420-1456&issue=9&author=N.+A.+Meanwell&title=Improving+Drug+Candidates+by+Design%3A+A+Focus+on+Physicochemical+Properties+As+a+Means+of+Improving+Compound+Disposition+and+Safety"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Improving Drug Candidates by Design: A Focus on Physicochemical Properties As a Means of Improving Compound Disposition and Safety</span></div><div class="casAuthors">Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1420-1456</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The development of small mol. drug candidates from the discovery phase to a marketed product continues to be a challenging enterprise with very low success rates that have fostered the perception of poor productivity by the pharmaceutical industry.  Although there have been significant advances in preclin. profiling that have improved compd. triaging and altered the underlying reasons for compd. attrition, the failure rates have not appreciably changed.  As part of an effort to more deeply understand the reasons for candidate failure, there has been considerable interest in analyzing the physicochem. properties of marketed drugs for the purpose of comparing with drugs in discovery and development as a means capturing recent trends in drug design.  The scenario that has emerged is one in which contemporary drug discovery is thought to be focused too heavily on advancing candidates with profiles that are most easily satisfied by mols. with increased mol. wt. and higher overall lipophilicity.  The preponderance of mols. expressing these properties is frequently a function of increased arom. ring count when compared with that of the drugs launched in the latter half of the 20th century and may reflect a preoccupation with maximizing target affinity rather than taking a more holistic approach to drug design.  These attributes not only present challenges for formulation and absorption but also may influence the manifestation of toxicity during development.  By providing some definition around the optimal physicochem. properties assocd. with marketed drugs, guidelines for drug design have been developed that are based largely on calcd. parameters and which may readily be applied by medicinal chemists as an aid to understanding candidate quality.  The physicochem. properties of a mol. that are consistent with the potential for good oral absorption were initially defined by Lipinski, with addnl. insights allowing further refinement, while deeper analyses have explored the correlation with metabolic stability and toxicity.  These insights have been augmented by careful analyses of physicochem. aspects of drug-target interactions, with thermodn. profiling indicating that the signature of best-in-class drugs is a dependence on enthalpy to drive binding energetics rather than entropy, which is dependent on lipophilicity.  Optimization of the entropic contribution to the binding energy of a ligand to its target is generally much easier than refining the enthalpic element.  Consequently, in the absence of a fundamental understanding of the thermodn. complexion of an interaction, the design of mols. with increased lipophilicity becomes almost inevitable.  The application of ligand efficiency, a measure of affinity per heavy atom, group efficiency, which assesses affinity in the context of structural changes, and lipophilic ligand efficiency, which relates potency to lipophilicity, offer less sophisticated but practically useful anal. algorithms to assess the quality of drug-target interactions.  These parameters are readily calcd. and can be applied to lead optimization programs in a fashion that helps to maximize potency while minimizing the kind of lipophilic burden that has been dubbed "mol. obesity".  Several recently described lead optimization campaigns provide illustrative, informative, and productive examples of the effect of paying close attention to carefully controlling physicochem. properties by monitoring ligand efficiency and lipophilic ligand efficiency.  However, to be successful during the lead optimization phase, drug candidate identification programs will need to adopt a holistic approach that integrates multiple parameters, many of which will have unique dependencies on both the drug target and the specific chemotype under prosecution.  Nevertheless, there are many important drug targets that necessitate working in space beyond that which has been defined by the retrospective analyses of marketed drugs and which will require adaptation of some of the guideposts that are useful in directing lead optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQrUfIwZiIR7Vg90H21EOLACvtfcHk0lgD2bFiMcFbkg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXptlCitLs%253D&md5=9ddcf6dc81bf8ab0441df5037979ff4e</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Ftx200211v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx200211v%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DImproving%2520Drug%2520Candidates%2520by%2520Design%253A%2520A%2520Focus%2520on%2520Physicochemical%2520Properties%2520As%2520a%2520Means%2520of%2520Improving%2520Compound%2520Disposition%2520and%2520Safety%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2011%26volume%3D24%26issue%3D9%26spage%3D1420%26epage%3D1456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Yu, G.; Ellsworth, B. A.; Mikkilineni, A.; Wu, X.; Wang, Y.; Sitkoff, D.; Gu, Z.; Murugesan, N.; Swartz, S.; Carlson, K. E.; Kang, L.; Yang, Y.; Lee, N.; Baska, R. A.; Huang, Q.; Cullen, M. J.; Zuvich, E.; Thomas, M.; Rohrbach, K.; Devenny, J.; Godonis, H.; Harvey, S.; Johnghar, S.; Behnia, K.; Pelleymounter, M. A.; Ewing, W. R.</span><span> </span><span class="NLM_article-title">Discovery of Di-Aryl Triazolopyridazine Cannabinoid Receptor (CB1) Antagonists</span>. <span class="NLM_conf-name">Fall 2008 ACS National Meeting</span>, <span class="NLM_conf-loc">Philadelphia, PA</span>, <span class="NLM_conf-date">August 17â21, 2008</span>,  <span class="NLM_fpage">MEDI 010</span>, .</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Yu%2C+G.%3B+Ellsworth%2C+B.+A.%3B+Mikkilineni%2C+A.%3B+Wu%2C+X.%3B+Wang%2C+Y.%3B+Sitkoff%2C+D.%3B+Gu%2C+Z.%3B+Murugesan%2C+N.%3B+Swartz%2C+S.%3B+Carlson%2C+K.+E.%3B+Kang%2C+L.%3B+Yang%2C+Y.%3B+Lee%2C+N.%3B+Baska%2C+R.+A.%3B+Huang%2C+Q.%3B+Cullen%2C+M.+J.%3B+Zuvich%2C+E.%3B+Thomas%2C+M.%3B+Rohrbach%2C+K.%3B+Devenny%2C+J.%3B+Godonis%2C+H.%3B+Harvey%2C+S.%3B+Johnghar%2C+S.%3B+Behnia%2C+K.%3B+Pelleymounter%2C+M.+A.%3B+Ewing%2C+W.+R.+Discovery+of+Di-Aryl+Triazolopyridazine+Cannabinoid+Receptor+%28CB1%29+Antagonists.+Fall+2008+ACS+National+Meeting%2C+Philadelphia%2C+PA%2C+August+17%E2%80%9321%2C+2008%2C+MEDI+010%2C+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DG.%26atitle%3DDiscovery%2520of%2520Di-Aryl%2520Triazolopyridazine%2520Cannabinoid%2520Receptor%2520%2528CB1%2529%2520Antagonists%26spage%3DMEDI%2520010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murugesan, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâTanyi, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keim, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rohrbach, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnghar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behnia, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pelleymounter, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlson, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ewing, W. R.</span><span> </span><span class="NLM_article-title">Characterization of a novel and selective CB1 antagonist as a radioligand for receptor occupancy studies</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x"> (</span><span class="NLM_issue">22</span><span class="NLM_x">) </span> <span class="NLM_fpage">6856</span><span class="NLM_x">â</span> <span class="NLM_lpage">6860</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=6856-6860&issue=22&author=Y.+Yangauthor=K.+J.+Millerauthor=Y.+Zhuauthor=Y.+Hongauthor=Y.+Tianauthor=N.+Murugesanauthor=Z.+Guauthor=E.+O%E2%80%99Tanyiauthor=W.+J.+Keimauthor=K.+W.+Rohrbachauthor=S.+Johngharauthor=K.+Behniaauthor=M.+A.+Pelleymounterauthor=K.+E.+Carlsonauthor=W.+R.+Ewing&title=Characterization+of+a+novel+and+selective+CB1+antagonist+as+a+radioligand+for+receptor+occupancy+studies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DY.%26aulast%3DMiller%26aufirst%3DK.%2BJ.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DHong%26aufirst%3DY.%26aulast%3DTian%26aufirst%3DY.%26aulast%3DMurugesan%26aufirst%3DN.%26aulast%3DGu%26aufirst%3DZ.%26aulast%3DO%25E2%2580%2599Tanyi%26aufirst%3DE.%26aulast%3DKeim%26aufirst%3DW.%2BJ.%26aulast%3DRohrbach%26aufirst%3DK.%2BW.%26aulast%3DJohnghar%26aufirst%3DS.%26aulast%3DBehnia%26aufirst%3DK.%26aulast%3DPelleymounter%26aufirst%3DM.%2BA.%26aulast%3DCarlson%26aufirst%3DK.%2BE.%26aulast%3DEwing%26aufirst%3DW.%2BR.%26atitle%3DCharacterization%2520of%2520a%2520novel%2520and%2520selective%2520CB1%2520antagonist%2520as%2520a%2520radioligand%2520for%2520receptor%2520occupancy%2520studies%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26issue%3D22%26spage%3D6856%26epage%3D6860" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><div class="note"><p class="first last">The regiochemistry of Grignard addition that we report herein appears to be previously unreported; however, Grignard reagents are found to add to pyridazin-3(2<i>H</i>)-ones as reported in:</p></div><span class="NLM_contrib-group">Verhelst, T.; Verbeeck, S.; Ryabtsova, O.; Depraetere, S.; Maes, B. U. W.</span><span> </span><span class="NLM_article-title">Synthesis of Functionalized Pyridazin-3(2<i>H</i>)-ones via Nucleophilic Substitution of Hydrogen (SnH)</span>.  <span class="citation_source-journal">Org. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">272</span><span class="NLM_x">â</span> <span class="NLM_lpage">275</span>.</span><div class="citationLinks">[<a href="/doi/10.1021/ol102703w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2011&pages=272-275&author=T.+Verhelst&author=S.+Verbeeck&author=O.+Ryabtsova&author=S.+Depraetere&author=B.+U.+W.+Maes&title=Synthesis+of+Functionalized+Pyridazin-3%282H%29-ones+via+Nucleophilic+Substitution+of+Hydrogen+%28SnH%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fol102703w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol102703w%26sid%3Dliteratum%253Aachs%26aulast%3DVerhelst%26aufirst%3DT.%26atitle%3DSynthesis%2520of%2520Functionalized%2520Pyridazin-3%25282H%2529-ones%2520via%2520Nucleophilic%2520Substitution%2520of%2520Hydrogen%2520%2528SnH%2529%26jtitle%3DOrg.%2520Lett.%26date%3D2011%26volume%3D13%26spage%3D272%26epage%3D275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><div class="note"><p class="first last">Experimental log P â<i>e</i> log Pâ was determined by the HPLC method, as described in:</p></div><span class="NLM_contrib-group">Valko, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bevan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, D.</span><span> </span><span class="NLM_article-title">Chromatographic Hydrophobicity Index by Fast-Gradient RP-HPLC: A High-Throughput Alternative to log P/log D</span> <span class="citation_source-journal">Anal. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">2022</span><span class="NLM_x">â</span> <span class="NLM_lpage">2029</span></span><div class="citationLinks">[<a href="/doi/10.1021/ac961242d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm4010835&amp;key=1%3ACAS%3A528%3ADyaK2sXivVertLs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=1997&pages=2022-2029&author=K.+Valkoauthor=C.+Bevanauthor=D.+Reynolds&title=Chromatographic+Hydrophobicity+Index+by+Fast-Gradient+RP-HPLC%3A+A+High-Throughput+Alternative+to+log+P%2Flog+D"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Chromatographic Hydrophobicity Index by Fast-Gradient RP-HPLC: A High-Throughput Alternative to Log P/log D</span></div><div class="casAuthors">Valko, Klara; Bevan, Chris; Reynolds, Derek</div><div class="citationInfo"><span class="NLM_cas:title">Analytical Chemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2022-2029</span>CODEN:
                <span class="NLM_cas:coden">ANCHAM</span>;
        ISSN:<span class="NLM_cas:issn">0003-2700</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new chromatog. hydrophobicity index (CHI) is described which can be used as part of a protocol for high-throughput (50-100 compds./day) physicochem. property profiling for rational drug design.  The index is derived from retention times (tR) obsd. in a fast gradient reversed-phase HPLC method.  The isocratic retention factors (log k') were measured for a series of 76 structurally unrelated compds. by using various concns. of acetonitrile in the mobile phase.  By plotting the log k' as a function of the acetonitrile concn., the slope (S) and the intercept (log k'w) values were calcd.  The previously validated index of hydrophobicity Ï0 was calcd. as -log k'w/S.  A good linear correlation was obtained between the gradient retention time values, tR and the isocratically detd. Ï0 values for the 76 compds.  The consts. of this linear correlation can be used to calc. CHI.  For most compds., CHI is between 0 and 100 and in this range it approximates to the percentage (by vol.) of acetonitrile required to achieve an equal distribution of compd. between the mobile and the stationary phases.  CHI values can be measured using acidic, neutral, or slightly basic eluents.  Values corresponding to the neutral form of mols. could be measured for 52 of the compds. and showed good correlation (r = 0.851) to the calcd. octanol/water partition coeff. (c log P) values.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozvQI1B1cnpbVg90H21EOLACvtfcHk0liV3i0U8fEBrg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXivVertLs%253D&md5=fcbb641105c12dc490d4a20db8fc5032</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fac961242d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fac961242d%26sid%3Dliteratum%253Aachs%26aulast%3DValko%26aufirst%3DK.%26aulast%3DBevan%26aufirst%3DC.%26aulast%3DReynolds%26aufirst%3DD.%26atitle%3DChromatographic%2520Hydrophobicity%2520Index%2520by%2520Fast-Gradient%2520RP-HPLC%253A%2520A%2520High-Throughput%2520Alternative%2520to%2520log%2520P%252Flog%2520D%26jtitle%3DAnal.%2520Chem.%26date%3D1997%26volume%3D69%26spage%3D2022%26epage%3D2029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Rohrbach, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâTanyi, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chi, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taub, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Largent, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, D.</span><span> </span><span class="NLM_article-title">Disconnection Between the Early Onset Anorectic Effects by C75 and Hypothalamic Fatty Acid Synthase Inhibition in Rodents</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">511</span><span class="NLM_x">, </span> <span class="NLM_fpage">31</span><div class="note"><p class="first last">Where indicated, % reduction in food intake is recorded at a shorter timepoint.</p></div></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm4010835&amp;key=10.1016%2Fj.ejphar.2005.01.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm4010835&amp;key=15777777" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm4010835&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitlCjsL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=511&publication_year=2005&pages=31&author=K.+W.+Rohrbachauthor=S.+Hanauthor=J.+Ganauthor=E.+J.+O%E2%80%99Tanyiauthor=H.+Zhangauthor=C.+L.+Chiauthor=R.+Taubauthor=B.+L.+Largentauthor=D.+Cheng&title=Disconnection+Between+the+Early+Onset+Anorectic+Effects+by+C75+and+Hypothalamic+Fatty+Acid+Synthase+Inhibition+in+Rodents"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Disconnection between the early onset anorectic effects by C75 and hypothalamic fatty acid synthase inhibition in rodents</span></div><div class="casAuthors">Rohrbach, Kenneth W.; Han, Songping; Gan, Jinping; O'Tanyi, Eva J.; Zhang, Hongwei; Chi, Cecilia L.; Taub, Rebecca; Largent, Brian L.; Cheng, Dong</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">511</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">31-41</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In order to explore the relationship between the anorectic effect of 3-carboxy-4-octyl-2-methylenebutyrolactone (C75) and its pharmacokinetic properties, studies of in vivo and in vitro pharmacol. characterization of C75 were performed in Fischer rats.  In a quant. measurement of food intake, we detd. that appetite suppression by C75 takes place within 4 h.  The C max for C75 of 2.6Â±1.5 Î¼M was reached within 1-4 h after i.p. administration at 30 mg/kg, a drug level that causes complete blockade of food intake.  However, this concn. is substantially lower than the effective concn. used to inhibit rat fatty acid synthase enzyme activity in vitro (IC50: â¼200 Î¼M) and hypothalamic enzyme activity was found not to be inhibited by i.p. administration of C75 at 30 mg/kg.  Instead, a dramatic induction of c-Fos expression was found in area postrema.  Collectively, these data indicate that the anorectic effect of C75 is independent of its inhibition of fatty acid synthase in the hypothalamus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphbCknlWT3JrVg90H21EOLACvtfcHk0liV3i0U8fEBrg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitlCjsL8%253D&md5=bae875aacd7aa736cb95107bf170c6ab</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2005.01.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2005.01.034%26sid%3Dliteratum%253Aachs%26aulast%3DRohrbach%26aufirst%3DK.%2BW.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DGan%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Tanyi%26aufirst%3DE.%2BJ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DChi%26aufirst%3DC.%2BL.%26aulast%3DTaub%26aufirst%3DR.%26aulast%3DLargent%26aufirst%3DB.%2BL.%26aulast%3DCheng%26aufirst%3DD.%26atitle%3DDisconnection%2520Between%2520the%2520Early%2520Onset%2520Anorectic%2520Effects%2520by%2520C75%2520and%2520Hypothalamic%2520Fatty%2520Acid%2520Synthase%2520Inhibition%2520in%2520Rodents%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2005%26volume%3D511%26spage%3D31" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><div class="note"><p class="first last">For experimental details, see:</p></div><span class="NLM_contrib-group">Sitkoff, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellsworth, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baska, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pendri, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malley, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scaringe, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gougoutas, J. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reggio, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ewing, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pelleymounter, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carlson, K. E.</span><span> </span><span class="NLM_article-title">Cannabinoid CB<sub>1</sub> Receptor Ligand Binding and Function Examined Through Mutagenesis Studies of F200 and S383</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">651</span><span class="NLM_x"> (</span><span class="NLM_issue">1â3</span><span class="NLM_x">) </span> <span class="NLM_fpage">9</span><span class="NLM_x">â</span> <span class="NLM_lpage">17</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm4010835&amp;key=10.1016%2Fj.ejphar.2010.10.056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm4010835&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1ajsrvJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=651&publication_year=2011&pages=9-17&issue=1%E2%80%933&author=D.+F.+Sitkoffauthor=N.+Leeauthor=B.+A.+Ellsworthauthor=Q.+Huangauthor=L.+Kangauthor=R.+Baskaauthor=Y.+Huangauthor=C.+Sunauthor=A.+Pendriauthor=M.+F.+Malleyauthor=R.+P.+Scaringeauthor=J.+Z.+Gougoutasauthor=P.+H.+Reggioauthor=W.+R.+Ewingauthor=M.+A.+Pelleymounterauthor=K.+E.+Carlson&title=Cannabinoid+CB1+Receptor+Ligand+Binding+and+Function+Examined+Through+Mutagenesis+Studies+of+F200+and+S383"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid CB1 receptor ligand binding and function examined through mutagenesis studies of F200 and S383</span></div><div class="casAuthors">Sitkoff, Doree F.; Lee, Ning; Ellsworth, Bruce A.; Huang, Qi; Kang, Liya; Baska, RoseAnn; Huang, Yanting; Sun, Chongqing; Pendri, Annapurna; Malley, Mary F.; Scaringe, Raymond P.; Gougoutas, Jack Z.; Reggio, Patricia H.; Ewing, William R.; Pelleymounter, Mary Ann; Carlson, Kenneth E.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">651</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">9-17</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The cannabinoid CB1 G protein-coupled receptor has been shown to be a regulator of food consumption and has been studied extensively as a drug target for the treatment of obesity.  To advance understanding of the receptor's three-dimensional structure, we performed mutagenesis studies at human cannabinoid CB1 receptor residues F200 and S383 and measured changes in activity and binding affinity of compds. from two recently discovered active chemotypes, arylsulfonamide agonists and tetrahydroquinoline-based inverse agonists, as well as literature compds.  Our results add support to previous findings that both agonists and inverse agonists show varied patterns of binding at the two mutated residue sites, suggesting multiple subsites for binding to the cannabinoid CB1 receptor for both functional types of ligands.  We addnl. find that an F200L mutation in the receptor largely restores binding affinity to ligands and significantly decreases constitutive activity when compared to F200A, resulting in a receptor phenotype that is closer to the wild-type receptor.  The results downplay the importance of arom. stacking interactions at F200 and suggest that a bulky hydrophobic contact is largely sufficient to provide significant receptor function and binding affinity to cannabinoid CB1 receptor ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoH99h-4jg7VbVg90H21EOLACvtfcHk0liV3i0U8fEBrg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1ajsrvJ&md5=cd037c4ec201cf09066f9af25c915c40</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2010.10.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2010.10.056%26sid%3Dliteratum%253Aachs%26aulast%3DSitkoff%26aufirst%3DD.%2BF.%26aulast%3DLee%26aufirst%3DN.%26aulast%3DEllsworth%26aufirst%3DB.%2BA.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DKang%26aufirst%3DL.%26aulast%3DBaska%26aufirst%3DR.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DC.%26aulast%3DPendri%26aufirst%3DA.%26aulast%3DMalley%26aufirst%3DM.%2BF.%26aulast%3DScaringe%26aufirst%3DR.%2BP.%26aulast%3DGougoutas%26aufirst%3DJ.%2BZ.%26aulast%3DReggio%26aufirst%3DP.%2BH.%26aulast%3DEwing%26aufirst%3DW.%2BR.%26aulast%3DPelleymounter%26aufirst%3DM.%2BA.%26aulast%3DCarlson%26aufirst%3DK.%2BE.%26atitle%3DCannabinoid%2520CB1%2520Receptor%2520Ligand%2520Binding%2520and%2520Function%2520Examined%2520Through%2520Mutagenesis%2520Studies%2520of%2520F200%2520and%2520S383%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D651%26issue%3D1%25E2%2580%25933%26spage%3D9%26epage%3D17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><div class="note"><p class="first last">Methods and results described in:</p></div><span class="NLM_contrib-group">Azzara, A.; Behnia, K.; Cullen, M. J.; Devenny, J.; Ellsworth, B.; Ewing, W.; Glick, S.; Godonis, H.; Harvey, S.; Keim, W.; Murugesan, N.; Rohrbach, K.; Thomas, M.; Pelleymounter, M. A.</span><span> </span><span class="NLM_article-title">The Novel Cannabinoid-1 Receptor Antagonists BMS-812204 and BMS-811064 Reduce Food Intake and Body Weight in Preclinical Models of Obesity</span>. <span class="NLM_conf-name">Obesity Society 27th Annual Scientific Meeting</span>, <span class="NLM_conf-loc">Washington, DC</span>, <span class="NLM_conf-date">October 24â28, 2009</span>,  <span class="NLM_fpage">Poster 750-P</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Methods+and+results+described+in%3AAzzara%2C+A.%3B+Behnia%2C+K.%3B+Cullen%2C+M.+J.%3B+Devenny%2C+J.%3B+Ellsworth%2C+B.%3B+Ewing%2C+W.%3B+Glick%2C+S.%3B+Godonis%2C+H.%3B+Harvey%2C+S.%3B+Keim%2C+W.%3B+Murugesan%2C+N.%3B+Rohrbach%2C+K.%3B+Thomas%2C+M.%3B+Pelleymounter%2C+M.+A.+The+Novel+Cannabinoid-1+Receptor+Antagonists+BMS-812204+and+BMS-811064+Reduce+Food+Intake+and+Body+Weight+in+Preclinical+Models+of+Obesity.+Obesity+Society+27th+Annual+Scientific+Meeting%2C+Washington%2C+DC%2C+October+24%E2%80%9328%2C+2009%2C+Poster+750-P."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DAzzara%26aufirst%3DA.%26atitle%3DThe%2520Novel%2520Cannabinoid-1%2520Receptor%2520Antagonists%2520BMS-812204%2520and%2520BMS-811064%2520Reduce%2520Food%2520Intake%2520and%2520Body%2520Weight%2520in%2520Preclinical%2520Models%2520of%2520Obesity%26spage%3DPoster%2520750-P" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="note"><p class="first last">Bioavailability was determined from a comparison of exposures from iv vs oral administration of compound; clearance was determined from the terminal time points of the plasma profile upon iv administration. %<i>F</i> in rat, dog, and cynomologous monkey: 50, 40, and 15%, respectively. Clearance in rat, dog, and cynomologous monkey: 10, 12, 31 mL/min/kg. Intravenous elimination half-life in rat, dog, and cynomologous monkey: 5, 38, and 6 h, respectively.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="note"><p class="first last">Compound <b>28</b> displays 3 Î¼g/mL aqueous solubility from an amorphous form and immeasurable solubility from a crystalline form.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Riley, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGinnity, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Austin, R. P.</span><span> </span><span class="NLM_article-title">A Unified Model for Predicting Human Hepatic, Metabolic Clearance from in Vitro Intrinsic Clearance Data in Hepatocytes and Microsomes</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">1304</span><span class="NLM_x">â</span> <span class="NLM_lpage">1311</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm4010835&amp;key=10.1124%2Fdmd.105.004259" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm4010835&amp;key=15932954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm4010835&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpsFamt74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2005&pages=1304-1311&author=R.+J.+Rileyauthor=D.+F.+McGinnityauthor=R.+P.+Austin&title=A+Unified+Model+for+Predicting+Human+Hepatic%2C+Metabolic+Clearance+from+in+Vitro+Intrinsic+Clearance+Data+in+Hepatocytes+and+Microsomes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes</span></div><div class="casAuthors">Riley, Robert J.; McGinnity, D. F.; Austin, R. P.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1304-1311</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The aim of this study was to evaluate a unified method for predicting human in vivo intrinsic clearance (CLint, in vivo) and hepatic clearance (CLh) from in vitro data in hepatocytes and microsomes by applying the unbound fraction in blood (fub) and in vitro incubations (fuinc).  Human CLint, in vivo was projected using in vitro data together with biol. scaling factors and compared with the unbound intrinsic clearance (CLint, ub, in vivo) estd. from clin. data using liver models with and without the various fu terms.  For incubations conducted with fetal calf serum (n = 14), the obsd. CLint, in vivo was modeled well assuming fuinc and fub were equiv.  CLint, ub, in vivo was predicted best using both fub and fuinc for other hepatocyte data (n = 56; r2 = 0.78, p = 3.3Ã10-19, av. fold error = 5.2).  A similar model for CLint, ub, in vivo was established for microsomal data (n = 37; r2 = 0.77, p = 1.2Ã10-12, av. fold error = 6.1).  Using the model for CLint, ub, in vivo (including a further empirical scaling factor), the CLh in humans was also calcd. according to the well stirred liver model for the most extensive dataset.  CLint, in vivo and CLh were both predicted well using in vitro human data from several labs. for acidic, basic, and neutral drugs.  The direct use of this model using only in vitro human data to predict the metabolic component of CLh is attractive, as it does not require extra information from preclin. studies in animals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnrU05rRTm6LVg90H21EOLACvtfcHk0livE3_guW6rYA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpsFamt74%253D&md5=79b80848977739267e4dd0ae82e5cbab</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1124%2Fdmd.105.004259&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.105.004259%26sid%3Dliteratum%253Aachs%26aulast%3DRiley%26aufirst%3DR.%2BJ.%26aulast%3DMcGinnity%26aufirst%3DD.%2BF.%26aulast%3DAustin%26aufirst%3DR.%2BP.%26atitle%3DA%2520Unified%2520Model%2520for%2520Predicting%2520Human%2520Hepatic%252C%2520Metabolic%2520Clearance%2520from%2520in%2520Vitro%2520Intrinsic%2520Clearance%2520Data%2520in%2520Hepatocytes%2520and%2520Microsomes%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2005%26volume%3D33%26spage%3D1304%26epage%3D1311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Parrott, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paquereau, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coassolo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lave, T.</span><span> </span><span class="NLM_article-title">An Evaluation of the Utility of Physiologically Based Models of Pharmacokinetics in Early Drug Discovery</span> <span class="citation_source-journal">J. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">94</span><span class="NLM_x">, </span> <span class="NLM_fpage">2327</span><span class="NLM_x">â</span> <span class="NLM_lpage">2343</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2005&pages=2327-2343&author=N.+Parrottauthor=N.+Paquereauauthor=P.+Coassoloauthor=T.+Lave&title=An+Evaluation+of+the+Utility+of+Physiologically+Based+Models+of+Pharmacokinetics+in+Early+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DParrott%26aufirst%3DN.%26aulast%3DPaquereau%26aufirst%3DN.%26aulast%3DCoassolo%26aufirst%3DP.%26aulast%3DLave%26aufirst%3DT.%26atitle%3DAn%2520Evaluation%2520of%2520the%2520Utility%2520of%2520Physiologically%2520Based%2520Models%2520of%2520Pharmacokinetics%2520in%2520Early%2520Drug%2520Discovery%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2005%26volume%3D94%26spage%3D2327%26epage%3D2343" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Tamaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Komura, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kogayu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamada, S.</span><span> </span><span class="NLM_article-title">Comparative Assessment of Empirical and Physiological Approaches on Predicting Human Clearances</span> <span class="citation_source-journal">J. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">1147</span><span class="NLM_x">â</span> <span class="NLM_lpage">1155</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2011&pages=1147-1155&author=S.+Tamakiauthor=H.+Komuraauthor=M.+Kogayuauthor=S.+Yamada&title=Comparative+Assessment+of+Empirical+and+Physiological+Approaches+on+Predicting+Human+Clearances"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTamaki%26aufirst%3DS.%26aulast%3DKomura%26aufirst%3DH.%26aulast%3DKogayu%26aufirst%3DM.%26aulast%3DYamada%26aufirst%3DS.%26atitle%3DComparative%2520Assessment%2520of%2520Empirical%2520and%2520Physiological%2520Approaches%2520on%2520Predicting%2520Human%2520Clearances%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2011%26volume%3D100%26spage%3D1147%26epage%3D1155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><div class="note"><p class="first last">The physicochemical characteristics of ligands for lipophilic GPCRs have been reviewed in</p></div><span class="NLM_contrib-group">Vieth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sutherland, J. J.</span><span> </span><span class="NLM_article-title">Dependence of Molecular Properties on Proteomic Family for Marketed Oral Drugs</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">3451</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0603825" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=3451&author=M.+Viethauthor=J.+J.+Sutherland&title=Dependence+of+Molecular+Properties+on+Proteomic+Family+for+Marketed+Oral+Drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm0603825&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0603825%26sid%3Dliteratum%253Aachs%26aulast%3DVieth%26aufirst%3DM.%26aulast%3DSutherland%26aufirst%3DJ.%2BJ.%26atitle%3DDependence%2520of%2520Molecular%2520Properties%2520on%2520Proteomic%2520Family%2520for%2520Marketed%2520Oral%2520Drugs%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D3451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Masimirembwa, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bredberg, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andersson, T. B.</span><span> </span><span class="NLM_article-title">Metabolic Stability for Drug Discovery and Development</span> <span class="citation_source-journal">Clin. Pharmacokinet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">515</span><span class="NLM_x">â</span> <span class="NLM_lpage">528</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Fjm4010835&amp;key=10.2165%2F00003088-200342060-00002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm4010835&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmtVGmuro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2003&pages=515-528&issue=6&author=C.+M.+Masimirembwaauthor=U.+Bredbergauthor=T.+B.+Andersson&title=Metabolic+Stability+for+Drug+Discovery+and+Development"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolic stability for drug discovery and development: Pharmacokinetic and biochemical challenges</span></div><div class="casAuthors">Masimirembwa, Collen M.; Bredberg, Ulf; Andersson, Tommy B.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">515-528</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Adis International Ltd.</span>)
        </div><div class="casAbstract">A review.  Metabolic stability refers to the susceptibility of compds. to biotransformation in the context of selecting and/or designing drugs with favorable pharmacokinetic properties.  Metabolic stability results are usually reported as measures of intrinsic clearance, from which secondary pharmacokinetic parameters such as bioavailability and half-life can be calcd. when other data on vol. of distribution and fraction absorbed are available.  Since these parameters are very important in defining the pharmacol. and toxicol. profile of drugs as well as patient compliance, the pharmaceutical industry has a particular interest in optimizing for metabolic stability during the drug discovery and development process.  In the early phases of drug discovery, new chem. entities cannot be administered to humans; hence, predictions of these properties have to be made from in vivo animal, in vitro cellular/subcellular and computational systems.  The utility of these systems to define the metabolic stability of compds. that is predictive of the human situation will be reviewed here.  The timing of performing the studies in the discovery process and the impact of recent advances in research on drug absorption, distribution, metab. and excretion (ADME) will be evaluated with respect to the scope and depth of metabolic stability issues.  Quant. prediction of in vivo clearance from in vitro metab. data has, for many compds., been shown to be poor in retrospective studies.  One explanation for this may be that there are components used in the equations for scaling that are missing or uncertain and should be an area of more research.  For example, as a result of increased biochem. understanding of drug metab., old assumptions (e.g. that the liver is the principal site of first-pass metab.) need revision and new knowledge (e.g. the relationship between transporters and drug metabolizing enzymes) needs to be incorporated into in vitro-in vivo correlation models.  With ADME parameters increasingly being detd. on automated platforms, instead of using results from high throughput screening (HTS) campaigns as simple go/no-go filters, the time saved and the many compds. analyzed using the robots should be invested in careful processing of the data.  A logical step would be to investigate the potential to construct computational models to understand the factors governing metabolic stability.  A rational approach to the use of HTS assays should aim to screen for many properties (e.g. physicochem. parameters, absorption, metab., protein binding, pharmaco-kinetics in animals and pharmacol.) in an integrated manner rather than screen against one property on many compds., since it is likely that the final drug will represent a global av. of these properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMaQNLSmN907Vg90H21EOLACvtfcHk0livE3_guW6rYA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmtVGmuro%253D&md5=c2386c9c2e20ccb3b085fe4a2683eef8</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.2165%2F00003088-200342060-00002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003088-200342060-00002%26sid%3Dliteratum%253Aachs%26aulast%3DMasimirembwa%26aufirst%3DC.%2BM.%26aulast%3DBredberg%26aufirst%3DU.%26aulast%3DAndersson%26aufirst%3DT.%2BB.%26atitle%3DMetabolic%2520Stability%2520for%2520Drug%2520Discovery%2520and%2520Development%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2003%26volume%3D42%26issue%3D6%26spage%3D515%26epage%3D528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Davis-Bruno, K.</span><span> </span><span class="NLM_article-title">Non-clinical Overview: CNS Toxicity with Rimonabant</span>; <span class="NLM_publisher-name">U.S. Food and Drug Administration Center for Drug Evaluation and Research</span>: <span class="NLM_publisher-loc">Silver Spring, MD</span>, <span class="NLM_month">June</span><span class="NLM_day">13</span>,<span class="NLM_x"> </span><span class="NLM_year">2007</span><span class="NLM_x">; </span><a href="http://www.fda.gov/ohrms/dockets/ac/07/slides/2007-4306s1-09-FDA-Bruno.ppt" class="extLink">www.fda.gov/ohrms/dockets/ac/07/slides/2007-4306s1-09-FDA-Bruno.ppt</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=K.+Davis-Bruno&title=Non-clinical+Overview%3A+CNS+Toxicity+with+Rimonabant"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26aulast%3DDavis-Bruno%26aufirst%3DK.%26atitle%3DNon-clinical%2520Overview%253A%2520CNS%2520Toxicity%2520with%2520Rimonabant%26pub%3DU.S.%2520Food%2520and%2520Drug%2520Administration%2520Center%2520for%2520Drug%2520Evaluation%2520and%2520Research%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Okada, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinomura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higashiyama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeuchi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hojo, M.</span><span> </span><span class="NLM_article-title">A Simple and Convenient Synthetic Method for Alpha-Trifluoromethylpyridines</span> <span class="citation_source-journal">Heterocycles</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">129</span><span class="NLM_x">â</span> <span class="NLM_lpage">132</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=1997&pages=129-132&author=E.+Okadaauthor=T.+Kinomuraauthor=Y.+Higashiyamaauthor=H.+Takeuchiauthor=M.+Hojo&title=A+Simple+and+Convenient+Synthetic+Method+for+Alpha-Trifluoromethylpyridines"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOkada%26aufirst%3DE.%26aulast%3DKinomura%26aufirst%3DT.%26aulast%3DHigashiyama%26aufirst%3DY.%26aulast%3DTakeuchi%26aufirst%3DH.%26aulast%3DHojo%26aufirst%3DM.%26atitle%3DA%2520Simple%2520and%2520Convenient%2520Synthetic%2520Method%2520for%2520Alpha-Trifluoromethylpyridines%26jtitle%3DHeterocycles%26date%3D1997%26volume%3D46%26spage%3D129%26epage%3D132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><div class="note"><p class="first last">Synthesized according to the method described in:</p></div><span class="NLM_contrib-group">Wu, G.; Sher, P.; Ellsworth, B. A.; Wu, X.; Ewing, W. R.</span> Manuscript in preparation.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Synthesized+according+to+the+method+described+in%3AWu%2C+G.%3B+Sher%2C+P.%3B+Ellsworth%2C+B.+A.%3B+Wu%2C+X.%3B+Ewing%2C+W.+R.+Manuscript+in+preparation."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dunpublished%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DG." title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Kazimierczuk, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaminshi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flavio, M.</span><span> </span><span class="NLM_article-title">Studies on Improved Synthesis of 2â²-Deoxyribonucleosides of Pyridazine Derivatives</span> <span class="citation_source-journal">Collect. Czech. Chem. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">889</span><span class="NLM_x">â</span> <span class="NLM_lpage">898</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Fjm4010835&amp;key=10.1135%2Fcccc20060889" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm4010835&amp;key=1%3ACAS%3A528%3ADC%252BD28Xmt1aruro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2006&pages=889-898&issue=6&author=Z.+Kazimierczukauthor=J.+Kaminshiauthor=M.+Flavio&title=Studies+on+Improved+Synthesis+of+2%E2%80%B2-Deoxyribonucleosides+of+Pyridazine+Derivatives"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Studies on improved synthesis of 2'-deoxyribonucleosides of pyridazine derivatives</span></div><div class="casAuthors">Kazimierczuk, Zygmunt; Kaminski, Jaroslaw; Meggio, Flavio</div><div class="citationInfo"><span class="NLM_cas:title">Collection of Czechoslovak Chemical Communications</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">889-898</span>CODEN:
                <span class="NLM_cas:coden">CCCCAK</span>;
        ISSN:<span class="NLM_cas:issn">0010-0765</span>.
    
            (<span class="NLM_cas:orgname">Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic</span>)
        </div><div class="casAbstract">A no. of 2'-deoxyribonucleosides of halogenated pyridazine derivs. were prepd. by glycosylation of their resp. potassium or DBU salts in acetone.  The reaction yielded predominantly Î²-anomers that could be purified by simple crystn. or column chromatog.  Of the studied pyridazines and deoxynucleosides, only 4-bromo-6-chloro-pyridazin-3-one and 6-chloro-2-(2'-deoxyribofuranosyl)pyridazin-3-one showed modest inhibition of CK2 kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUzc-31Z0fgrVg90H21EOLACvtfcHk0ljzx-wN4I7ofQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xmt1aruro%253D&md5=8d533bf31bc79b7c09d5b9b1d9fc3b39</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1135%2Fcccc20060889&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1135%252Fcccc20060889%26sid%3Dliteratum%253Aachs%26aulast%3DKazimierczuk%26aufirst%3DZ.%26aulast%3DKaminshi%26aufirst%3DJ.%26aulast%3DFlavio%26aufirst%3DM.%26atitle%3DStudies%2520on%2520Improved%2520Synthesis%2520of%25202%25E2%2580%25B2-Deoxyribonucleosides%2520of%2520Pyridazine%2520Derivatives%26jtitle%3DCollect.%2520Czech.%2520Chem.%2520Commun.%26date%3D2006%26volume%3D71%26issue%3D6%26spage%3D889%26epage%3D898" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Howlett, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barth, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonner, T. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cabral, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casellas, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devane, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felder, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herkenham, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mackie, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mechoulam, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pertwee, R. G.</span><span> </span><span class="NLM_article-title">International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors</span> <span class="citation_source-journal">Pharmacol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">161</span><span class="NLM_x">â</span> <span class="NLM_lpage">202</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Fjm4010835&amp;key=10.1124%2Fpr.54.2.161" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Fjm4010835&amp;key=12037135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm4010835&amp;key=1%3ACAS%3A528%3ADC%252BD38XltVOiuro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2002&pages=161-202&author=A.+C.+Howlettauthor=F.+Barthauthor=T.+I.+Bonnerauthor=G.+Cabralauthor=P.+Casellasauthor=W.+A.+Devaneauthor=C.+C.+Felderauthor=M.+Herkenhamauthor=K.+Mackieauthor=B.+R.+Martinauthor=R.+Mechoulamauthor=R.+G.+Pertwee&title=International+Union+of+Pharmacology.+XXVII.+Classification+of+Cannabinoid+Receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">International Union of Pharmacology. XXVII. Classification of cannabinoid receptors</span></div><div class="casAuthors">Howlett, A. C.; Barth, F.; Bonner, T. I.; Cabral, G.; Casellas, P.; Devane, W. A.; Felder, C. C.; Herkenham, M.; Mackie, K.; Martin, B. R.; Mechoulam, R.; Pertwee, R. G.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">161-202</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  Two types of cannabinoid receptor have been discovered so far, CB1 (2.1: CBD:1:CB1:), cloned in 1990, and CB2 (2.1:CBD:2:CB2:), cloned in 1993.  Distinction between these receptors is based on differences in their predicted amino acid sequence, signaling mechanisms, tissue distribution, and sensitivity to certain potent agonists and antagonists that show marked selectivity for one or the other receptor type.  Cannabinoid receptors CB1 and CB2 exhibit 48% amino acid sequence identity.  Both receptor types are coupled through G proteins to adenylyl cyclase and mitogen-activated protein kinase.  CB1 receptors are also coupled through G proteins to several types of calcium and potassium channels.  These receptors exist primarily on central and peripheral neurons, one of their functions being to inhibit neurotransmitter release.  Indeed, endogenous CB1 agonists probably serve as retrograde synaptic messengers.  CB2 receptors are present mainly on immune cells.  Such cells also express CB1 receptors, albeit to a lesser extent, with both receptor types exerting a broad spectrum of immune effects that includes modulation of cytokine release.  Of several endogenous agonists for cannabinoid receptors identified thus far, the most notable are arachidonoylethanolamide, 2-arachidonoylglycerol, and 2-arachidonylglyceryl ether.  It is unclear whether these eicosanoid mols. are the only, or primary, endogenous agonists.  Hence, the authors consider it premature to rename cannabinoid receptors after an endogenous agonist as is recommended by the International Union of Pharmacol. Committee on Receptor Nomenclature and Drug Classification.  Although pharmacol. evidence for the existence of addnl. types of cannabinoid receptor is emerging, other kinds of supporting evidence are still lacking.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeoe-6izzgsrVg90H21EOLACvtfcHk0ljzx-wN4I7ofQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltVOiuro%253D&md5=4a8345d34b5724ee3cd999b71956ab54</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1124%2Fpr.54.2.161&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.54.2.161%26sid%3Dliteratum%253Aachs%26aulast%3DHowlett%26aufirst%3DA.%2BC.%26aulast%3DBarth%26aufirst%3DF.%26aulast%3DBonner%26aufirst%3DT.%2BI.%26aulast%3DCabral%26aufirst%3DG.%26aulast%3DCasellas%26aufirst%3DP.%26aulast%3DDevane%26aufirst%3DW.%2BA.%26aulast%3DFelder%26aufirst%3DC.%2BC.%26aulast%3DHerkenham%26aufirst%3DM.%26aulast%3DMackie%26aufirst%3DK.%26aulast%3DMartin%26aufirst%3DB.%2BR.%26aulast%3DMechoulam%26aufirst%3DR.%26aulast%3DPertwee%26aufirst%3DR.%2BG.%26atitle%3DInternational%2520Union%2520of%2520Pharmacology.%2520XXVII.%2520Classification%2520of%2520Cannabinoid%2520Receptors%26jtitle%3DPharmacol.%2520Rev.%26date%3D2002%26volume%3D54%26spage%3D161%26epage%3D202" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i51"><a href="/doi/suppl/10.1021/jm4010835">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_76763"></div></div></div></div></div><hr /></hr><p class="last">Experimental procedures for the synthesis of compounds <b>47</b>â<b>49</b> and <b>S1</b>â<b>S6</b>, methods for in vitro and in vivo biological studies, and data used to generate graphs in Figures <a id="rightTab-" class=" internalNav" href="#fig4">4</a>A,B and Figure <a id="rightTab-" class=" internalNav" href="#fig5">5</a> may be found in the Supporting Information section. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm4010835/suppl_file/jm4010835_si_001.pdf">jm4010835_si_001.pdf (343.31 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm4010835&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2013.56.issue-23%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Fjm4010835%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm4010835" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                1MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799bb483b053cca","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
